,id,ticker,title,category,content,date,provider,url,article_id
198688,420204,CVS,U S  sues CVS for fraudulently billing Medicare  Medicaid for invalid prescriptions,news,"By Jonathan Stempel NEW YORK  Reuters    CVS Health Corp  N CVS  and its Omnicare unit were sued on Tuesday by the U S  government  which accused them of fraudulently billing Medicare and other programs for drugs for older and disabled people without valid prescriptions  The Department of Justice joined whistleblower litigation accusing Omnicare of violating the federal False Claims Act for illegally dispensing drugs to tens of thousands of patients in assisted living facilities  group homes for people with special needs  and other long term care facilities  According to a civil complaint filed in Manhattan federal court  Omnicare would often assign new numbers to prescriptions after the original prescriptions expired or ran out of refills  The government said this enabled Omnicare to bill Medicare Medicaid  and Tricare  which serves military personnel  for hundreds of thousands of drugs  under what the company internally called  rollover  prescriptions  from 2010 to 2018  Many of the drugs were anticonvulsants  antidepressants and antipsychotics and treated serious conditions such as dementia  depression and heart disease  and sometimes had dangerous side effects requiring supervision by doctors  the government said   A pharmacy s fundamental obligation is to ensure that drugs are dispensed only under the supervision of treating doctors who monitor patients  drug therapies   U S  Attorney Geoffrey Berman in Manhattan said in a statement   Omnicare put at risk the health of tens of thousands of elderly and disabled individuals living in assisted living and other residential long term care facilities   he added  The lawsuit seeks civil penalties and other damages  CVS  one of the largest U S  drugstore chains and pharmacy benefit managers  said it did not believe the claims had merit  and that it intended to defend itself in court   We are confident that Omnicare s dispensing practices will be found to be consistent with state requirements and industry accepted practices   the company said in a statement  CVS  based in Woonsocket  Rhode Island  bought Omnicare in 2015 for about  10 4 billion  The government joined a lawsuit originally brought in June 2015 by Uri Bassan  a pharmacist who worked for Omnicare in Albuquerque  New Mexico  It said Omnicare s compliance department had acknowledged the dispensing problem internally two months earlier  when a regional officer expressed concern in an email that its systems allowed rollover prescriptions  without any documentation or pharmacist intervention   The False Claims Act lets whistleblowers sue on behalf of the federal government  and share in recoveries  Twenty nine U S  states and the District of Columbia are also named as plaintiffs  
The cases is U S  ex rel  Bassan v  Omnicare Inc  U S  District Court  Southern  NYSE SO  District of New York  No  15 04179 ",2019-12-17,Reuters,https://www.investing.com/news/stock-market-news/us-files-civil-healthcare-fraud-lawsuit-against-cvs-and-its-omnicare-unit-2043114,2043114
198689,420205,CVS,CVS Health declares  0 50 dividend,news,"CVS Health  NYSE CVS  declares  0 50 share quarterly dividend  in line with previous 
Forward yield 2 71 
Payable Feb  3  for shareholders of record Jan  23  ex div Jan  22 
See CVS Dividend Scorecard  Yield Chart    Dividend Growth ",2020-01-02,Seeking Alpha,https://invst.ly/pcjis,2051427
198690,420206,CVS,Day Ahead  Top 3 Things to Watch for Feb  12,news,"Investing com   Here are three things that could rock the markets tomorrow 
1  Cisco  NASDAQ CSCO   CVS Health  NYSE CVS  Weigh In
Networking giant Cisco  NASDAQ CSCO  reports quarterly results after the bell Wednesday 
Cisco is expected to report a profit of 76 cents per share on revenue of about  12 billion  according to analysts  forecasts compiled by Investing com 
In early January  Bank of American Merrill Lynch moved its rating on the stock to neutral from buy  nudging down its price target to  52 per share from  56 
Merrill said it saw a lack of catalysts for shares in 2020 
The stock is down more than 4  in the last six months 
Before the bell  CVS Health Corp  NYSE CVS  will report numbers 
The company is expected to earn  1 68 per share on revenue of about  64 billion 
Like other stocks tied to healthcare  CVS will also be tethered somewhat to developments in the Democratic primaries  especially with the respect to Sen  Bernie Sanders  who is running on a platform of single payer health care 
2  Oil Inventories Seen Rising Again
OPEC decisions and indecisions have been calling the tune for oil prices so far this week  But tomorrow will bring some fundamental trading on the weekly oil inventories numbers 
The Energy Information Administration will report the latest weekly figures at 10 30 AM  15 30 GMT  
Analysts  on average  are expecting the EIA to report a rise in inventories of about 3 million barrels  according to forecasts compiled by Investing com 
Late today  the American Petroleum Institute said that according to its measure crude stockpiles rose by 6 million barrels for the week ended Feb  7 
3  Powell Back for Day Two
The economic calendar is pretty bare tomorrow  but Federal Reserve Chairman Jerome Powell will be back on Capitol Hill for the second half of his semiannual Congressional testimony 
Powell will start speaking to the Senate Banking Committee at 10 00 AM ET  15 00 GMT  
Prepared remarks will be the same  so attentional will be on the question and answer session with lawmakers 
Investors will also be looking at results from the New Hampshire Democratic Primary ",2020-02-12,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-for-feb-12-2082311,2082311
198693,420209,CVS,CVS Health s Selling Seasons Strong  Omnicare Arm Upsets,opinion,On Jan 13  we issued an updated research report on CVS Health   NYSE CVS    Increasing demand for both Pharmacy Benefit Management  PBM  and specialty pharmacy is a steady key driver  The company currently carries a Zacks Rank  3  Hold  Over the past three months  shares of CVS Health have outperformed its   The stock has rallied 15 4  compared with the 10 9  growth of its industry The company posted better than expected third quarter 2019 results  demonstrating successful execution of its strategic priorities  This led to all its three segments  in line or solid performances  Going by its strategic agenda  CVS Health is currently on track to make approximately 50 hubs operational by this year end along with its original plan to have 1 500 hubs active by the end of 2021  The company already started witnessing increased customer traffic and incremental sales in pharmacy front store and MinuteClinics CVS Health Corporation Price   In terms of segmental performances  year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in specialty services  We are also pleased with CVS Health s sturdy progress in the 2020 and 2021 selling seasons The company s 2020 PBM selling season is nearing completion with gross new business growing by  1 1 billion and net new business improving by approximately  1 billion since the sequential quarter s update The 2021 selling season is now underway and per the company  it is well positioned to serve both the new and the existing clients The company s recently launched Health Care Benefits segment following the Aetna  NYSE AET  acquisition is showing a robust momentum  particularly in government business On the flip side  Omnicare business performance is likely to have been soft through 2019  In the third quarter  persistent reimbursement pressure and the impact of recent generic introductions had a bearing on the company s retail LTC business Stocks to ConsiderA few better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    Hill Rom Holdings  Inc   NYSE HRC   and Vapotherm  Inc   NYSE VAPO   Haemonetics currently has a Zacks Rank  1  Strong Buy  and a projected long term earnings growth rate of 13 5   You can see Hill Rom s long term earnings growth rate is estimated at 11 7   The company currently carries a Zacks Rank  2  Buy  Vapotherm s long term earnings growth rate is estimated at 49 5   It currently holds a Zacks Rank of 2 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-selling-seasons-strong-omnicare-arm-upsets-200498585,200498585
198694,420210,CVS,Why CVS Health  CVS  Could Beat Earnings Estimates Again,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  CVS Health  NYSE CVS   which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  could be a great candidate to consider 
This drugstore chain and pharmacy benefits manager has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 7 57  
For the most recent quarter  CVS Health was expected to post earnings of  1 77 per share  but it reported  1 84 per share instead  representing a surprise of 3 95   For the previous quarter  the consensus estimate was  1 70 per share  while it actually produced  1 89 per share  a surprise of 11 18  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for CVS Health lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
CVS Health has an Earnings ESP of  1 53  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on February 12  2020 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/why-cvs-health-cvs-could-beat-earnings-estimates-again-200498713,200498713
198695,420211,CVS,CVS Health  CVS  Expected To Beat Earnings Estimates  Can The Stock Move Higher ,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when CVS Health  NYSE CVS  reports results for the quarter ended December 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 12  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugstore chain and pharmacy benefits manager is expected to post quarterly earnings of  1 68 per share in its upcoming report  which represents a year over year change of  21 5  
Revenues are expected to be  64 21 billion  up 18  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 13  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for CVS Health 
For CVS Health  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 57  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that CVS Health will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that CVS Health would post earnings of  1 77 per share when it actually produced earnings of  1 84  delivering a surprise of  3 95  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
CVS Health appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-expected-to-beat-earnings-estimates-can-the-stock-move-higher-200504921,200504921
198696,420212,CVS,Can Pharmacy Services Growth Aid CVS Health  CVS  Q4 Earnings ,opinion,CVS Health Corporation   NYSE CVS   is scheduled to report fourth quarter 2019 results on Feb 12  before the opening bell In the last reported quarter  the company delivered a positive surprise of 3 95   repeating its beat streak from the remaining three of the trailing four quarters  the average being 6 63  Let s take a look at how things are shaping up prior to this announcement Factors at PlayWithin Pharmacy Services  despite a tough pricing competition  CVS Health has been gaining on strong net new business  particularly in specialty segment and from the continued adoption of Maintenance Choice offerings  Within PBM  the company s new guaranteed net cost pricing model is garnering interest from clients and benefit consultants  which is likely to have led to strong client wins in the fourth quarter  Further  increased claims volume  the shift of Aetna  NYSE AET  Mail order and specialty operations into Pharmacy Services segment and improved purchasing economics are also expected to have added to the company s top line in the fourth quarter With respect to the newly incorporated Health Care Benefits segment  the company earlier expected to see government programs gaining momentum  driven by industry leading Medicare growth and the key Medicaid wins through the fourth quarter  Hopefully  this might get reflected in the to be reported results CVS Health Corporation Price and EPS Surprise   Notably  the Health Care Benefits business already started to register top line contributions for the company  In the third quarter of 2019  this segment had posted significant Medicare Advantage membership growth  particularly in the government space  SilverScript Medicare Part D business is showing a strong revenue performance as well  These trends most likely continued in the fourth quarter as well  However  per the company s earlier projection  the quarter to be reported is also expected to have incurred higher sequential spending on CVS Health s transformation programs Within the Retail Long Term Care Segment  CVS Health is likely to have thrived in the fourth quarter on the back of higher prescription volumes and consistently solid adjusted script growth owing to the steady success of the pharmacy clinical care program that improved patient retention  Additionally  CVS Health earlier predicted an uptick in the recently formed Medicare partnerships and the new regional preferred alliances forged in the ongoing year  The continued uptake of the company s Patient Care Programs in collaboration with PBM and its preferred status in a number of Medicare Part D networks are expected to have aided the fourth quarter top line However  persistent reimbursement pressure might have acted as a deterrent to fourth quarter Retail Long Term Care growth Meanwhile  the Zacks Consensus Estimate for fourth quarter adjusted EPS of  1 68 suggests a 21 5  fall from the year ago reported figure  The consensus estimate for revenues is currently pegged at  64 21 billion  indicating 17 9  growth from the year earlier reported number What the Quantitative Model PredictsPer our proven model  a stock needs to have a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for delivering a positive earnings surprise  But this is not the case here as you will see below Earnings ESP   CVS Health has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  CVS Health carries a Zacks Rank  3 Stocks Worth a LookHere are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season DexCom  Inc    NASDAQ DXCM   has a Zacks Rank  2 and an Earnings ESP of  12 27  Tandem Diabetes Care  Inc    NASDAQ TNDM   has a Zacks Rank of of 2 and an Earnings ESP of  27 59   You can see  Nevro Corp    NYSE NVRO   has a Zacks Rank of 3 and an Earnings ESP of  10 42  The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-02-09,Zacks Investment Research,https://www.investing.com/analysis/can-pharmacy-services-growth-aid-cvs-health-cvs-q4-earnings-200506074,200506074
198697,420213,CVS,CVS tops profit estimates on Aetna strength,news," Reuters    CVS Health Corp  N CVS  posted a better than expected quarterly profit on Wednesday  boosted by its pharmacy benefit management unit and the Aetna  NYSE AET  health insurance business it acquired last year 
Shares of the company rose 3  in premarket trading after the company also raised its 2019 adjusted profit forecast range to  6 97 to  7 05 per share  from  6 89 to  7 00 
Sales in the company s pharmacy services unit increased 6 4  to  36 02 billion in the third quarter  helped by a rise in prices of branded drugs and increased claims 
The company  which also runs drugstores  closed its  69 billion purchase of Aetna in November 2018 
Sales in its health care benefits business  which houses Aetna  soared to  17 18 billion  helped by lower than expected medical costs  The unit reported a medical benefit ratio of 83 3   compared with estimates of 84 3  according to four analysts polled by Refinitiv 
CVS Health s net profit rose 10 1  to  1 53 billion  or  1 17 per share  in the quarter ended Sept  30 
Excluding items  the company earned  1 84 per share  above analysts  estimates of  1 77 




Revenue jumped 36 5  to  64 81 billion ",2019-11-06,Reuters,https://www.investing.com/news/stock-market-news/cvs-tops-profit-estimates-on-aetna-strength-2013274,2013274
198702,420218,CVS,Why Is CVS Health  CVS  Up 3 8  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for CVS Health  NYSE CVS   Shares have added about 3 8  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is CVS Health due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  CVS Health s PBM Selling Season Remains Solid  Retail GrowsCVS Health s third quarter 2019 adjusted earnings per share of  1 84 increased 6 4  year over year and also exceeded the Zacks Consensus Estimate by 3 9   The quarter s adjusted earnings per share considered certain transaction and integration costs pertaining to the buyout of Aetna  NYSE AET  and store rationalization charges along with other adjustments On a reported basis  the company registered earnings of  1 17 per share  reflecting a 13 9  drop from the year ago period Moreover  total revenues in the third quarter surged 36 5  year over year  after adjusting the interest income on financing the Aetna acquisition  adjusted revenues increased 37 1  year over year  to  64 81 billion  The same also topped the Zacks Consensus Estimate by 2 8  The year over year revenue rise was primarily driven by the acquisition of Aetna  expanded volume and the brand name drug price inflation in both the Pharmacy Services and Retail LTC segments  partially offset by a persistent reimbursement pressure in the Retail LTC  price compression in the Pharmacy Services segment and an increased generic dispensing rate Quarter in Detail Earlier this year  CVS Health realigned the composition of its segments  As a result  the company s SilverScript Medicare Part D prescription drug plan  PDP  was shifted from the Pharmacy Services segment to Health Care Benefits  In addition  the mail order and specialty pharmacy operations of Aetna were transitioned from the Health Care Benefits segment to Pharmacy Services Pharmacy Services revenues were up 6 4  to  36 billion in the reported quarter  driven by growth in total pharmacy claims volume and the brand name drug price inflation  This was  however  partially offset by a continued client price compression and an increase in generic dispensing rate Total pharmacy claims processed rose 9 3  on a 30 day equivalent basis  attributable to net new business and the steady adoption of Maintenance Choice offerings Revenues from CVS Health s Retail LTC were up 2 9  year over year to  21 47 billion  Per the company  the result was based on higher prescription volume and branded drug price inflation  partially offset by a persistent reimbursement pressure and the impact of an increased generic dispensing rate  Front store revenues represented 21 5  of total Retail LTC revenues in the reported quarter  primarily banking on improved sales of health and beauty products  which benefited from consistent strength in cough and cold products Total prescription volume grew 6 4  on a 30 day equivalent basis  boosted by the steady uptake of patient care programs Within Health Care Benefits segment  the company registered revenues worth  16 5 billion in the third quarter Gross profit soared 52 6  to  11 52 billion  Accordingly  gross margin expanded 188 bps to 17 8   However  operating margin in the quarter under review contracted 90 bps to 4 5  despite a 13 7  rise in operating profit to  2 93 billion OutlookCVS Health has updated its 2019 guidance Adjusted earnings per share expectation is raised to the band of  6 97  7 05 from the earlier provided range of  6 89  7  The Zacks Consensus Estimate for current year earnings is pegged at  6 98  within the company s guided range This apart  the company s 2019 adjusted operating profit estimate is lifted to the  15 22  15 40 billion band from the previous view of 15 16  15 36 billion Further  the company reaffirmed its cash flow from operations guidance at  10 1  10 6 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates revision 
VGM Scores
Currently  CVS Health has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  CVS Health has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-cvs-health-cvs-up-38-since-last-earnings-report-200490776,200490776
198703,420219,CVS,CVS Health Rides On Aetna Prospects  Strong Selling Season,opinion,On Dec 10  we issued an updated research report on CVS Health   NYSE CVS    Increasing demand for Pharmacy Benefit Management  PBM  and specialty pharmacy is a major steady driver  The company currently carries a Zacks Rank  3  Hold  Over the past three months  shares of CVS Health have outperformed its   The stock has gained 14 4  compared with its industry s 10 6  growth The company posted better than expected third quarter 2019 results  demonstrating successful execution of its strategic priorities  This led to all three segments  in line or solid performances  Going by its strategic priorities  CVS Health is currently on track to make approximately 50 hubs operational by this year end along with its original plan to have 1 500 hubs by the end of 2021  The company already started witnessing increased customer traffic and incremental sales in pharmacy front store and MinuteClinics In terms of segmental performances  year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in specialty services  We are also pleased with CVS Health s sturdy progress in the 2020 and 2021 selling seasons The company s 2020 PBM selling season is nearing completion with gross new business growing by  1 1 billion and net new business improving by approximately  1 billion since the sequential quarter s update The 2021 selling season is now underway and per the company  it is well positioned to serve both new and existing clients The company s recently introduced Health Care Benefits segment following the Aetna  NYSE AET  acquisition is showing a robust momentum  particularly in government business On the flip side  Omnicare business performance is likely to be soft through 2019  In the third quarter  persistent reimbursement pressure and the impact of recent generic introductions had a bearing on the company s retail LTC business Stocks to ConsiderSome better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    National Vision Holdings  Inc   NASDAQ EYE   and ResMed Inc   NYSE RMD   Haemonetics currently has a Zacks Rank  2  Buy  and a projected long term earnings growth rate of 13 5  National Vision s long term earnings growth rate is estimated at 17 8   The company currently carries a Zacks Rank of 2  You can see ResMed s long term earnings growth rate is anticipated at 12 9   It currently flaunts a Zacks Rank  1 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-10,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-rides-on-aetna-prospects-strong-selling-season-200491882,200491882
198704,420220,CVS,First peanut allergy therapy gets backing from U S  regulators  expert advisers,news,"By Tamara Mathias and Saumya Joseph
 Reuters    A U S  Food and Drug Administration advisory panel on Friday recommended approving the first therapy for peanut allergies  which affect over 1 6 million children in the United States  despite raising concerns about the risk of severe allergic reactions it poses to young patients 
The body of independent advisers voted 7 2 in favor of effectiveness and 8 1 backing safety of the therapy Palforzia  developed by  Aimmune Therapeutics Inc   O AIMT   The verdict of the panel is traditionally an influential factor in the agency s final decision 
Peanut allergies are the leading cause of death from food induced allergic reactions in the United States but a lack of approved preventive treatments has left patients and caregivers desperate for options 
Palforzia  previously known as AR101  is an oral immunotherapy consisting of fixed doses of powdered peanut that is sprinkled over food daily 
While it does not aim to cure peanut allergy  the treatment s clinical trials have shown that patients consuming small doses of the substance to which they are allergic become desensitized over time  reducing the likelihood or severity of a reaction to it 
Aimmune says extended therapy will result in patients tolerating at least one peanut s worth of the protein which causes the anaphylactic reaction  protecting them from accidental consumption of the food 
Industry projections suggest that  if a number of treatments in development are approved  by 2027 the U S  peanut allergy therapy market could be worth  3 9 billion  with Aimmune capturing about two thirds of that market  according to research firm GlobalData 
Patient advocacy groups have been keenly awaiting an FDA greenlight  which would offer the hope of relief to parents living in constant fear of their children being accidentally exposed 
While some allergy specialists in the United States provide non approved versions of oral immununotherapy  analysts say Aimmune s more precisely dosed oral drug could bring in more than  1 billion in annual sales at its peak 
 It would be comforting for our community to have this option   Kenneth Mendez  who heads patient group Asthma and Allergy Foundation of America  told Reuters ahead of the panel meeting 
However  some experts worry that the treatment might give patients a false sense of security and trigger risky behavior  Others say it puts patients at unnecessary risk  because the very nature of the drug poses a risk of an allergic reaction 
Dr  Robert Wood  director of pediatric allergy and immunology at Johns Hopkins School of Medicine  says he believes the excitement will be tempered when patients realize what being on therapy involves 
 I will offer the treatment to all patients and recommend it to no one   he said 
FDA representative Sofia Chaudhry told the panel on Friday that the agency was still deciding on what safety restrictions or  REMS  requirements to place on the drug 
 We do take a very conservative approach   she said 
If approved  Palforzia is expected to have a black box warning  the FDA s harshest  and strict restrictions requiring the therapy to be administered in a certified facility 
Aimmune s closest rival  France s  DBV Technologies  SA  O DBVT   is developing a patch for peanut allergic patients aged 4 to 11  The company last month resubmitted an application to the FDA for its stick on patch therapy called Viaskin Peanut 
Aimmune hopes to win approval for use of Palforzia in patients aged 4 to 17 and said it is considering a list price range of between  3 000 and  20 000 a year 
 I think we ll be lower than in the middle  of that range    Chief Executive Officer Jayson Dallas told Reuters in an interview ahead of the meeting 
 Insurers will cover this  We ve spoken to the insurers so far who cover about 70  of the lives of patients with peanut allergies  
Earlier this year  pharmacy benefits manager CVS Health Corp  N CVS  put out a blog on its website about new treatments  saying it was considering what type of patient access policy to put in place 
The FDA is expected to make a decision on approval early next year ",2019-09-13,Reuters,https://www.investing.com/news/stock-market-news/first-peanut-allergy-therapy-gets-backing-from-us-regulators-expert-advisers-1977928,1977928
198705,420221,CVS,CVS drug coverage plan based on outside pricing review is off to a slow start,news,"By Caroline Humer
NEW YORK  Reuters    A CVS Health Corp  N CVS  health plan that uses an outside drug pricing group to help it decide whether to cover certain new medicines has gained little traction with customers  according to its top medical executive  and has drawn fierce criticism from patient advocacy groups 
The company has held back on marketing the pharmacy benefit plan while it talks to these groups  CVS said 
The plan  launched a year ago  is based on analyses by the Institute for Clinical and Economic Review  ICER   a Boston based group that assesses effectiveness of drugs to determine appropriate prices 
Using ICER s cost effectiveness assessment  CVS decides whether to include second or third medicines entering the market if there are already similar ones in the plan 
Opposition to the CVS plan is part of much broader concerns cited by drug companies and advocacy groups  many of which receive funding from the pharmaceutical industry  Some say that ICER s analysis based on additional years of  quality life  gained from a given treatment is arbitrary and disregards the costs of drug development and patient needs 
More than 50 groups  including drugmakers  PhRMA  the industry s main lobby group  and other advocacy groups  have provided comment during a public input period included in a review by ICER of its assessment methods  Many asked ICER to eliminate price recommendations from its efficacy analyses 
ICER has defended its methods  which are based on a widely used cost effectiveness analysis 
The soft rollout of CVS  ICER related product comes as employer health plan sponsors   its biggest clients   are showing increased concern over their cost for new high priced drugs  and are considering refusing to pay for them at all  CVS Chief Medical Officer Troy Brennan said in a recent interview 
If corporate customers follow through on that threat  CVS said it could change tactics with the plan 
Rising drug prices  particularly for expensive specialty treatments for severe or deadly conditions  have pushed annual U S  healthcare spending to  3 65 trillion  and made them unaffordable for many individuals 
Earlier this year   Novartis  AG  S NOVN  launched Zolgensma  a more than  2 million gene therapy for a rare but deadly disease called spinal muscular atrophy 
The new CVS program  cited as an example of ICER s growing influence on U S  drug pricing  would not apply to such a breakthrough treatment  It is a tiny plan by CVS standards as the company manages pharmaceutical benefits for more than 102 million people and also owns Aetna  NYSE AET  insurance and a national pharmacy chain 
NOT WIDELY PROMOTED
The plan s scope is limited to so called me too drugs  those where similar effective treatments already exist  and aims to pressure drugmakers to set lower prices  For example  two of three very similar drugs for migraine approved in 2018 could have been excluded  but drugmakers set prices ICER deemed cost effective 
CVS has limited sales and marketing for the plan while it talks to patient groups who oppose it  About 240 000 CVS employees and a few large clients  employees are enrolled thus far  The company declined to comment on exact membership 
 We are not widely promoting this program   Brennan said  adding that CVS is working to address patient groups  concerns 
Meanwhile  Brennan said some employers are considering refusing to pay for million dollar treatments like gene therapy  They are saying   I m not going to cover these kinds of therapies no matter what their comparative effectiveness is if they ve got a really high cost  
Large healthcare consultant and brokerage Mercer said it has begun to field similar concerns 
 We have certainly gotten some plan sponsors saying  What if we don t cover specialty drugs    said David Dross  who runs Mercer s managed pharmacy practice  Two years ago  it never received any such questions  he said 
Steve Wojcik  an executive with the National Business Group on Health which represents large employers  said he does not believe many will take that drastic step 
Still  ICER President Steven Pearson said employers tell him they worry about their ability to cover everything and have suggested they might drop some high cost treatments  He said employers can use cost effectiveness analysis to help them manage their spending 
ICER has responded to outside criticism by meeting with patient advocates and by adding new measurements for a drug s effectiveness  such as the value of life years gained  which does not focus on quality of life improvements  Pearson said 
Since 2015  ICER has published up to a dozen reviews each year of drugs and classes of medicines 
Most U S  private insurers now use ICER clinical and cost analyses to inform coverage negotiations with drugmakers  ICER funding primarily comes from a non profit foundation  but drug companies and health insurers provide some funds for ICER related activities ",2019-10-03,Reuters,https://www.investing.com/news/stock-market-news/cvs-drug-coverage-plan-based-on-outside-pricing-review-is-off-to-a-slow-start-1991743,1991743
198707,420223,CVS,CVS Health s Aetna Prospects Solid  Omnicare Sluggish,opinion,On Nov 8  we issued an updated research report on CVS Health   NYSE CVS    Increasing demand for Pharmacy Benefit Management  PBM  and specialty pharmacy has been a major growth driver for the stock  The company currently carries a Zacks Rank  3  Hold  Over the past three months  shares of CVS Health have outperformed its   The stock has gained 30 9  compared with its industry s 20 9  growth The company posted better than expected third quarter results demonstrating successful execution of its strategic priorities  This led to all three segments  in line or better than expected performances  Going by these priorities  CVS Health is currently on track to make approximately 50 hubs operational by this year end along with its original plan to have 1 500 hubs by the end of 2021  The company already started witnessing increased customer traffic and incremental sales in pharmacy front store and MinuteClinics CVS Health Corporation Price   In terms of segmental performances  year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in specialty services  We are also pleased with CVS Health s solid progress in terms of the 2020 and 2021 selling seasons With regard to CVS Health s 2020 PBM selling season  its next year selling season is nearing completion with gross new business increasing by  1 1 billion and net new business improving by approximately  1 billion since the sequential quarter s update The 2021 selling season is now underway and according to the company  it is well positioned to serve both new and existing clients The company s recently introduced Health Care Benefits segment following the Aetna  NYSE AET  acquisition is showing a strong momentum  particularly in government business On the flip side  per CVS Health  Omnicare business performance is likely to be soft through 2019  In the third quarter  persistent reimbursement pressure and the impact of recent generic introductions had a bearing on the company s retail LTC business Stocks to ConsiderSome better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and GW Pharmaceuticals PLC   NASDAQ GWPH   Haemonetics  currently sporting a Zacks Rank  1  Strong Buy   has a projected long term earnings growth rate at 13 5   You can see NuVasive  with a Zacks Rank  2  Buy   has projected long term earnings growth rate of 10 9  GW Pharmaceuticals estimates fourth quarter earnings growth rate to be 67 9   It currently carries a Zacks Rank  2 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-aetna-prospects-solid-omnicare-sluggish-200484333,200484333
198708,420224,CVS,Want To Retire Early  Learn The Intelligent Investing Secret   November 13  2019,opinion,"Achieving the financial freedom to retire early a dream for most  Making that dream a reality isn t as tricky as it sounds  The secret is simple  Save a lot more each month  Sounds easy  right  Not so fast 
Typically  advisors peg 15  to 20  of total income saved each month as a goal   but if you want to retire earlier  you probably have to ratchet that number up to 40  or 50  of your income  Not a feat easily accomplished when you review your take into account that a good portion of your paycheck goes to essential  non negotiable lifestyle items  However  if you are willing to make some serious lifestyle changes and sacrifices  it s possible 
A generally new development called Financial Independence  Retire Early  FIRE  has been created around this  sacrifice and over save now to retire early  idea  FIRE supporters create exacting savings plans  up to 75  of income  and make related compromises like living in small homes  walking to work every day  prohibitive weight control plans  etc  This way might be unreasonably prohibitive for many  yet the mentality offers a few takeaways that may merit consideration 
First  stick with the fundamentals of long term growth investing  Choose a diversified portfolio of stocks with exposure to different styles  sizes  sectors  and regions 
To speed up the retirement investment cycle  you can build a portfolio structured with more risk   and the potential for higher returns  It should in any case be adequately diversified to safeguard against sharper than normal market downturns that can be hard to recuperate from and that can ruin any opportunity to achieve your early retirement goal  There are various strategies to diversify a portfolio  and how you do so should be guided by your age  your risk appetite  your growth and income needs  and your long term objectives 
Once you ve begun saving at a higher rate and you have an investment plan  put that money to work in your plan as quickly as you can  Don t worry about finding the  perfect time  to invest   simply put the money in and keep it in  Let compounding work to help you grow your retirement savings at an exponential rate 
You may want to look at growth stocks with attributes acceptable for retirement investing like low beta  strong earnings estimates  positive sales growth  and expected future growth 
The Zacks Rank regularly identifies attractive growth stocks ideal for retirement investing  Here are just a few that might be worth consideration  AT T  T   Southwest Gas  SWX  and CVS Health  NYSE CVS   These are top ranked stocks  with at least 5  earnings and sales growth over the past five years  and boast beta equal to or lower than 1 
Do You Know the Top 9 Retirement Investing Mistakes 
Whether you re planning to retire early or not  don t let investing mistakes derail your plans 
If you have  500 000 or more to invest and want to learn more  click the link to download our free report  9 Retirement Mistakes that will Ruin Your Retirement This report will help you steer clear of the most common mistakes  like trying to time the market  lack of diversification in your portfolio  and many more  Get Your FREE Guide Now",2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/want-to-retire-early-learn-the-intelligent-investing-secret--november-13-2019-200485025,200485025
198709,420225,CVS,CVS Health s New Plans With Aetna May Improve Health Outcomes,opinion,CVS Health   NYSE CVS    with its newly acquired Aetna  NYSE AET  business  developed a Social Isolation Index to assess each Medicare beneficiary s risk of social isolation  The mentioned index is based on claims data and multifaceted data on social determinants of health  and will help in identifying high risk candidates The company s outreach program  Resources For Living  which is accessible to all members of Aetna Medicare Advantage and their caregivers  will provide further support to the high risk candidates  The specially trained consultants of Resources For Living will reach out to the candidates  who are potentially at a higher risk of facing social isolation While amplifying the customer base for Aetna s products  the current offering aims to strengthen its newly introduced Health Care Benefits segment  The segment came into effect after CVS Health acquired Aetna in November 2018  Rationale Behind the ProgramPer the company  social connection is an important determinant of health for most people  but especially for the Medicare population  The company believes that with its help  this population will be able to care for themselves or have reliable support  be safe in their homes  and will be able to lead fulfilling lives  This will likely delay the development and progression of chronic health conditions As part of this program  consultants will work directly with members to understand their needs and identify local resources  This serves as an early point of intervention for issues that are not health related and might affect members  health The company believes that personal connections are more important for beneficiaries aged 65 or more instead of digital solutions  A study conducted by CVS Health revealed that 24  of members did not have any immediate support system in the form of a friend or family and 27  did not know where to visit to meet new people How Does This Work The Resources For Living program and the social isolation index  both part of Aetna s overall Medicare social connectedness strategy  will work toward the improvent of the holistic well being of the members  The program will customize its support per individual requirement Plans in FocusIn 2020  Aetna will offer a new companionship benefit in partnership with Papa to reduce social isolation and provide the required support to the elderly population in select plans in Florida  Aetna will also continue offering SilverSneakers  a fitness program  at over 15 000 locations across the country through most of its Individual Medicare Advantage plans in 2020 Industry ProspectsPer a report by   the global health insurance market was valued at  99 million in 2018 and is expected to reach  1 30 billion by 2026  witnessing a CAGR of 3 5  between 2019 and 2026  The key factors driving the insurance market are increasing health expenses and rising elderly population along with rapidly growing chronic diseases among the general population globally Given the current trend in the insurance market as well as increasing incidents of loneliness and social isolation  resulting from adverse health behaviors and illnesses   the isolation index as part of the Resources For Living program has been developed at the right time Price PerformanceThe company s shares have risen 37 9  in the past six months compared with the  s growth of 27 3  Zacks Rank   Key PicksCurrently  CVS Health carries a Zacks Rank  3  Hold  A few better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and GW Pharmaceuticals plc   NASDAQ GWPH   Haemonetics  currently carrying a Zacks Rank  2  Buy   has a projected long term earnings growth rate at 13 5   You can see NuVasive estimates long term earnings growth of 10 9   The stock currently has a Zacks Rank  2 GW Pharmaceuticals estimates fourth quarter earnings growth rate at 69 6   It currently carries a Zacks Rank  2 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/cvs-healths-new-plans-with-aetna-may-improve-health-outcomes-200485306,200485306
198710,420226,CVS,CVS Health Set To Acquire Centene s IlliniCare Health Plan,opinion,"CVS Health   NYSE CVS   recently signed a definitive agreement with Centene Corporation   NYSE CNC    Per the terms of the agreement  CVS Health will acquire Centene s Illinois health plan subsidiary  IlliniCare Health Plan  Inc  Also  Centene s Medicaid and Medicare Advantage business lines in Illinois will be sold to CVS Health This collaboration is set to expand CVS Health s Medicaid and Medicare Advantage base in Illinois More About the CollaborationThe strengthening of CVS Health s Medicaid and Medicare Advantage businesses in Illinois should enable it to cater to a larger consumer network  The company s verified holistic approach that is in line with physical  behavioral and social determinants of healthcare is also likely to serve as a positive The closing of the deal with Centene is contingent upon U S  federal antitrust approval  receipt of Illinois state regulatory clearance  other routine closing conditions  and the completion of a previously announced merger deal between Centene and WellCare   Per the agreement  Centene will retain IlliniCare s Medicare Medicaid Alignment Initiative business and IlliniCare s statewide YouthCare foster care contract  Notably  the financial terms of this transaction will be kept under wraps Recent DevelopmentsRecently  CVS Health invested in a crucial development with the aim of bolstering the Medicaid and Medicare business lines In November 2019  CVS Health   with its newly acquired Aetna  NYSE AET  business   developed a Social Isolation Index to assess each Medicare beneficiary s risk of social isolation  The mentioned index is based on claims data and multifaceted information on social determinants of health  and will help in identifying high risk candidates  The company s outreach program  Resources For Living  which is accessible to all members of Aetna Medicare Advantage and their caregivers  will provide further support to high risk candidates Price PerformanceOver the past six months  the stock has rallied 38 3   outperforming the broader  s growth of 27 7  Zacks Rank   Stocks Worth a LookCVS Health currently carries a Zacks Rank  3  Hold  
Some better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE   and NuVasive  Inc    NASDAQ NUVA    each carrying  a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2019-12-03,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-set-to-acquire-centenes-illinicare-health-plan-200489521,200489521
198711,420227,CVS,U S  judge approves CVS purchase of insurer Aetna,news,"By Diane Bartz WASHINGTON  Reuters    A federal judge reviewing a Justice Department decision to allow U S  pharmacy chain and benefits manager CVS Health Corp  N CVS  to merge with health insurer Aetna  NYSE AET  said on Wednesday that the agreement was in fact legal under antitrust law  Judge Richard Leon of U S  District Court for the District of Columbia had been examining a government plan announced in October to allow the merger on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  N WCG   Both deals have already closed  Leon had initially balked at approving the merger conditions and insisted on hearing from critics of the deal  but finally decided to grant the motion to approve the consent agreement  But he took aim at the common practice of companies  closing multibillion dollar deals while the court review  required by the Tunney Act  was still in process   If the Tunney Act is to mean anything   Leon wrote   it surely must mean that no court should rubberstamp a consent decree approving the merger of  one of the largest companies in the United States  and  the nation s third largest health insurance company       simply because the Government requests it   In December  Leon said he was  less convinced  than the government that the asset sale to WellCare would resolve antitrust concerns  Since then   Centene  Corp  N CNC  agreed to acquire WellCare for  15 27 billion  Assistant Attorney General Makan Delrahim  head of the Justice Department s Antitrust Division  said he was pleased with Leon s decision  CVS said the judge s decision reinforced that CVS and Aetna have already merged   CVS Health and Aetna have been one company since November 2018  and today s action by the District Court makes that 100 percent clear  We remain focused on transforming the consumer health care experience in America   CVS spokesman T J  Crawford said in an emailed statement  Critics of the CVS Aetna deal included the American Medical Association and the AIDS Healthcare Foundation  Another critic  U S  PIRG  expressed skepticism that savings from the merger would end up in consumers  pockets   Again and again  CVS Caremark has used its market power to both increase the cost of medications for consumers and rip off the government  instead of passing on savings its promised to consumers   PIRG said in a statement   Pending Leon s approval  CVS agreed to temporarily allow Aetna to independently make critical product  pricing and personnel decisions  CVS has been in the process of converting itself into a healthcare company and said in June that it would offer expanded health services such as nutrition counseling and blood pressure screenings in 1 500 stores by the end of 2021  Most consent agreements that the antitrust agencies strike with companies to resolve competitive concerns are approved by federal courts with little fuss under the 1974 Tunney Act  which requires courts to ensure the agreements are in the public interest  
Companies generally do not wait for final court approval before closing their transactions ",2019-09-04,Reuters,https://www.investing.com/news/stock-market-news/us-judge-approves-cvs-purchase-of-insurer-aetna-1970600,1970600
198717,420233,CVS,CVS Health  CVS  Q3 Earnings And Revenues Top Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 84 per share  beating the Zacks Consensus Estimate of  1 77 per share  This compares to earnings of  1 73 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 95   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  1 70 per share when it actually produced earnings of  1 89  delivering a surprise of 11 18  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  64 81 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 2 83   This compares to year ago revenues of  47 27 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have added about 2 8  since the beginning of the year versus the S P 500 s gain of 22 7  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 70 on  64 62 billion in revenues for the coming quarter and  6 98 on  252 63 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 32  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-q3-earnings-and-revenues-top-estimates-200482819,200482819
198718,420234,CVS,CVS Higher On Earnings But Now Due For A Pullback,opinion,"Summary CVS Health  NYSE CVS  rose 5  on Wednesday after the company posted earnings that beat Wall Street expectations  
Based on its market cycles  we believe the stock is due for a modest pullback  but looking good into early next year  
CVS Stock Weekly Chart The company reported earnings per share of  1 84 and total revenue of  64 8 billion  compared to analyst estimates of  1 77 and  63 billion  Looking forward  management projects earnings between  6 97 and  7 05  compared to the consensus of  6 98  
CVS also announced that it would close 22 stores in the coming year  which is in addition to the 46 stores it closed in 2019  This is part of a retail trend  with its competitor Walgreens closing 200 stores  
Our approach to stock analysis uses market cycles to project price action  While CVS is still in the rising phase of its current cycle  it is now trading near the top of a major resistance zone  In any case  the stock is in great shape  We see it much higher into early 2020  
For the  Best and Worst Stocks of the Week  check out the askSlim Market Week show every Friday on our  ",2019-11-07,Steve Miller,https://www.investing.com/analysis/cvs-higher-on-earnings-but-now-due-for-a-pullback-200483276,200483276
198719,420235,CVS,CVS Health Corp Earnings  Revenue Beat in Q1,news,"Investing com   CVS Health Corp  NYSE CVS  reported first quarter earnings  that Beat analysts  expectations on Wednesday and revenue that topped forecasts 
The firm reported earnings per share of  1 62 on revenue of  61 65B  Analysts polled by Investing com forecast EPS of  1 5 on revenue of  60 46B  That compared to EPS of  1 48 on revenue of  45 69B in the same period a year earlier  The company had reported EPS of  2 14 on revenue of  54 42B in the previous quarter 

CVS Health Corp follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on Tuesday  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  13B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-05-01,Investing.com,https://www.investing.com/news/stock-market-news/cvs-health-corp-earnings-revenue-beat-in-q1-1852118,1852118
198720,420236,CVS,CVS Health raises full year profit forecast on Aetna strength,news,"By Manas Mishra and Caroline Humer  Reuters    CVS Health Corp  NYSE CVS  on Wednesday raised its full year profit forecast and reported first quarter earnings that topped Wall Street estimates due to growth in its Aetna  NYSE AET  health insurance business  and as drug prices fell within its expectations   Shares rose more than 5 percent to  57 35  They had fallen 17 percent this year  hurt by a weak forecast in February and a cut to rival Walgreen Boots Alliance s full year outlook last month due to lower generic drug prices   Aetna  CVS s health insurance unit  beat analysts  consensus by more than a billion dollars in the quarter  helped by its accounting for lower medical costs than anticipated during the fourth quarter   The company  which bought Aetna for  69 billion in November  said 2019 cost savings from the deal were tracking near the high end of its  300 million to  350 million range  and that 2020 savings would likely exceed its  750 million target   The company said a handful of new  HealthHub  pharmacies launched in Houston this year that provide healthcare services  such as chronic care management for diabetes  have drawn more customers than expected  It plans to launch more such stores in Houston and plans to provide details of a national roll out next month   Consumerism in healthcare is here to stay   CVS Chief Executive Larry Menlo said   We are beginning to see this evolution through the HealthHubs  We are not just selling hundreds of products  it s a combination of products and services   Menlo also said the company would take part in a pilot project announced by the U S  Center for Medicare and Medicaid Services to expand point of sale rebates to patients in Medicare plans  The government has also proposed a rule that would require health plans to pass on all rebates  but it is not clear if it will be finalized for 2020  Sales in its health care benefits unit rose by  16 55 billion to  17 78 billion with the addition of Aetna to its operations   Sales of prescription drugs at its pharmacies were hurt as the company gets paid less for filling prescriptions  That was offset by higher volumes and higher prices of brand name drugs  CVS in February had cautioned that rebate payments it guaranteed to customers were larger than what it has received from drugmakers due to lower than expected increases in drug prices   Considering that expectations have been low  we see this as the first positive catalyst that restores investor confidence in this management team   SVB Leerink analyst Ana Gupte said of the first quarter profit and raised 2019 forecast   CVS said it now expects full year adjusted profit of  6 75 to  6 90 per share  compared with its prior forecast of  6 68 to  6 88  Overall sales at its retail unit  which also sells over the counter drugs and consumer health products  rose 3 3 percent to  21 12 billion   The drugstore chain operator and pharmacy benefits manager said it earned  1 62 per share excluding items  beating analysts  average estimate by 12 cents per share  according to IBES data from Refinitiv  
Net income rose 42 4 percent to  1 42 billion in the first quarter  Revenue rose 34 8 percent to  61 65 billion ",2019-05-01,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-beats-profit-estimates-raises-fullyear-forecast-1852212,1852212
198721,420237,CVS,StockBeat   CVS Rallies on Earnings Beat  but Gloom Over Healthcare Stocks Remain,news,"Investing com   CVS rallied on Wednesday as its first quarter earnings beat expectations and healthier full year guidance suggested that the company is in better shape than expected 
CVS Health  NYSE CVS  raised guidance on full year earnings to a range of  6 75 to  6 90  from its earlier forecast of  6 68 to  6 88  That sent its shares more than 6  higher 
Wall Street was bracing for a difficult quarter from CVS after the company warned in February that this year would be a transition amid rising costs and poor results from a nursing home pharmacy unit 
But its recently acquired health insurance business boosted results and its pharmacies filled more expensive prescription drugs  helping the company deliver a beat on both the top and bottom lines  The company acquired Aetna  NYSE AET  in a  68 billion deal that closed in November 
The company reported earnings of  1 62 on revenue of  61 65 billion  above estimates from Investing com for earnings of  1 50 on revenue of  60 39 billion 
The upbeat results from CVS did little to prop up support for the broader healthcare sector  as sentiment has been soured by ongoing pressure from politicians  many of whom continued to push for measures to bring down drug costs  The Health Care Select Sector ETF  NYSE XLV  was basically flat Wednesday and is up just 3 3  this year 
As the U S  election campaign heats up in the months to come  analysts have warned that politicians will continue to bash health care companies  raising the prospect of further negative headline risk ",2019-05-01,Investing.com,https://www.investing.com/news/stock-market-news/stockbeat--cvs-rallies-on-earnings-bear-but-gloom-over-healthcare-stocks-remain-1852675,1852675
198722,420238,CVS,CVS to expand health hubs to 1 500 stores by end of 2021,news,"By Caroline Humer NEW YORK  Reuters    CVS Health Corp  NYSE CVS  said it will offer expanded health services such as nutrition counseling and blood pressure screenings in 1 500 stores by the end of 2021  following through on plans announced during the pharmacy chain s 2018 acquisition of health insurer Aetna  NYSE AET   It plans to convert a total of 50 stores this year in Houston  Atlanta  Philadelphia  and Tampa  representing about 15  of the stores in each of the markets  the company said ahead of a meeting on Tuesday with Wall Street analysts and investors in New York  The bulk of the expansion will be split between 2020 and 2021  CVS first launched a handful of these stores with expanded health services it is calling health hubs in Houston earlier this year  The new format includes an employee with the title of  care concierge  who will direct customers to health services such as a nutritionist or nurse practitioner  It also will offer screenings for sleep apnea and opthalmology issues related to diabetes  among other services  These CVS stores have experienced increases in foot traffic  front of store sales and MinuteClinic visits per day  as well as prescriptions dispensed  CVS pharmacy executive Kevin Hourican said in a phone interview  He declined to provide specific figures  MinuteClinics are walk in health clinics located in CVS pharmacies  When CVS bought Aetna for  69 billion  it said the companies would work to bring more health services into its stores beyond the MinuteClinic offerings to tackle chronic conditions like obesity  high blood pressure and diabetes  Separately  CVS this week is in federal court in Washington D C   where a judge is reviewing the Aetna deal  The U S  Department of Justice and the companies agreed on an anti trust settlement that included the sale of Medicare prescription drug plans to WellCare Health Plans Inc  but the court has not yet signed off on it  
In addition to its retail stores with pharmacies  CVS is one of the nation s largest pharmacy benefit managers ",2019-06-04,Reuters,https://www.investing.com/news/stock-market-news/cvs-to-expand-health-hubs-to-1500-stores-by-end-of-2021-1887376,1887376
198727,420243,CVS,Easy Investing Secrets To An Early Retirement   November 05  2019,opinion,"Accomplishing the financial cushion to retire early is a fantasy for most  Bringing the fantasy to reality is not as difficult as it sounds  The key is straightforward  Save significantly more every month  Sounds simple  correct  One moment 
The typical rule of thumb given by financial planners is to have a goal of saving up to 20  of total earnings  But if you want to retire when you re younger  that percentage will probably need to be more like 40  to 50  of your income  Of course  that s not so simple since a big part of your paycheck goes to day to day  necessary expenses  So if you want to save that much  you need to make some serious lifestyle adjustments  It requires making changes  but it s doable 
A generally new development called Financial Independence  Retire Early  FIRE  has been created around this  sacrifice and over save now to retire early  idea  FIRE supporters create exacting savings plans  up to 75  of income  and make related compromises like living in small homes  walking to work every day  prohibitive weight control plans  etc  This way might be unreasonably prohibitive for many  yet the mentality offers a few takeaways that may merit consideration 
The first point is to adhere to the key principles of long term investing  including developing a diversified portfolio that includes stocks with various styles  sizes  sectors and regions 
To accelerate the retirement investment cycle  you can construct a portfolio designed with more risk   and the potential for higher returns   but it should still be appropriately diversified to protect against larger than average market drawdowns that can be difficult to recover from and ruin any chance to accomplish your early retirement goal  There are numerous ways to diversify a portfolio  and how you do so should depend on your age  your risk tolerance  your growth and income needs  and your long term goals 
Once you have accelerated your savings and put an ongoing plan in place  invest your savings into your portfolio as soon as possible  Don t try to time the market  Leave your portfolio alone  and let the compounding nature of the markets do its magic to help grow your retirement nest egg exponentially over time 
Growth stocks with low beta  strong earnings estimates  positive sales growth  and expected future growth are an excellent way to determine investable growth stocks for your retirement 
Zacks offers investors useful rankings for lower risk growth stocks for retirement portfolios  The following are a few selections that merit a closer look  Armada Hoffler Properties  AHH   Heritage Commerce  HTBK  and CVS Health  NYSE CVS   Earnings and revenue has seen growth of at least 5  or higher over the last five years  with a beta of 1 or lower 
Do You Know the Top 9 Retirement Investing Mistakes 
Whether you re planning to retire early or not  don t let investing mistakes derail your plans 
If you have  500 000 or more to invest and want to learn more  click the link to download our free report  9 Retirement Mistakes that will Ruin Your Retirement This report will help you steer clear of the most common mistakes  like trying to time the market  lack of diversification in your portfolio  and many more  Get Your FREE Guide Now",2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/easy-investing-secrets-to-an-early-retirement--november-05-2019-200482490,200482490
198730,420246,CVS,Easy Investing Secrets To An Early Retirement   October 09  2019,opinion,"Accomplishing the financial cushion to retire early is a fantasy for most  Bringing the fantasy to reality is not as difficult as it sounds  The key is straightforward  Save significantly more every month  Sounds simple  correct  One moment 
The typical rule of thumb given by financial planners is to have a goal of saving up to 20  of total earnings  But if you want to retire when you re younger  that percentage will probably need to be more like 40  to 50  of your income  Of course  that s not so simple since a big part of your paycheck goes to day to day  necessary expenses  So if you want to save that much  you need to make some serious lifestyle adjustments  It requires making changes  but it s doable 
This concept of intensive saving for an early retirement has spawned a movement called FIRE  Financial Independence  Retire Early   Followers of FIRE strive to save up to three quarters of their income  and make other adjustments too  live in small homes  walk to work each day  practice strict diet plans  and more  Even if this lifestyle may sound a bit unreasonable  the ideas behind it are worth considering 
The first point is to adhere to the key principles of long term investing  including developing a diversified portfolio that includes stocks with various styles  sizes  sectors and regions 
To accelerate the retirement investment cycle  you can construct a portfolio designed with more risk   and the potential for higher returns   but it should still be appropriately diversified to protect against larger than average market drawdowns that can be difficult to recover from and ruin any chance to accomplish your early retirement goal  There are numerous ways to diversify a portfolio  and how you do so should depend on your age  your risk tolerance  your growth and income needs  and your long term goals 
Once you ve begun saving at a higher rate and you have an investment plan  put that money to work in your plan as quickly as you can  Don t worry about finding the  perfect time  to invest   simply put the money in and keep it in  Let compounding work to help you grow your retirement savings at an exponential rate 
Growth stocks with low beta  strong earnings estimates  positive sales growth  and expected future growth are an excellent way to determine investable growth stocks for your retirement 
Zacks offers investors useful rankings for lower risk growth stocks for retirement portfolios  The following are a few selections that merit a closer look  CVS Health  NYSE CVS   Jernigan Capital  JCAP  and Orix  IX   Earnings and revenue has seen growth of at least 5  or higher over the last five years  with a beta of 1 or lower 
Do You Know the Top 9 Retirement Investing Mistakes 
Whether you re planning to retire early or not  don t let investing mistakes derail your plans 
If you have  500 000 or more to invest and want to learn more  click the link to download our free report  9 Retirement Mistakes that will Ruin Your Retirement This report will help you steer clear of the most common mistakes  like trying to time the market  lack of diversification in your portfolio  and many more  Get Your FREE Guide Now",2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/easy-investing-secrets-to-an-early-retirement--october-09-2019-200471835,200471835
198731,420247,CVS,Is CVS Health  CVS  Stock Undervalued Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
One company to watch right now is CVS Health  NYSE CVS   CVS is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock is trading with P E ratio of 8 69 right now  For comparison  its industry sports an average P E of 8 96  Over the past 52 weeks  CVS s Forward P E has been as high as 11 05 and as low as 7 34  with a median of 8 46 
Value investors will likely look at more than just these metrics  but the above data helps show that CVS Health is likely undervalued currently  And when considering the strength of its earnings outlook  CVS sticks out at as one of the market s strongest value stocks ",2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/is-cvs-health-cvs-stock-undervalued-right-now-200473219,200473219
198732,420248,CVS,Want To Retire Early  Learn The Intelligent Investing Secret   October 28  2019,opinion,"Accomplishing the financial cushion to retire early is a fantasy for most  Bringing the fantasy to reality is not as difficult as it sounds  The key is straightforward  Save significantly more every month  Sounds simple  correct  One moment 
Typically  advisors peg 15  to 20  of total income saved each month as a goal   but if you want to retire earlier  you probably have to ratchet that number up to 40  or 50  of your income  Not a feat easily accomplished when you review your take into account that a good portion of your paycheck goes to essential  non negotiable lifestyle items  However  if you are willing to make some serious lifestyle changes and sacrifices  it s possible 
This concept of intensive saving for an early retirement has spawned a movement called FIRE  Financial Independence  Retire Early   Followers of FIRE strive to save up to three quarters of their income  and make other adjustments too  live in small homes  walk to work each day  practice strict diet plans  and more  Even if this lifestyle may sound a bit unreasonable  the ideas behind it are worth considering 
To start  stick with the essentials of long term growth investing  Build a diversified portfolio of stocks with exposure to various styles  sizes  sectors  and regions 
To accelerate the retirement investment cycle  you can construct a portfolio designed with more risk   and the potential for higher returns   but it should still be appropriately diversified to protect against larger than average market drawdowns that can be difficult to recover from and ruin any chance to accomplish your early retirement goal  There are numerous ways to diversify a portfolio  and how you do so should depend on your age  your risk tolerance  your growth and income needs  and your long term goals 
Once you have accelerated your savings and put an ongoing plan in place  invest your savings into your portfolio as soon as possible  Don t try to time the market  Leave your portfolio alone  and let the compounding nature of the markets do its magic to help grow your retirement nest egg exponentially over time 
You may want to look at growth stocks with attributes acceptable for retirement investing like low beta  strong earnings estimates  positive sales growth  and expected future growth 
Zacks offers investors useful rankings for lower risk growth stocks for retirement portfolios  The following are a few selections that merit a closer look  CVS Health  NYSE CVS   Medifast  MED  and Orix  IX   Earnings and revenue has seen growth of at least 5  or higher over the last five years  with a beta of 1 or lower 
Do You Know the Top 9 Retirement Investing Mistakes 
Whether you re planning to retire early or not  don t let investing mistakes derail your plans 
If you have  500 000 or more to invest and want to learn more  click the link to download our free report  9 Retirement Mistakes that will Ruin Your Retirement This report will help you steer clear of the most common mistakes  like trying to time the market  lack of diversification in your portfolio  and many more  Get Your FREE Guide Now",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/want-to-retire-early-learn-the-intelligent-investing-secret--october-28-2019-200478921,200478921
198733,420249,CVS,CVS Health  CVS  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"The market expects CVS Health  NYSE CVS  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on November 6  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drugstore chain and pharmacy benefits manager is expected to post quarterly earnings of  1 77 per share in its upcoming report  which represents a year over year change of  2 3  
Revenues are expected to be  63 03 billion  up 33 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 75  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for CVS Health 
For CVS Health  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 05  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that CVS Health will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that CVS Health would post earnings of  1 70 per share when it actually produced earnings of  1 89  delivering a surprise of  11 18  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
CVS Health appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-reports-next-week-wall-street-expects-earnings-growth-200480126,200480126
198734,420250,CVS,U S  asks judge to give final approval to settlement with CVS to buy Aetna,news,"WASHINGTON  Reuters    The U S  Justice Department formally asked a judge on Monday to approve its deal to allow CVS Health Corp  NYSE CVS  to merge with insurer Aetna  NYSE AET    Judge Richard Leon of the U S  District Court for the District of Columbia scolded the government and parties late last year for closing the  69 billion dollar merger before the consent order was approved by the court  In response  CVS offered to halt some integration of the two companies  With the government s request for final approval of the merger  Leon may sign off on the deal with no further ado or may decide to hold a hearing to allow critics to raise their concerns  said Andre Barlow of the law firm Doyle  Barlow and Mazard PLLC  an antitrust expert who has been following the case  The Justice Department approved the merger of CVS  a U S  pharmacy chain and benefits manager  and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  Both deals have closed   
CVS declined comment for this story ",2019-02-25,Reuters,https://www.investing.com/news/stock-market-news/us-asks-judge-to-give-final-approval-to-settlement-with-cvs-to-buy-aetna-1789854,1789854
198735,420251,CVS,U S  seeks to cut dialysis costs with more home care versus clinics,news,"By Caroline Copley and Caroline Humer  Reuters    The Trump administration is working on a new payment approach for treating kidney disease that favors lower cost care at home and transplants  a change that would upend a dialysis industry that provides care in thousands of clinics nationwide  The goal is to reduce the  114 billion paid by the U S  government each year to treat chronic kidney disease and end stage renal disease  a top area of spending  The U S  Centers for Medicare and Medicaid Services  CMS   which provides Medicare health benefits to more than 55 million Americans  is looking at a trial payment design that would improve care in the early stages of kidney disease  increase access to kidney transplants and favor home dialysis over clinic based treatment  CMS head Seema Verma told Reuters in an interview    A lot of the way the program has been set up  it creates a lot of perverse incentives to actually keep people in an institutional setting   said Verma  who first signaled in a speech this year that CMS wanted to curb costs and improve quality of life for kidney disease patients through a new payment structure  Indeed  consultants say home dialysis has been slow to take off because doctors prefer to send patients to clinics  The changes pose a particular risk to DaVita Inc and Fresenius Medical Care AG  which operate more than 5 000 U S  dialysis clinics and control around 70 percent of the market   Shares in Fresenius Medical Care were down 3 percent at 0817 GMT after the Reuters report  They could also provide an opening for new rivals  including CVS Health Corp  NYSE CVS   which seeks to offer lower cost home dialysis  and startups Cricket Health and Somatus  which focus on early intervention to slow progression to kidney failure   We have to be open to what I m hearing coming out of  CMS   that they want to look at different ways for us being paid and how can we really try to create more opportunities for these patients to be better served   Fresenius Medical Care Chief Executive Rice Powell told analysts  The company is expanding in home dialysis with its  2 billion purchase of NxStage  a U S  maker of home use dialysis machines  Fresenius Medical Care said it plans to convert some dialysis clinics into  transitional care units  to train people for care at home  It aims to boost the percentage of its U S  customers using home dialysis to more than 15 percent by 2022 from around 12 percent currently  DaVita recently launched new technology  including remote monitoring and telehealth  to improve the patient experience at home and  champions  home dialysis  a company spokeswoman said  KIDNEY DISEASE ON THE RISE Nearly 15 percent of the U S  adult population was suffering from chronic kidney disease in 2018  fueled by growing rates of diabetes and hypertension  according to the government s U S  Renal Data System  In 2016  more than 720 000 people were estimated to have progressed to kidney failure  That is forecast to climb as high as 1 26 million people by 2030  Without a transplant  patients with end stage kidney disease require dialysis to clear their blood of waste and excess fluid  which involves spending three to five hours hooked up to a machine three times a week   Home dialysis would not only be cheaper  since it would not require nursing assistance once a patient is properly trained  but could be done at night  freeing people for a regular work schedule  DaVita and Fresenius Medical Care offer two forms of home dialysis  hemodialysis  which requires a machine and special filter much like in clinics  and peritoneal dialysis  which utilizes the lining of the abdomen to filter waste from the blood  CMS is considering the benefits of peritoneal dialysis  which is used more widely outside the United States  Peritoneal dialysis machines are around the size of a desktop printer  smaller than home hemodialysis machines  DaVita believes home dialysis could eventually account for up to 25 percent of treatments if physicians are educated on its merits  and it plans to build fewer new clinics  Meanwhile  U S  pharmacy chain CVS is preparing to enter the dialysis business and has more retail outlets than Fresenius Medical Care and DaVita clinics combined  as well as deep enough pockets to drive disruption   CVS said last April its kidney care plans involve a program to identify the disease early and delay the need for dialysis  It will also seek regulatory approval for its own home dialysis device   CVS Chief Executive Larry Merlo  in an interview  said it wants a home care solution  which is going to be more patient friendly and we believe lower cost than the therapies that exist today    Medicare pays for home dialysis  but adoption has been slow  Only around 8 percent of end stage renal disease patients were on home dialysis in 2016   The U S  Department of Health and Human Services  which oversees CMS  is also seeking to increase the number of kidney transplants through proposals it hopes will expedite access to organs  More than 20 000 people received kidney transplants in the United States in 2018  a fraction of the more than 100 000 people on the waiting list   CMS has also finalized new rules that beginning next year will offer financial incentives for new drugs to treat kidney failure   KILLER GAP  Proponents of home care say more frequent dialysis can improve patient outcomes by avoiding the so called  killer gap    a two day wait between clinic sessions associated with increased hospitalization and death  Hospitalization accounts for about 40 percent of Medicare spending on dialysis patients   Imagine if we could keep patients out of the hospital by dealing with this killer gap     giving them the tools to treat themselves   said John Milad  CEO of Britain based Quanta Dialysis Technologies  which is working on a simpler dialysis machine for home use   The savings that are available there are as big as everything that is being spent on dialysis   CVS is working on its home hemodialysis device with DEKA Research   Development Corp  a New Hampshire based company owned by Segway scooter inventor Dean Kamen  according to sources familiar with the arrangement  Startups including Quanta  France s Physidia and California based Outset Medical  are working on user friendly dialysis machines for home use  U S  based Cricket Health and Somatus use data analysis to detect high risk chronic kidney disease patients earlier  educate them on treatment options and provide home dialysis services   Cricket CEO Arvind Rajan said the government could save money via a flat fee to manage patients earlier in the disease and reward providers who keep costs down   
 The most profitable thing you can do is keep a patient from kidney failure and the least profitable thing you can do is have the patient on in center dialysis   he said ",2019-03-04,Reuters,https://www.investing.com/news/stock-market-news/us-seeks-to-cut-dialysis-costs-with-more-home-care-versus-clinics-1796575,1796575
198736,420252,CVS,U S  judge assessing CVS merger with Aetna orders hearing,news,"By Diane Bartz WASHINGTON  Reuters    A U S  judge who has been asked to sign off on a government agreement that allowed CVS Health Corp  NYSE CVS  to buy health insurer Aetna  NYSE AET  ordered a hearing for April 5  Judge Richard Leon of the U S  District Court for the District of Columbia issued the order on Thursday  saying that he wanted the hearing to discuss which witnesses  if any  should testify before he decides whether to approve the government s deal with the companies  The  69 billion transaction closed in November  The Justice Department approved the merger of CVS  a U S  pharmacy chain and benefits manager  and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  That deal has also closed  Judges usually approve merger agreements that the government strikes with companies with little fanfare but Leon has balked  In December  he said he was  less convinced  than the government that the asset sale to WellCare would resolve antitrust concerns  Critics of the deal include the American Medical Association and the AIDS Healthcare Foundation   Pending Leon s approval  CVS agreed to temporarily allow Aetna to independently make critical product  pricing and personnel decisions  
Both CVS and the Justice Department declined comment ",2019-03-14,Reuters,https://www.investing.com/news/stock-market-news/us-judge-assessing-cvs-merger-with-aetna-orders-hearing-1807869,1807869
198740,420256,CVS,Why CVS Health  CVS  Is Poised To Beat Earnings Estimates Again,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  CVS Health  NYSE CVS   which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  could be a great candidate to consider 
This drugstore chain and pharmacy benefits manager has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 9 59  
For the most recent quarter  CVS Health was expected to post earnings of  1 70 per share  but it reported  1 89 per share instead  representing a surprise of 11 18   For the previous quarter  the consensus estimate was  1 50 per share  while it actually produced  1 62 per share  a surprise of 8  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for CVS Health  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
CVS Health currently has an Earnings ESP of  0 46   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/why-cvs-health-cvs-is-poised-to-beat-earnings-estimates-again-200471201,200471201
198741,420257,CVS,Signs That Your Trading Will Ruin Your Retirement   October 07  2019,opinion,"You have a significant retirement portfolio  You re an experienced investor  You ve done pretty well at picking stocks  You probably even own a few of Zacks Top Retirement stock picks like 
EQT Midstream Partners  LP  EQM   CVS Health  NYSE CVS  and Brinker International  EAT  
If you did something similar  would it be advisable for you to trade your own retirement nest egg 
Maybe   if you re an exceptional investor who can expertly manage risk and keep up perfectly resolute emotional control in the face of market volatility  Be that as it may  for most investors  there might be better ways to accomplish long term retirement investing objectives 
That s because the risk   reward scenario and investing approach is completely different for long term wealth building and active stock trading 
Diversification vs  Stock Picking
While stock picking can potentially result in outsized returns  its outsized concentrated risk can pose significant hazards for retirement investors 
In fact  a study done by Hendrik Bessembinder revealed that only 4  of equities produced all of the stock market s gains over the last 90 years  All other stocks  broke even  with the increases of 38  canceled out by the losses of the bottom 58  
For even the most expert stock pickers  the chances for long term achievement are thin 
Is Successful Investing a Mind Game 
Investors think they can make rational decisions  but research shows that the opposite is often true  A recent DALBAR study tracked investors from 1986 to 2015 and found that the average investor substantially underperformed compared to the S P 500  Over 30 years  the S P 500 returned 10 35   but the average investor return was just 3 66  
Importantly  this period included the 1987 crash and big bear markets in 2000 and 2008  but also the bull market of the 1990s 
This study suggests that one key reason for investor underperformance is trying to time volatile markets   and that irrational behavior biases tend to compound investor mistakes 
Interestingly  even savvy traders tend to underperform because they can t help but allow emotions to drive investment decisions  They may be overconfident and misjudge risk  latch onto a price target  or perceive a pattern that isn t there  This  behavior gap   over the long term  can be catastrophic with potential underperformance of hundreds of thousands of dollars sabotaging your retirement 
The Key Takeaway for Retirement Investors
Your retirement portfolio ought to be dealt with a technique of performance over decades   not days  weeks or quarters  Most self coordinated investors will in general miss the mark with regards to long term outcomes 
Does that mean you should give up trading  Not necessarily  One solution is to take 10  of your investable assets and trade to generate alpha and seek outsized returns 
However  the major part of your wealth   those assets reserved for retirement   ought to be invested utilizing a more careful  conservative  risk management strategy to produce steady  compounded returns so you can securely achieve your retirement objectives 
Did you know that one in six people retire a multi millionaire 
Read our just released report  7 Things You Can Do Now to Retire a Multi Millionaire This report can help you maintain and increase assets heading into retirement while avoiding costly mistakes  Click here for a free report  ",2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/signs-that-your-trading-will-ruin-your-retirement--october-07-2019-200471262,200471262
198742,420258,CVS,CVS Health  CVS  Stock Moves  0 4   What You Should Know,opinion,"CVS Health  NYSE CVS  closed at  61 99 in the latest trading session  marking a  0 4  move from the prior day  This move was narrower than the S P 500 s daily loss of 0 45   At the same time  the Dow lost 0 36   and the tech heavy Nasdaq lost 0 33  
Coming into today  shares of the drugstore chain and pharmacy benefits manager had lost 0 83  in the past month  In that same time  the Retail Wholesale sector lost 1 25   while the S P 500 gained 0 59  
Investors will be hoping for strength from CVS as it approaches its next earnings release  On that day  CVS is projected to report earnings of  1 77 per share  which would represent year over year growth of 2 31   Our most recent consensus estimate is calling for quarterly revenue of  63 04 billion  up 33 37  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  6 97 per share and revenue of  252 44 billion  These totals would mark changes of  1 55  and  30 06   respectively  from last year 
Investors might also notice recent changes to analyst estimates for CVS  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 05  higher  CVS currently has a Zacks Rank of  2  Buy  
In terms of valuation  CVS is currently trading at a Forward P E ratio of 8 93  For comparison  its industry has an average Forward P E of 8 94  which means CVS is trading at a discount to the group 
Also  we should mention that CVS has a PEG ratio of 1 36  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Retail   Pharmacies and Drug Stores stocks are  on average  holding a PEG ratio of 1 34 based on yesterday s closing prices 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 175  putting it in the bottom 32  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-stock-moves-04-what-you-should-know-200471294,200471294
198743,420259,CVS,CVS Tumbles After Fresh  2 2 Billion Hit to Long Term Care Business,news,"Investing com   Shares in CVS  NYSE CVS  tumbled Wednesday after the company was forced to take another  2 2 billion charge against its struggling long term care business  built around its 2015 acquisition of Omnicare 
The charge follows a  3 9 billion hit for the same business line only six months ago  It overshadowed a set of results that were otherwise largely in line with expectations  but also hinted at a challenging year as it digests the  70 billion acquisition of Aetna  NYSE AET  
The shares fell 5 1  to  66 30 in premarket trading in response 
 The LTC business has continued to experience industry wide challenges that have impacted our ability to grow the business at the rate that was originally estimated when the Company acquired Omnicare   CVS said in a statement 
It said it had decided to write off more goodwill after  LTC management submitted an updated final budget for 2019 which showed significant additional deterioration in the reporting unit s projected financial results for 2019  
The company forecast that adjusted earnings per share will fall this year to a range of  6 68 to  6 88  from  7 08 in 2018  due in part to a higher debt burden after the Aetna acquisition  It expects operating cash flow of between  9 8 billion and  10 3 billion  up from  8 9 billion in 2018 
 2019 will be a year of transition as we integrate Aetna and focus on key pillars of our growth strategy   chief executive Larry Merlo said in a statement 
 We are fully aware of the need to address the impact of certain headwinds that are having a disproportionate impact in 2019 compared to prior years  and importantly  we are taking comprehensive actions to move past them   he added in a nod to the LTC unit s troubles 
The firm reported earnings per share of  2 14 on revenue of  54 42B  Analysts polled by Investing com forecast EPS of  2 09 on revenue of  54 61B  That compared to EPS of  1 92 on revenue of  48 39B in the same period a year earlier  The company had reported EPS of  1 73 on revenue of  47 27B in the previous quarter 

CVS Health Corp follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings beat analyst s expectations on January 29  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 63 on revenue of  13 9B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-20,Investing.com,https://www.investing.com/news/stock-market-news/cvs-health-corp-earnings-beat-revenue-misses-in-q4-1784550,1784550
198744,420260,CVS,CVS Health s forecast points to more pain at long term care business,news," Reuters    CVS Health Corp  NYSE CVS  blamed weakness in its long term healthcare business for a shortfall in its full year profit forecast  indicating more troubles at the unit it bought about four years ago  The company s shares fell 7 percent as it also revealed a  2 2 billion goodwill impairment charge related to the business  which houses the Omnicare unit  in the fourth quarter  taking the total charges at the unit to more than  6 billion in the past year  The Omnicare business  which the company bought for about  10 billion in 2015  provides prescription drugs to nursing homes and other long term care centers  It has been hit by lower occupancy rates in skilled nursing facilities and reimbursement pressures in the past few quarters   The long term care business has continued to experience industry wide challenges that have impacted our ability to grow the business at the rate that was originally estimated when the company acquired Omnicare   the company said in a statement  CVS said the unit s final budget for 2019 showed a significant deterioration in its forecasts for 2019  resulting in further updates to its long term forecast beyond 2019   We are taking comprehensive actions to move past them   Chief Executive Officer Larry Menlo said  The company  which bought health insurer Aetna  NYSE AET  last year  forecast full year 2019 adjusted profit of  6 68 per share to  6 88 per share  while analysts on average currently expect  7 41 per share  according to IBES data from Refinitiv  Evercore ISI analysts said the main issues with the company appeared to be long term care challenges  pharmacy reimbursement pressure  lower drug price rise and questions around rebates  For the fourth quarter  CVS Health earned  2 14 per share excluding items  beating the average estimate of  2 05 per share  Same store sales at the company s pharmacies that sell prescription drugs rose 7 4 percent in the quarter  compared with an expected 6 1 percent rise forecast by analysts  The company booked a net loss of  419 million in the fourth quarter ended Dec  31  compared with a net income of  3 29 billion  a year earlier when it benefited from changes to U S  tax laws  
Revenue rose to  54 42 billion in the quarter from  48 39 billion a year earlier ",2019-02-20,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-quarterly-revenue-rises-125-percent-1784618,1784618
198745,420261,CVS,Stocks   Wall Street Mixed After Earnings  Trade Talk Caution,news,"Investing com   Wall Street was mixed on Wednesday amid downbeat earnings releases and as investors waited for news of trade talks between the U S  and China 
The S P 500 fell half a point  or 0 02   as of 9 44 AM ET  14 44 GMT   while the Dow gained 1 point  or 0 01   and the tech heavy Nasdaq Composite increased 10 points  or 0 14  
A fresh round of talks began on Tuesday in Washington  with higher level discussions scheduled for later this week  U S  President Donald Trump repeated Tuesday that he would consider extending the March 1 deadline  when tariffs on about  200 billion worth of Chinese imports are set to rise to 25  from the current 10  if a deal is not reached 
 A market friendly outcome this week will be for both sides to agree on extending the March 1 deadline  which should provide more time for finding a middle ground on trade policy   FXTM analyst Lukman Otunuga wrote in a client note   Trump stating that the talks are  very complex  and the current March deadline is not a  magical date    means  a breakthrough deal is still some distance away  
US Global Investors  NASDAQ GROW  was among the top gainers after the morning bell  rising 3   while Facebook  NASDAQ FB  gained 0 75  and  Alibaba   NYSE BABA  increased 1 15  
CVS Health  NYSE CVS  slumped 8 9  after it missed its full year profit forecast  while Southwest Airlines  NYSE LUV  dipped 4 6  after it cuts its first quarter forecast for revenue per seat mile amid weak passenger demand 
LendingClub  NYSE LC  fell 10 8  after the online lender said it expected a bigger than expected quarterly loss due to economic uncertainty 
On the central banking front  the Federal Reserve will release the minutes from its Jan  30 policy meeting at 2 00 PM ET  19 00 GMT  Wednesday  Investors will pore over the minutes for further details on the bank s pause in rate hikes 
In commodities  gold futures rose 0 17  to  1 347 15 a troy ounce  while crude oil fell 0 39  to  56 23 a barrel  The U S  dollar index  which measures the greenback against a basket of six major currencies  inched up 0 10  to 96 44 ",2019-02-20,Investing.com,https://www.investing.com/news/stock-market-news/stocks--wall-street-mixed-after-earnings-trade-talk-caution-1784859,1784859
198747,420263,CVS,Are Investors Undervaluing CVS Health  CVS  Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits  For example  value investors will be interested in stocks with great grades in the  Value  category  When paired with a high Zacks Rank   A  grades in the Value category are among the strongest value stocks on the market today 
One stock to keep an eye on is CVS Health  NYSE CVS   CVS is currently holding a Zacks Rank of  2  Buy  and a Value grade of A  The stock holds a P E ratio of 8 78  while its industry has an average P E of 8 93  Over the past year  CVS s Forward P E has been as high as 11 05 and as low as 7 34  with a median of 8 50 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  This is a prefered metric because revenue can t really be manipulated  so sales are often a truer performance indicator  CVS has a P S ratio of 0 35  This compares to its industry s average P S of 0 36 
Value investors will likely look at more than just these metrics  but the above data helps show that CVS Health is likely undervalued currently  And when considering the strength of its earnings outlook  CVS sticks out at as one of the market s strongest value stocks ",2019-09-26,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-cvs-health-cvs-right-now-200468720,200468720
198751,420267,CVS,Is CVS Health  CVS  A Great Value Stock Right Now ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
Luckily  Zacks has developed its own Style Scores system in an effort to find stocks with specific traits  Value investors will be interested in the system s  Value  category  Stocks with both  A  grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now 
One company to watch right now is CVS Health  NYSE CVS   CVS is currently sporting a Zacks Rank of  2  Buy  and an A for Value  The stock is trading with P E ratio of 8 41 right now  For comparison  its industry sports an average P E of 8 44  Over the past 52 weeks  CVS s Forward P E has been as high as 11 05 and as low as 7 34  with a median of 8 50 
These are just a handful of the figures considered in CVS Health s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that CVS is an impressive value stock right now ",2019-09-01,Zacks Investment Research,https://www.investing.com/analysis/is-cvs-health-cvs-a-great-value-stock-right-now-200460792,200460792
198752,420268,CVS,CVS Health  CVS  Up 6 3  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for CVS Health  NYSE CVS   Shares have added about 6 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is CVS Health due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  CVS Health s PBM Selling Season Remains Solid  Retail GrowsCVS Health second quarter 2019 adjusted earnings per share  EPS  of  1 89 increased 11 8  year over year and also exceeded the Zacks Consensus Estimate by 11 2   The quarter s adjusted EPS considered certain transaction and integration costs pertaining to the buyout of Aetna  NYSE AET  On a reported basis  the company registered earnings of  1 49 per share against the year ago loss of  2 52 Moreover  total revenues in the second quarter surged 35 2  year over year  after adjusting the interest income on financing the Aetna acquisition  adjusted revenues increased 35 8  year over year  to  63 43 billion  The same also topped the Zacks Consensus Estimate of  62 61 billion by 1 3  The year over year revenue rise was primarily driven by the acquisition of Aetna  expanded volume and the brand name drug price inflation in both the Pharmacy Services and Retail LTC segments  partially offset by a persistent reimbursement pressure in the Retail LTC  price compression in the Pharmacy Services segment and an increased generic dispensing rate Quarter in Detail In the second quarter of 2019  the company realigned the composition of its segments  As a result of this move  the company s SilverScript Medicare Part D prescription drug plan  PDP  was shifted from the Pharmacy Services segment to the Health Care Benefits one  In addition  the mail order and specialty pharmacy operations of Aetna were transitioned from the Health Care Benefits segment to the Pharmacy Services one Pharmacy Services revenues inched up 4 2  to  34 84 billion in the reported quarter  driven by growth in total pharmacy claims volume and the brand name drug price inflation  This was  however  partially offset by a continued client price compression and a hiked generic dispensing rate Total pharmacy claims processed rose 4  on a 30 day equivalent basis  attributable to net new business and the steady adoption of Maintenance Choice offerings Revenues from CVS Health s Retail LTC were nudged up 3 7  year over year to  21 45 billion  Per the company  the result was based on higher prescription volume and branded drug price inflation  partially offset by a relentless reimbursement pressure and the impact of recent generic introductions  Front store revenues represented 22 7  of total Retail LTC revenues in the reported quarter  primarily banking on improved health product sales Total prescription volume grew 5 9  on a 30 day equivalent basis  boosted by the steady uptake of patient care programs and collaborations with PBMs as well as the preferred status in a number of Medicare Part D networks Within Health Care Benefits segment  the company registered revenues of  17 40 billion in the June quarter Gross profit skyrocketed 204  to  24 46 billion  Accordingly  gross margin expanded 2141 bps to 38 6   Adjusted operating margin in the quarter under review also grew 1911 bps to 25 9  despite 65 2  escalation in operating expenses to  8 04 billion OutlookCVS Health has updated its 2019 guidance Adjusted EPS expectation has been raised to the band of  6 89  7 from the earlier provided range of  6 75  6 90  The Zacks Consensus Estimate for earnings is pegged at  6 84  lower than the company s guided range  This apart  the company s 2019 adjusted operating profit estimate has been lifted to the  15 2  15 4 billion band from the previous view of 15  15 2 billion Further  the company has upped its cash flow from operations guidance to  10 1  10 6 billion from  9 8  10 3 billion The company has also issued view for the third quarter of 2019  Adjusted EPS is projected in the range of  1 75  1 79  The Zacks Consensus Estimate for earnings of  1 67 remains below the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in estimates revision  The consensus estimate has shifted 5 77  due to these changes 
VGM Scores
Currently  CVS Health has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise CVS Health has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-09-05,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-up-63-since-last-earnings-report-can-it-continue-200462363,200462363
198753,420269,CVS,Top Ranked Momentum Stocks To Buy For September 16th,opinion,Here are four stocks with buy rank and strong momentum characteristics for investors to consider today  September 16th Westpac Banking Corporation  WBK   This financial services company has a Zacks Rank  2  Buy  and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 8  over the last 60 days Westpac Banking Corporation Price and Consensus   Westpac Banking s shares gained 7 4  over the last one month more than S P 500 s rise of 4 1   The company possesses a  of B Westpac Banking Corporation Price   CVS Health  NYSE CVS  Corporation  CVS   This healthcare company has a Zacks Rank  2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 5  over the last 60 days CVS Health Corporation Price and Consensus   CVS Health s shares gained 6 3  over the last one month  The company possesses a Momentum Score of B CVS Health Corporation Price   Hutchison China MediTech Limited  HCM   This pharmaceutical company has a Zacks Rank  2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 19 7  over the last 60 days Hutchison China MediTech Limited Price and Consensus   Hutchison China MediTech s shares gained 6  over the last one month  The company possesses a Momentum Score of B Hutchison China MediTech Limited Price   Live Oak Bancshares  Inc   LOB   This nationwide bank that offers financial solutions has a Zacks Rank  2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 60  over the last 60 days Live Oak Bancshares  Inc  Price and Consensus   Live Oak s shares gained 7 2  over the last one month  The company possesses a Momentum Score of B Live Oak Bancshares  Inc  Price   See the Learn more about the  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-09-15,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-momentum-stocks-to-buy-for-september-16th-200465044,200465044
198754,420270,CVS,Judge accepts CVS offer on Aetna while reviewing consent decree,news,"WASHINGTON  Reuters    A U S  federal judge reviewing an agreement between the government and CVS Health Corp  N CVS  allowing it to buy health insurer Aetna  NYSE AET  has indicated that he will not halt most integration between the two companies  Judge Richard Leon said in an order on Friday evening that he would accept CVS s offer to allow Aetna to independently make critical product  pricing and personnel decisions during his review   Based on CVS s constructive and appropriate representations  I am satisfied that  so long as these measures remain in place  the assets involved in the challenged acquisition will remain sufficiently separate  during the review period    Leon wrote in his order  The Justice Department approved the  69 billion merger of CVS  a U S  pharmacy chain and benefits manager  and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  N WCG   Both deals have closed   
Antitrust consent decrees are usually approved without much fanfare but Leon has said that he was  less convinced  than the government that the agreement would resolve antitrust concerns ",2018-12-22,Reuters,https://www.investing.com/news/stock-market-news/judge-accepts-cvs-offer-on-aetna-while-reviewing-consent-decree-1729522,1729522
198755,420271,CVS,U S  government says shutdown may slow resolution of CVS Aetna court process,news,"By Diane Bartz WASHINGTON  Reuters    The Justice Department has said in a court filing that a partial government shutdown could delay its response to comments on pharmacy chain CVS Health  NYSE CVS  Corp s purchase of health insurer Aetna  NYSE AET   a necessary step in a court giving final approval to the deal  Judge Richard Leon of the U S  District Court for the District of Columbia has been reviewing a consent decree reached by the government and the companies in October to allow their  69 billion merger  The deal has closed  although Judge Leon has required that some aspects of integration be halted during the review process  Additionally  the Justice Department is required to respond to public comments on the consent agreement  It said in a court filing late on Tuesday that a lapse in funding as of midnight on Jan  4 meant that the Antitrust Division could not process those comments until its appropriations were restored  An exception could be made if the court orders them to do so  the department said in the filing  The partial shutdown began hitting government agencies on Dec  22 as part of a battle between the White House  which is demanding billions to build a wall on the U S  border with Mexico  and congressional Democrats  who say the expenditure would be ineffective in slowing illegal immigration  
A spokesman for CVS had no immediate comment ",2019-01-09,Reuters,https://www.investing.com/news/stock-market-news/us-government-says-shutdown-may-slow-resolution-of-cvsaetna-court-process-1742430,1742430
198756,420272,CVS,Gov shutdown may slow resolution of CVS Aetna court process  DoJ says,news,CVS Health  NYSE CVS  fell 3 6  in today s trade after the U S  Department of Justice said in a court filing that a partial  government shutdown could delay its response to comments on the company s purchase of Aetna  NYSE AET   a necessary step in giving final approval to the deal Judge Leon of the D C  District Court has been reviewing a consent decree reached by the government  and the companies in October to allow the merger  the DoJ also is required to respond to public comments on the  consent agreement The DoJ said in a court filing that a  lapse in funding as of midnight on Jan  4 meant that its Antitrust  Division could not process the comments until its appropriations were  restored Now read ,2019-01-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/gov-shutdown-may-slow-resolution-of-cvsaetna-court-process-doj-says-1743089,1743089
198760,420276,CVS,CVS Health  CVS  Beats Q2 Earnings And Revenue Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 89 per share  beating the Zacks Consensus Estimate of  1 70 per share  This compares to earnings of  1 69 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 11 18   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  1 50 per share when it actually produced earnings of  1 62  delivering a surprise of 8  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  63 43 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 1 31   This compares to year ago revenues of  46 71 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have lost about 17 5  since the beginning of the year versus the S P 500 s gain of 15  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 67 on  63 17 billion in revenues for the coming quarter and  6 84 on  252 60 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 20  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-beats-q2-earnings-and-revenue-estimates-200452111,200452111
198761,420277,CVS,Should Value Investors Buy CVS Health  CVS  Stock ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits  For example  value investors will be interested in stocks with great grades in the  Value  category  When paired with a high Zacks Rank   A  grades in the Value category are among the strongest value stocks on the market today 
One company value investors might notice is CVS Health  NYSE CVS   CVS is currently sporting a Zacks Rank of  2  Buy  and an A for Value  The stock has a Forward P E ratio of 8 30  This compares to its industry s average Forward P E of 8 37  Over the last 12 months  CVS s Forward P E has been as high as 11 05 and as low as 7 34  with a median of 8 71 
These are just a handful of the figures considered in CVS Health s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that CVS is an impressive value stock right now ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-cvs-health-cvs-stock-200453656,200453656
198762,420278,CVS,U S  judge raises prospect of not approving CVS Aetna deal,news,"WASHINGTON  Reuters    In an unusual move on Thursday  a federal judge raised the prospect of not approving CVS Health Corp s  N CVS  deal to buy insurer  Aetna Inc   NYSE AET    which closed earlier this week  during a routine portion of the legal process   Judge Richard Leon of the U S  District Court for the District of Columbia objected to what he said was the government s and companies  treatment of him as a  rubber stamp  for the deal  noting that CVS had closed its deal to buy Aetna for  69 billion on Wednesday  CVS said in a statement   It s commonplace for acquisitions to close before this final step in the process is complete  and our focus remains on delivering on the combined company s potential    The Justice Department did not immediately return a request for comment   The Justice Department gave its OK in October for the merger of CVS  a pharmacy and benefits manager firm  and Aetna on condition that the health insurer sell its Medicare Part D drug plan business to WellCare Health Plans  The court must approve the agreement between the government and merging companies   Leon raised the prospect of not deciding on the deal until the summer  or perhaps rejecting it  before setting another hearing for Monday   I was reviewing your motion  which  of course is not opposed  And I kind of got this uneasy feeling that I was being kept in the dark  kind of like a mushroom   Leon told lawyers for the Justice Department and the two companies  noting that the American Medical Association  among others  had objected to the deal   I m very concerned  very concerned that you all are proceeding on a rubber stamp approach to this   he told them  according to a transcript of the hearing  
 This story corrects attribution in paragraph 3 to reflect merged companies ",2018-11-29,Reuters,https://www.investing.com/news/stock-market-news/us-judge-raises-prospect-of-not-approving-cvsaetna-deal-1705832,1705832
198763,420279,CVS,U S  judge says may order halt to integration of CVS Aetna,news,"By Diane Bartz WASHINGTON  Reuters    A federal judge who has been asked to sign off on the government s decision to approve CVS Health Corp s  N CVS  acquisition of insurer  Aetna Inc   NYSE AET  indicated on Monday he may ask the companies to halt integration pending his decision  Judge Richard Leon of the U S  District Court for the District of Columbia complained at a hearing last week that the two sides had treated him as a  rubber stamp  for the deal  CVS closed the  69 billion transaction last week and began the integration process  Leon said at a hearing on Monday that he would issue an order asking the two sides to argue why he should not require CVS and Aetna to be held separate until he decides whether he will approve the consent agreement reached in October between the companies and the U S  Justice Department  Makan Delrahim  the assistant attorney general for antitrust  declined comment after the hearing  A CVS spokesman said in an email after the hearing   CVS Health and Aetna are one company  and our focus is on transforming the consumer health experience   Leon said during the brief hearing that he was  concerned  the Justice Department s filing with the court pointed to antitrust issues  In October  the Justice Department approved the merger of CVS  a pharmacy chain and benefits manager  and Aetna on condition that the health insurer sell its Medicare Part D drug plan business to WellCare Health Plans Inc  N WCG    Most deals struck between the government and companies to resolve antitrust concerns are approved by federal courts with little fuss under the 1974 Tunney Act  which requires courts to ensure the agreement is in the public interest  
Companies generally do not wait for final court approval before closing their transactions ",2018-12-03,Reuters,https://www.investing.com/news/stock-market-news/judge-considering-ordering-halt-to-cvsaetna-integration-1708932,1708932
198764,420280,CVS,U S  judge concerned over government nod for CVS Aetna deal,news,"WASHINGTON  Reuters    A federal judge who has been asked to sign off on the U S  government s decision to approve CVS Health Corp s  N CVS  acquisition of insurer  Aetna Inc   NYSE AET  said Tuesday he was  less convinced  than the government that the companies had struck a deal that ensured the merger was legal under antitrust law  Judge Richard Leon of the U S  District Court for the District of Columbia had complained last week in a hearing that the two sides had treated him as a  rubber stamp  for the agreement  CVS closed the  69 billion transaction last week and began the integration process   At this stage  I am less convinced of the sufficiency of the government s negotiated remedy than the government is   he wrote in the order issued on Tuesday  The Justice Department approved the merger of CVS  a pharmacy chain and benefits manager  and Aetna on condition that the health insurer sell its Medicare Part D drug plan business to WellCare Health Plans Inc  N WCG   That sale was completed last month  Also in the order  Leon asked the government and the companies to file a brief by Dec  14 to show why their integration should not be halted while he considers whether or not to approve the consent decree reached in October  Most consent agreements that the antitrust agencies strike with companies to resolve competitive concerns are approved by federal courts with little fuss under the 1974 Tunney Act  which requires courts to ensure the agreements are in the public interest  
Companies generally do not wait for final court approval before closing their transactions ",2018-12-04,Reuters,https://www.investing.com/news/stock-market-news/us-judge-concerned-over-government-nod-for-cvsaetna-deal-1710638,1710638
198765,420281,CVS,CVS offers  guaranteed net cost  for pharmacy benefit clients,news,By Deena Beasley  Reuters    Pharmacy chain and benefits manager CVS Health Corp  NYSE CVS  on Wednesday said as of Jan  1 it will offer a new prescription benefit option guaranteeing its health plan clients 100 percent of any rebates  discounts or other fees paid by drugmakers  The new plan model is aimed at providing greater drug cost simplicity  predictability and transparency  CVS said   The  guaranteed net cost  option could also deflect growing criticism that pharmacy benefit managers  PBMs  reap gains off the widening gap between pharmaceutical list prices and their lower net cost after hefty rebates paid by drugmakers to secure coverage and access to their products  President Donald Trump  who has promised lower prescription drug costs for U S  consumers  earlier this year singled out industry  middlemen   such as PBMs and insurers  and the common practice of drugmakers offering rebates to them  PBMs like CVS  Caremark unit make a profit by using their scale to negotiate drug prices and by providing cost management strategies to health plans  Under its new option  CVS takes on the risk of drug price inflation and shifts in drug use   at least for the term of each contract  The new model guarantees average spending per prescription across each distribution channel   retail  mail order and specialty pharmacy  Derica Rice  president of CVS Caremark  said in an interview   Rival PBM Express Scripts  NASDAQ ESRX  Holding Co last month announced a new drug coverage list aimed at accommodating reduced prices for brand name drugs as a way to encourage drugmakers to move away from paying rebates after a prescription is filled  Trump Administration officials have also suggested ending the rebate practice    If rebates go away  this model accommodates that   Rice said   But as long as we get to the lowest net cost we are indifferent    He said plan sponsors still have the option to choose whether to pass on any rebates to patients at the pharmacy counter  CVS said it is first offering the net cost model to employer sponsored plans  but will eventually make it available to all clients  including government health plans  Rice said both existing and new clients have already chosen to adopt the net cost model next year  but he declined to estimate how many clients were expected to make the switch  The company  which last week completed its  69 billion acquisition of health insurer Aetna  NYSE AET   said it hopes that other PBMs will shift to similar net cost pricing models  allowing clients the ability to assess the net cost of their pharmacy benefit and select a PBM based on that criteria ,2018-12-05,Reuters,https://www.investing.com/news/stock-market-news/cvs-offers-guaranteed-net-cost-for-pharmacy-benefit-clients-1711695,1711695
198766,420282,CVS,Acorda down 12  on Goldman cut in premarket analyst action,news,Novavax   NASDAQ NVAX  initiated with Outperform rating and  4  87  upside  price target at Oppenheimer  Shares up 3  premarket Synthetic Biologics  NYSEMKT SYN  initiated with Buy rating at Alliance Global Partners BioTime  NYSEMKT BTX  resumed with Outperform rating and  3 50  169  upside  price target at Oppenheimer  Shares up 2  premarket CVS Health  NYSE CVS  resumed with Outperform rating and  100 price target at Leerink Partners  Shares up 2  premarket Medical Properties  NYSE MPW  upgraded to Market Perform at  Wells Fargo   NYSE WFC   Shares up 1  premarket  Acorda Therapeutics   NASDAQ ACOR  downgraded to Sell with a  10  47  downside risk  price target citing limited market opportunities for Parkinson s med Inbrija  levodopa inhalation powder   Shares down 12  premarket  Pfizer   NYSE PFE  downgraded to Neutral with a  46  4  upside  price target at JPMorgan  NYSE JPM   Shares down 1  premarket Quidel  NASDAQ QDEL  downgraded to Hold with a  51 price target at Craig Hallum  Vanda Pharmaceuticals   NASDAQ VNDA  downgraded to Market Perform with a  29  flat  price target at Oppenheimer  Shares down 3  premarket Now read ,2018-12-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/acorda-down-12-on-goldman-cut-in-premarket-analyst-action-1717999,1717999
198767,420283,CVS,CVS defends settlement that allowed Aetna merger as judge assesses,news,"By Diane Bartz WASHINGTON  Reuters    CVS Health Corp  N CVS  defended on Friday an agreement with the U S  Justice Department which allowed it to purchase health insurer Aetna  NYSE AET  for  69 billion  a settlement that a federal judge is still assessing  The Justice Department approved the merger of CVS  a U S  pharmacy chain and benefits manager  and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  N WCG   That sale was completed in November  Now  the Justice Department and companies have found themselves in the unusual position of defending their antitrust settlement to a skeptical federal judge  Most judges approve consent decrees aimed at resolving competition concerns with no fanfare  and deals normally close before the judge rules  But Judge Richard Leon of the U S  District Court for the District of Columbia wrote in an order that he was  less convinced  than the government that the agreement would resolve antitrust concerns  He also has seemed annoyed that CVS closed its purchase of Aetna in October before his ruling  In its brief  filed on Friday  CVS said that the deal had been extensively reviewed and urged the judge to allow the companies to continue integrating while he examines the settlement reached with the government  CVS also noted that Aetna would be run separately from CVS  including decisions pricing and product offerings  during the court process   In its filing  the government urged the judge to allow the companies to press on with integration  saying he did not have the power to stop the merger  only to reject the settlement   The United States remains mindful of the court s responsibility to independently determine whether the proposed settlement is in the public interest and looks forward to discussing why the settlement meets that standard   the government said  While CVS and Aetna operate in largely separate business segments  the deal attracted opposition from groups including the American Medical Association and independent pharmacists  represented by the Pharmacists Society of the State of New York and Pharmacists United for Truth and Transparency  The two pharmacist groups asked Leon to allow them to argue against the deal  
 We are asking the court to stop the consolidation so that the concerns of patients  providers and consumers can be heard   said Debbi Barber  president of New York pharmacists ",2018-12-14,Reuters,https://www.investing.com/news/stock-market-news/cvs-defends-settlement-that-allowed-aetna-merger-as-judge-assesses-1722564,1722564
198768,420284,CVS,Judge mulls using monitor to oversee CVS during court process,news,"WASHINGTON  Reuters    A federal judge said on Tuesday that he was considering using a court appointed monitor to make sure CVS Health Corp  NYSE CVS  refrains from fully integrating with insurer Aetna  NYSE AET  while he examines the companies  settlement with the government  Judge Richard Leon of the U S  District Court for the District of Columbia held the hearing as part of his review of the antitrust settlement reached with the Justice Department to win approval for the companies   69 billion merger  Most judges approve consent decrees aimed at resolving competition concerns with no fanfare  and deals normally close before the judge rules  But Leon has written that he was  less convinced  than the government that asset sales made by Aetna would resolve antitrust concerns raised by the deal   The Justice Department approved the merger of CVS  a U S  pharmacy chain and benefits manager  and Aetna in October on condition that Aetna sell its Medicare prescription drug plan business to WellCare Health Plans Inc  N WCG   That sale was completed in November  In a brief filed on Dec  14  CVS said the deal had been extensively reviewed and urged the judge to allow the companies to continue integrating while he examines the settlement  
But it also pledged that Aetna would be run separately from CVS  including decisions pricing and product offerings  during the court process ",2018-12-18,Reuters,https://www.investing.com/news/stock-market-news/judge-mulls-using-monitor-to-oversee-cvs-during-court-process-1725605,1725605
198772,420288,CVS,3 Retail Stocks Likely To Stand Tall This Earnings Season,opinion,The earnings season has reached its pinnacle but a chunk of  sector releases are still awaited  The sector comprises of apparel   shoes  discount and department stores  e commerce players and retail pharmacy to name a few Per the latest   the sector is anticipated to witness top line growth of 7 6  with bottom line expected to remain flat year over year  The earnings season has witnessed releases from about 36  of the retail companies in the S P 500 cohort For the companies that have reported results so far  total earnings increased 3 9  on 10  higher revenues  We note 64 3  of the companies have been successful in beating earnings  and revenue estimates Factors Shaping the OutcomeA buoyant consumer environment and strategic endeavors undertaken at the company level are working in favor of the sector  It goes without saying that the sector s prospects are closely tied to the purchasing power of consumers  In fact  strengthening labor market  improved consumer confidence and rising disposable income are conducive to higher consumer spending  An uptick in this metric is always welcome news for retailers Notably  retailers are also making prudent investments  focusing on cost savings and constantly revisiting their loyalty and marketing programs to engage better with customers  These apart  enhancement of omni channel capacities  introduction of new brands and refurbishment of stores have also been playing crucial roles  Simultaneously  the companies are investing in renovations and improved checkouts and mobile point of sale capabilities to make stores attractive These efforts have been aiding the top line performance for quite some time now  and the to be reported quarter is not likely to be an exception  However  one cannot ignore the fact that the sector has turned highly competitive with the increasing dominance of e commerce players on account of consumers growing preference for online shopping  This has compelled a number of brick and mortar players to strengthen their digital ecosystem and bolster shipping and delivery capabilities While these endeavors drive sales  they entail high costs  Continued investments in innovation  data and analytics  and new capabilities to speed up the digital transformation results in higher operating costs  Additionally  any deleverage in SG A rate  higher labor and occupancy costs  and increased marketing and other store related expenses are concerns  Margins will remain one of the key areas to watch out for this earnings season Likely Winners for the SeasonAll said  we used the Zacks methodology and identified retail stocks that not only boast solid fundamentals but are also poised to beat earnings estimates this reporting cycle  Our research shows that for stocks with the combination of a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  and a positive   the chance of a positive earnings surprise is as high as 70   You can uncover the best stocks to buy or sell before they re reported with our  3 Prominent PicksJD com  Inc    NASDAQ JD   with a Zacks Rank  2 and an Earnings ESP of  17 86   deserves a place in your portfolio  The Zacks Consensus Estimate for the second quarter of 2019 is pegged at 9 cents  indicating an improvement from 5 cents reported in the year ago period  The company  which operates as an e commerce company and retail infrastructure service provider  has outperformed the Zacks Consensus Estimate by a wide margin in the past three quarters  You can see  JD com  Inc  Price  Consensus and EPS Surprise    CVS Health Corporation   NYSE CVS   is a solid bet with a long term earnings growth rate of 6 5   The Zacks Consensus Estimate for the to be reported quarter is pegged at  1 70  which is penny above the prior year quarter reported figure  The company is slated to report second quarter 2019 results on Aug 7  The provider of health services and plans  has an Earnings ESP of  9 89  and a Zacks Rank  3  The company has an average positive earnings surprise of 4 4  in the trailing four quarters CVS Health Corporation Price  Consensus and EPS Surprise    Another lucrative option is Pinduoduo Inc    NASDAQ PDD    which operates an e commerce platform  The stock has a Zacks Rank  3 and an Earnings ESP of  28 57   The Zacks Consensus Estimate for the second quarter of 2019 is pegged at a loss of 21 cents  which is a penny wider from the year ago period reported figure Pinduoduo Inc  Sponsored ADR Price  Consensus and EPS Surprise    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/3-retail-stocks-likely-to-stand-tall-this-earnings-season-200449066,200449066
198773,420289,CVS,Can All Line Growth Aid CVS Health s  CVS  Earnings In Q2 ,opinion,CVS Health Corporation   NYSE CVS   is scheduled to report second quarter 2019 results on Aug 7  before the opening bell  In the last reported quarter  the company delivered a positive surprise of 8   the average trailing four quarter beat being 4 38  Let s take a look at how things are shaping up prior to this announcement Factors at PlayWithin Pharmacy Services  despite a tough pricing competition  CVS Health has been gaining on high level of service and execution  competitive pricing and a unique integrated model  This  in turn  might have a bearing on the company s second quarter results  Within PBM  the company s new guaranteed net cost pricing model is garnering interest from clients and benefit consultants  which could lead to client adoptions in the second quarter CVS Health Corporation Price and EPS Surprise   Turning to the Health Care Benefits segment  the company expects to see government programs gaining momentum  driven by industry leading Medicare growth and the key Medicaid wins This newly incorporated business has already started to register top line contributions for the company  In the first quarter  this segment had posted significant Medicare Advantage membership growth  particularly in the government space  SilverScript Medicare Part D business is also registering a strong revenue performance  This should further get reflected in second quarter earnings report However  this segment might suffer in anticipation that certain one time benefits realized by Aetna  NYSE AET  in 2018 are not likely to recur in 2019  This  in turn  could affect the segment in the June quarter Within the Retail Long Term Care Segment  CVS Health is likely to thrive on the back of consistently solid adjusted script growth owing to the steady success of the pharmacy clinical care program that improved patient retention  Additionally  CVS Health projects an uptick in the recently formed Medicare partnerships and the new regional preferred alliances forged in the ongoing year  The continued uptake of the company s Patient Care Programs in collaboration with PBM and its preferred status in a number of Medicare Part D networks are expected to drive the second quarter top line Here is What the Quantitative Model Predicts The proven Zacks model shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has maximum chances of beating estimates if it also has a positive  CVS Health has a Zacks Rank  3  which increases the predictive power of ESP  Moreover  its Earnings ESP of  9 89  n the combination indicates a likely positive surprise for the stock this earnings season You can uncover the best stocks to buy or sell before they re reported with our  Meanwhile  the Zacks Consensus Estimate for second quarter adjusted EPS of  1 70 suggests a 0 59  rise from the year ago reported figure Other Stocks Worth a LookHere are a few other medical stocks worth considering as these too have the right mix of elements to exceed expectations this reporting cycle Bio Techne Corporation   NASDAQ TECH   has an Earnings ESP of  1 27  and is Zacks  2 Ranked  You can see  Anavex Life Sciences Corp    NASDAQ AVXL   has an Earnings ESP of  4 00  and a Zacks Rank  2 Allena Pharmaceuticals  Inc    NASDAQ ALNA   has an Earnings ESP of  7 55  and a Zacks Rank of 3 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/can-allline-growth-aid-cvs-healths-cvs-earnings-in-q2-200450132,200450132
198774,420290,CVS,Can Pharmacy Services Drive CVS Health s  CVS  Q2 Earnings ,opinion,CVS Health Corporation s   NYSE CVS   Pharmacy Services business has been gaining momentum on the back of higher specialty pharmacy and pharmacy network claim volumes besides brand inflation We expect this strength to get reflected in second quarter 2019 results  which are scheduled for release on Aug 7  before market open  to know how the company is likely to perform in the quarter to be reported Pharmacy Services Segment in FocusConsistent with the prior quarters  net new business and the continued adoption of Maintenance Choice programs are expected to drive CVS  PBM business in the second quarter  The company s new guaranteed net cost pricing model is drawing attention from clients and benefit consultants  which could lead to client uptakes in the second quarter In terms of 2020 PBM selling season  the company is expected to report a strong retention rate in the second quarter  In the last reported quarter  PBM retention rate was in the mid 90  excluding the impact of the Centene  NYSE CNC  deal CVS Health Corporation Price and EPS Surprise   Caremark legacy business too is expected to deliver a strong quarter  banking on the company s solid execution of its formulary and cost management tools  In terms of unit cost  the company is successful in driving down the average out of pocket costs for plan members for the sixth consecutive year  retaining patients  adherence and improving their overall health  This trend should continue in the second quarter as well Last but not the least  the company earlier noted that post the Aetna  NYSE AET  integration  its Pharmacy Services segment s current year figures will be affected by two important changes  First  the company s Individual SilverScript PDP has been shifted from the PBM segment to its newly formed Health Care Benefits  HCB  one  Second  the company has already consolidated the pharmacy operations of Aetna into its PBM  We therefore expect these factors to influence the yet to be reported quarter s top line results Zacks Ranks and Key PicksCVs Health currently carries a Zacks Rank  3  Hold   You can see Acer Therapeutics Inc    NASDAQ ACER   has an Earnings ESP of  10 10  and is Zacks  3 Ranked Anavex Life Sciences Corp    NASDAQ AVXL   has an Earnings ESP of  4 00  and a Zacks Rank  2 BeiGene  Ltd    NASDAQ BGNE   has an Earnings ESP of  8 55  and a Zacks Rank  1  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/can-pharmacy-services-drive-cvs-healths-cvs-q2-earnings-200450903,200450903
198775,420291,CVS,CVS Health Corp Earnings  Revenue beat in Q3,news,"Investing com   CVS Health Corp  NYSE CVS  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 73 on revenue of  47 27B  Analysts polled by Investing com expected EPS of  1 71 on revenue of  47 21B  That compared to EPS of  1 5 on revenue of  46 18B in the same period a year earlier  The company had reported EPS of  1 69 on revenue of  46 71B in the previous quarter 
For the year  CVS Health Corp shares are up 1 64   broadly in line with the S P 500 which is up 2 03  year to date 
CVS Health Corp follows other major Healthcare sector earnings this month
 On October 16  J J reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
Pfizer earnings beat analyst s expectations on October 30  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 5B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-11-06,Investing.com,https://www.investing.com/news/stock-market-news/cvs-health-corp-earnings-revenue-beat-in-q3-1675592,1675592
198776,420292,CVS,CVS quarterly profit beats  expects to close Aetna deal this month,news,By Manas Mishra  Reuters    CVS Health Corp  N CVS   which expects to close its  69 billion purchase of  Aetna Inc   N AET  this month  reported third quarter profit that beat analysts  estimates on higher sales of prescription drugs   Shares of the drugstore chain and pharmacy benefit manager  PBM  were up 2 7 percent at  75 70 in morning trading   The company said it believes the Aetna deal will help it save more than  750 million in costs in the second year after it closes  as the combination reduces corporate expenses as well as produces  some  cuts in medical costs from decreased emergency room visits    The longer term medical cost savings will come from new programs that are only made possible through the combination and close integration of our two companies   Chief Executive Officer Larry Menlo said on call with analysts   CVS  which last month won U S  Department of Justice approval to buy Aetna  said it reached agreement with the state of California on the acquisition and expects to finalize terms over the coming days  The deal is expected to close before the Thanksgiving holiday  which falls on Nov  22  CVS said   The combination is expected to reshape the healthcare sector as it brings together one of the largest PBMs and one of the nation s oldest health insurers  CVS could offer more preventive care services and screenings to Aetna customers in its clinics  such as enabling diabetes patients to monitor blood sugar levels  avoiding higher cost visits to doctors or emergency rooms   Pharmacy same store sales rose 8 7 percent in the quarter  while analysts were expecting a 7 7 percent rise   Front end of the store same store sales rose 0 8 percent versus analysts  expectations of an 0 8 percent drop  despite brick and mortar drugstore chains like CVS coming under increasing pressure from consumer shifts to online options  Sales of beauty products at CVS stores have benefited from promotions and newer offerings  Last year  the company announced a initiative to offer over a hundred new South Korean beauty brands at its stores  Excluding items  CVS Health said it earned  1 73 per share  topping analysts  average estimates by 2 cents   Net revenue rose 2 4 percent to  47 27 billion  beating expectation of  47 18 billion  Net income rose to  1 39 billion  or  1 36 per share  in the quarter  Its income tax provision declined by  268 million   https   ,2018-11-06,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-quarterly-profit-rises-8-percent-1675658,1675658
198777,420293,CVS,CVS expects Aetna deal to close after Thanksgiving,news," Reuters    CVS Health Corp  N CVS  said on Tuesday that it expects to close its  69 billion purchase of health insurer  Aetna Inc   N AET  after the Thanksgiving holiday  The pharmacy chain and benefits manager had previously expected the transaction to close by Nov  22  
CVS said in a filing https    it had received approval from 26 of the 28 state departments of insurance and was in the final stages of the approval process with the two remaining states ",2018-11-20,Reuters,https://www.investing.com/news/stock-market-news/cvs-expects-aetna-deal-to-close-after-thanksgiving-1694714,1694714
198780,420296,CVS,CVS Health Banks On Aetna Prospects  Omnicare May Disappoint,opinion,"On Jul 5  we issued an updated research report on CVS Health   NYSE CVS    Increasing demand for Pharmacy Benefit Management  PBM  and specialty pharmacy has been a major growth driver for the stock  The company currently carries a Zacks Rank  3  Hold  CVS Health is demonstrating robust top line growth driven by strong performance of the Pharmacy Services segment   which is benefiting from an upside in specialty services  Although the company is witnessing certain challenges related to 2020 PBM selling season  the long term prospects look bright The company s retention rate currently stands in the mid 90   excluding the impact of the acquisition of Centene  NYSE CNC   Adjusted claims increased 2 8  from the year ago quarter  driven by net new business wins and continued adoption of maintenance choice  According to CVS Health  service levels and performance metrics are currently at historically high levels and the company expects to return to its historical retention levels going ahead CVS Health Corporation Price

   This apart  synergies from Aetna  NYSE AET  appear promising  Following the acquisition  CVS Health introduced a new segment  Health Care Benefits  which holds immense promise  The company views 2019 as a year of transition and expects its businesses to strengthen meaningfully from the integration of CVS and Aetna s core capabilities  According to CVS Health  the integration of capabilities will benefit Aetna and Caremark clients and their members  The company is on track to have this in market for the 2021 selling season On the flip side  the 2020 PBM selling season so far has been dull with lower than expected retention rate  CVS Health expects to see fewer RFP  Requests for Proposals  opportunities in the market than what it has seen over the past few years Also  according to CVS Health  Omnicare business performance is likely to remain soft through 2019  In the first quarter  persistent reimbursement pressure and the impact of recent generic introductions impacted the company s retail LTC business Over the past month  CVS Health has underperformed its   The stock has gained 3 8  compared with 4 9  rise of the industry Stocks to ConsiderSome better ranked stocks in the broader medical space are Teleflex Inc    NYSE TFX    Penumbra   NYSE PEN   and Bruker Corporation   NASDAQ BRKR    each currently carrying a Zacks Rank  2  Buy   You can see  Teleflex s long term earnings growth rate is expected to be 13 7  Penumbra s long term earnings growth rate is projected to be 21 5  Bruker s long term earnings growth rate is estimated at 11 7  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-07,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-banks-on-aetna-prospects-omnicare-may-disappoint-200437726,200437726
198781,420297,CVS,Can CVS Health  CVS  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  CVS Health  NYSE CVS   which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  could be a great candidate to consider 
This drugstore chain and pharmacy benefits manager has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 5 69  
For the most recent quarter  CVS Health was expected to post earnings of  1 50 per share  but it reported  1 62 per share instead  representing a surprise of 8   For the previous quarter  the consensus estimate was  2 07 per share  while it actually produced  2 14 per share  a surprise of 3 38  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for CVS Health  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
CVS Health has an Earnings ESP of  3 21  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on August 7  2019 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-10,Zacks Investment Research,https://www.investing.com/analysis/can-cvs-health-cvs-keep-the-earnings-surprise-streak-alive-200438894,200438894
198782,420298,CVS,Stock Market News For Jul 12  2019,opinion,The Dow and S P 500 closed at record highs on Thursday riding a rally among healthcare shares and Fed s indication of an easier monetary policy  Healthcare shares especially gained after the Trump administration abandoned a proposal to lower medicine costs  Investor expectations also grew of an imminent rate cut after Fed Chairman Jerome Powell cited trade uncertainties taking a toll on global economic outlook  Nasdaq  however  closed lower  The Dow Jones Industrial Average  DJI  gained 0 85  on Jul 11 to close at 27 088 08  while the S P 500 added 0 23  to finish at 2 999 91  The Nasdaq Composite Index shed 0 08  to close at 8 196 04  Decliners outnumbered advancers on the NYSE by a 1 19 to 1 ratio White House Scrapped Proposal to Lower Drug PricesOn Jul 11  the Trump administration dropped an ambitious proposal to decrease prescription medicine prices  Per the proposal  rebates from government drug plans would have been eliminated  This means that health insurers would have barred from receiving rebates from drug companies to Medicare patients However  since the proposal was dumped  it allowed shares of companies such as CVS Health Corporation   NYSE CVS   to gain on Thursday  These companies bargain rebates with drug making companies on behalf of the government s Medicare program  These companies can thus benefit from the discounts  You can see  Chances of a Fed Rate Cut are High This MonthPowell s two day testimony on monetary policy to the Congress hinted at a possible slashing of Fed rates during the FOMC meeting scheduled for July 30 31  The Fed Chair said that the central bank will  act as appropriate  in order to sustain expansion Powell also noted that business investment had slowed down considerably  Uncertainty around trade policies and concerns over the strength of global economy pressed heavily on the U S  economic outlook  Lagging inflation was also cited as a reason to ease monetary policy Economic DataAccording to the Bureau of Labor Statistics  Consumer Price Index increased 0 1  in June  The all items index increased 1 6  on an annual basis  The Core CPI  which is CPI minus food and energy  rose 0 3  last month Initial jobless claims for the week ended Jul 6 declined to 209 000 from 221 000 for the week ended Jun 29 Stocks That Made HeadlinesShares of American Airlines Group   NASDAQ AAL   gained 1 8  on Jul 10 to close the trading session at  32 94    The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/stock-market-news-for-jul-12-2019-200439340,200439340
198785,420301,CVS,Akorn down 12  ahead of hearing on disputed Fresenius merger,news,Investors are behaving like they expect bad news from today s post trial hearing in Delaware related to  Akorn  s  AKRX  11 7   dispute with former merger partner Fresenius SE  OTCQX FSNUY  OTCQX FSNUF  after the latter backed out of the  4 75B deal  Shares have retraced 17  this week Previously  Akorn rallies ahead of Fresenius trial  July 6 Previously  Akorn takes issue with Fresenius  planned exit from merger  shares down 34  premarket  April 23 Now read ,2018-08-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/akorn-down-12-ahead-of-hearing-on-disputed-fresenius-merger-1585150,1585150
198786,420302,CVS,U S  review of CVS deal for Aetna may end soon  source,news,"WASHINGTON  Reuters    The U S  Justice Department s antitrust review of CVS Health Corp s  N CVS  planned purchase of  Aetna Inc   N AET  may conclude soon  a source familiar with the review said on Monday  That said  arranging divestitures needed to resolve antitrust concerns in the proposed transaction takes time and it is not clear that possible approval will come in September  said the source  
The  69 billion deal was announced in December ",2018-09-17,Reuters,https://www.investing.com/news/stock-market-news/us-review-of-cvs-deal-for-aetna-may-end-soon-source-1613447,1613447
198791,420307,CVS,CVS Health  CVS  Down 7  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for CVS Health  NYSE CVS   Shares have lost about 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is CVS Health due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  CVS Health s PBM Selling Season Remains Solid  Retail GrowsCVS Health s first quarter 2019 adjusted earnings per share  EPS  of  1 62 increased 9 5  year over year and also exceeded the Zacks Consensus Estimate by 8  The quarter s adjusted EPS considered certain transaction and integration costs pertaining to the buyout of Aetna  NYSE AET  and the purchase of Omnicare  It also adjusted certain store rationalization charge related to the planned closure of 46 underperforming retail pharmacy stores during the second quarter of 2019 On a reported basis  the company registered earnings of  1 09 per share  up 11 2  from the year ago period Net revenues in the first quarter surged 34 8  year over year to  61 65 billion  The same also topped the Zacks Consensus Estimate of  60 47 billion Quarter in Detail Effective first quarter 2019  the company has realigned the composition of its segments  As a result of this move  the company s SilverScript Medicare Part D prescription drug plan  PDP  has shifted from the Pharmacy Services segment to the Health Care Benefits segment  In addition  the mail order and specialty pharmacy operations of Aetna have been transitioned from the Health Care Benefits segment to the Pharmacy Services segment Pharmacy Services revenues inched up 3 1  to  33 56 billion in the reported quarter  driven by growth in total pharmacy claims volume andthe brand name drug price inflation  This was  however  partially offset by a continued client price compressionand an increased generic dispensing rate Total pharmacy claims processed increased 2 8  on a 30 day equivalent basis  attributable to net new business and the steady adoption of Maintenance Choice offerings Revenues from CVS Health s Retail LTC were nudged up by 3 3  year over year to  21 12 billion  Per the company  the result was based on increased prescription volume and branded drug price inflation  partially offset by a persistent reimbursement pressure and the impact of recent generic introductions  Front store revenues rose 22 7  in the reported quarter  primarily banking on improved health product sales Total prescription volume grew 5 5  on a 30 day equivalent basis  boostedby the continued uptake of patient care programs and collaborations with PBMs as well as the preferred status in a number of Medicare Part D networks Following the closing of CVS Health s acquisition of Aetna  the company has integrated Aetna s Health Care segment to its business and renamed it as Health Care Benefits segment  In the reported quarter  the company registered revenues of  17 87 billion within this segment Gross profit skyrocketed 196 2  to  24 39 billion  Accordingly  gross margin expanded 2157 bps to 39 6   Adjusted operating margin in the quarter under review expanded 1893 bps to 26 2   OutlookCVS Health has updated its 2019 guidance Adjusted EPS expectation has been raised to the band of  6 75  6 90 from the earlier provided range of  6 68  6 88  The Zacks Consensus Estimate for earnings is pegged at  6 78  within but close to the lower end of the company s guided range  This apart  its 2019 adjusted operating profit estimate has been narrowed to the  15  15 2 billion band from the previous view of  14 8  15 2 billion Further  the company anticipates cash flow from operations from  9 8 billion to  10 3 billion  unchanged  The company has also issued outlook for the second quarter of 2019  Adjusted EPS is projected in the range of  1 68  1 72  The Zacks Consensus Estimate for earnings of  1 68 meets the lower end of the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  CVS Health has a nice Growth Score of B  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  CVS Health has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-30,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-down-7-since-last-earnings-report-can-it-rebound-200427090,200427090
198792,420308,CVS,CVS Pops On Growth Plans  Cycles Point Higher,opinion,"Summary 
CVS Health Corp  NYSE CVS  rose 2  on Tuesday after the company delivered a compelling vision for how it plans to thrive in the US healthcare sector 
Based on the stock s market cycles  we see further upside 
CVS Stock Weekly Chart 
At its investor day event  CVS explained its plans for reshaping healthcare in America  According to management  this begins with its acquisition of Aetna  NYSE AET  and building out the CVS HealthHub concept  which has the capacity to meet 80  of the scope of a primary care practice 
CEO Larry Merlo said   Our mission is to be the most consumer centric health company in the country  With nearly 70  of people living within 3 miles of a CVS pharmacy  we believe we have an unparalleled community presence  
Our approach to stock analysis focuses on market cycles  CVS is likely still in the rising phase of its current cycle  which points to further upside  Using our Fibonacci based intermediate resistance zone  our near term target is  59 61 
For more from Slim  or to learn about cycle analysis  check out the askSlim Market Week show every Friday on our YouTube channel ",2019-06-05,Steve Miller,https://www.investing.com/analysis/cvs-pops-on-growth-plans-cycles-point-higher-200428542,200428542
198793,420309,CVS,American Medical Association opposes merger of CVS and Aetna,news,WASHINGTON  Reuters    The American Medical Association  which represents U S  physicians  urged the U S  Justice Department on Wednesday to stop CVS Health  NYSE CVS  Corp s plan to buy insurance provider  Aetna Inc   NYSE AET   saying the deal could result in higher prices for prescription medicines  The AMA said that the  69 billion deal  announced in December  would lead to a  substantial reduction  of competition in pharmacy benefit  PBM  services market and the Medicare Part D prescription drug plan for seniors   The AMA said the deal would increase concentration in 10 of the 34 Medicare Part D regional markets to the point where it is presumed likely to increase market power    CVS and Aetna     operate as rivals in some of the same markets  raising substantial concerns   said AMA President Barbara McAneny in a statement  McAneny said the merger would mean higher prices  less choice and stifled innovation in PBM services  health insurance and pharmacy services  CVS said in a statement that it strongly disagreed with the AMA s assessment of the deal    We believe that competition within each of the business segments in which we operate   pharmacy benefit management  pharmacies and insurers   is fierce and will remain so   the company said in a statement ,2018-08-08,Reuters,https://www.investing.com/news/stock-market-news/american-medical-association-opposes-merger-of-cvs-and-aetna-1565998,1565998
198802,420318,CVS,CVS Health  CVS  Surpasses Q1 Earnings And Revenue Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 62 per share  beating the Zacks Consensus Estimate of  1 50 per share  This compares to earnings of  1 48 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  2 07 per share when it actually produced earnings of  2 14  delivering a surprise of 3 38  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  61 65 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 94   This compares to year ago revenues of  45 69 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have lost about 17  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 68 on  62 53 billion in revenues for the coming quarter and  6 78 on  251 51 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 7  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-surpasses-q1-earnings-and-revenue-estimates-200414762,200414762
198803,420319,CVS,CVS Health  CVS  Surpasses Q1 Earnings And Revenue Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 62 per share  beating the Zacks Consensus Estimate of  1 50 per share  This compares to earnings of  1 48 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  2 07 per share when it actually produced earnings of  2 14  delivering a surprise of 3 38  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  61 65 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 94   This compares to year ago revenues of  45 69 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have lost about 17  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 68 on  62 53 billion in revenues for the coming quarter and  6 78 on  251 51 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 7  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-surpasses-q1-earnings-and-revenue-estimates-200414593,200414593
198804,420320,CVS,CVS Health  CVS  Surpasses Q1 Earnings And Revenue Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 62 per share  beating the Zacks Consensus Estimate of  1 50 per share  This compares to earnings of  1 48 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  2 07 per share when it actually produced earnings of  2 14  delivering a surprise of 3 38  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  61 65 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 1 94   This compares to year ago revenues of  45 69 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have lost about 17  since the beginning of the year versus the S P 500 s gain of 17 5  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 68 on  62 53 billion in revenues for the coming quarter and  6 78 on  251 51 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the bottom 7  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-surpasses-q1-earnings-and-revenue-estimates-200414348,200414348
198805,420321,CVS,Bull Of The Day  Tabula Rasa HealthCare  TRHC ,opinion,Tabula Rasa HealthCare  TRHC  is a  1 2 billion medical IT firm focused on patient specific  data driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes  reduce hospitalizations  lower healthcare costs and manage risk  The company s cloud based software applications  including platforms EireneRx and MedWise Advisor  deliver control and certainty to payers  providers and other healthcare organizations  And their innovative use of artificial intelligence technologies and cross provider integrations for doctors and pharmacies to cross reference prescription complications is becoming more important in an aging population taking more medicines  Tabula Rasa is expected to grow sales 40  this year to  285 million  Below is a snapshot I took last month when I bought TRHC shares for the Zacks Healthcare Innovators portfolio  This view highlights projected sales growth in the face of the recent valuation haircut  What you are seeing is 12 month forward sales estimates  the green line  rising from  210 million at the start of Q3 2018 to over  325 million projected into 2020  while price has dropped from  90 to  55     Part of the pessimism is that while the company became profitable last year  it is expected to show no EPS growth this year and deliver a repeat of  0 77  giving it a P E multiple of over 70X  And this after analysts held loftier expectations about 2019 growth as recently as last October when the consensus was for EPS of over  1 10   But the reason the stock became a Zacks  1 Rank again is due to upward EPS revisions that came in after the company s Q4 report on Feb 28 where management raised revenue guidance  Full year 2019 consensus moved back up 10  from  0 70 to  0 77 and next year moved from  1 07 to  1 19  New Partnerships  Acquisitions  and Innovations One of the most exciting innovations for Tabula Rasa is their development of a complete medical records and IT solutions suite that integrates with other providers  In September  the company announced the creation of TRHC 2 0 for  Innovative Integrations  Interoperability and Advanced Healthcare Analytics   From the 9 7 18 press release    Through accretive acquisitions and continued research and development  TRHC s technology innovations and growing data lake provide a data continuum for clients enhancing the care of patients across the U S  and abroad   MOORESTOWN  N J   Sept  07  2018  GLOBE NEWSWIRE     Tabula Rasa HealthCare  Inc    TRHC    NASDAQ TRHC   a healthcare technology company advancing the field of medication safety  today announced its strategy to integrate and open its various technologies  facilitating seamless interoperability and access to vast data resources for its clients  This technology strategy  referred to as TRHC 2 0  is designed to harness the power of TRHC s core technologies  MedWise  and EireneRx   and to leverage other technologies brought into the company through acquisition  like SinfoniaRx s RxCompanion   and the recent Mediture and eClusive technologies for electronic health records and health plan management   end of TRHC press release excerpt  The company also recently announced an important API integration with fellow healthcare IT company AthenaHealth  formerly public under the symbol ATHN and taken private in February by Elliot Management and Veritas Capital who teamed up to buy ATHN for over  5 5 billion in cash  or  135 per share   Athenahealth serves over 100 million patients through provider networks and will embed Tabula Rasa platforms in care and pharmacy settings  The integration is expected to be complete by Q4 19 and create a recurring revenue SaaS fee as well as a consulting fee for Tabula Rasa  In December  Tabula Rasa announced an agreement to acquire Brisbane  Australia based DoseMe  DoseMe is the developer of DoseMeRx  an advanced precision dosing tool to help physicians and pharmacists accurately dose patients  high risk parenteral medications based on individual needs  resulting in significant improvements to mortality  risk  and patient outcomes  Already available in over 100 hospitals and infusion providers worldwide  DoseMeRx s precision dosing capabilities will now be combined with TRHC s proprietary Medication Risk Mitigation  MRM  technologies in order to enhance and accelerate medication safety solutions available in the hospital setting  Adding Another Prescription for Wellness In early March  Oppenheimer analysts reworked their estimates model to account for a recent  285 million convertible share offering and  you guessed it  another key acquisition  Oppenheimer analyst Mohan Naidu lowered his price target for Tabula Rasa HealthCare to  88 from  97  while reiterating an Outperform rating on the shares after the company announced the acquisition of PrescribeWellness for  150 million in cash  The analyst believes the acquisition should provide leverage to Tabula Rasa HealthCare in pushing its solutions into the pharmacies by expanding on PrescribeWellness relationships to promote the combined company s proprietary technologies  This synergy should add high margin service revenues to the numbers  with Naidu expecting growth in about 20  range  The Oppenheimer analyst team increased their 2019 and 2020 estimates to incorporate the higher growth implied in company guidance and also the contribution from the acquisitions  Their 2020 revenue estimate went up to  322 million from  310M  In early April  investment bank Piper Jaffray reiterated their bull case for TRHC    Tabula Rasa HealthCare Strengthened by SinfoniaRx Piper Jaffray analyst Sean Wieland kept his Overweight rating and  73 price target on Tabula Rasa HealthCare after its SinfoniaRx unit put out its annual report  saying the company s key metrics demonstrate its ability to  help health plans meet CMS requirements and help pharmacists generate revenue   Wieland noted that the unit strengthens the value proposition of the combined Tabula Rasa HealthCare platforms and he remains positive on its revenue growth potential of over 20  for years to come  Since reporting earnings in late Feb  here is where other analysts stand on their forward valuation  i e   price targets     Cantor Fitz 3 1   99Benchmark 3 15   90Stifel Nicolaus 3 5   70Wells Fargo  NYSE WFC  3 6   55  obviously the Neutral view here  And here was commentary from the Cantor analyst in late January when shares were trading  68    Tabula Rasa shares attractive with 50  upside potential Analyst Steven Halper reiterated an Overweight rating on Tabula Rasa HealthCare with a  99 price target  After meeting with management the analyst says the company remains upbeat regarding adoption of its Medication Risk Mitigation platform  Halper continues to believe Tabula Rasa is poised for sustained long term growth amid  favorable  policy and market tailwinds  Halper viewed the stock as attractive up near  70  and he recently reiterated his  99 target  implying over 80  upside from between  50 and  55  CMS  New Value Based Payment Program is a Catalyst for TRHC Finally  as healthcare stocks recover from the fallout of last month s  single payer panic  and  Medicare for All  scares  Tabula Rasa has found opportunity in the chaos  On April 25 commended a new initiative from the U S  Department of Health and Human Services  HHS  and Centers for Medicare   Medicaid Services  CMS  to introduce new payment models for primary care that will require payment for health and outcomes rather than fee for service  According to HHS Secretary Alex Azar  these models represent the biggest step ever taken toward building an American healthcare system that pays for value  The CMS projects that the new voluntary programs will shift at least a quarter of people in traditional Medicare out of fee for service  which will motivate providers to compete for these beneficiaries and be rewarded for their ability to keep patients healthy and out of the hospital  among other quality measures  And on April 18  Piper Jaffray analyst Sean Wieland put out a note saying that TRHC stock weakness brings a  compelling entry point   Wieland said he was  incrementally more positive  on Tabula Rasa HealthCare s growth outlook after traveling with the company s CFO Brian Adams  He also noted that a new CVS Health  NYSE CVS   CVS  partnership provides a  strong validation  of Tabula Rasa s value proposition  and multiple opportunities should result in a higher margin product mix  He reiterated an Overweight rating on Tabula Rasa HealthCare with a  73 price target  Bottom line for Tabula Rasa  TRHC   There are few ways to directly capitalize on the IT trends in medical records  systems  and data management    especially after Athenahealth was taken private  So for me  buying a  1 2 billion innovator trading at only 3X sales    which are growing at a blended rate over 30  for this year and next    is an irresistible investment opportunity  Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day-tabula-rasa-healthcare-trhc-200416742,200416742
198809,420325,CVS,CVS Health  CVS  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when CVS Health  NYSE CVS  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on May 1  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugstore chain and pharmacy benefits manager is expected to post quarterly earnings of  1 51 per share in its upcoming report  which represents a year over year change of  2  
Revenues are expected to be  60 52 billion  up 32 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 03  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for CVS Health 
For CVS Health  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 22  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that CVS Health will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that CVS Health would post earnings of  2 07 per share when it actually produced earnings of  2 14  delivering a surprise of  3 38  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
CVS Health doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200410253,200410253
198810,420326,CVS,U S  DoJ will not challenge Aetna CVS deal  report,news," Reuters    Shares of CVS Health Corp  N CVS  and health insurer  Aetna Inc   N AET  rose more than 2 percent on Thursday after CNBC reported that the U S  Justice Department will not challenge their planned merger  CNBC said Bloomberg reported the news  citing trade publication Reorg Research  CVS Health Corp and Aetna announced the  69 billion deal on Dec  3 last year  arguing it would enable the companies to tackle soaring healthcare spending by offering lower cost medical services in pharmacies   
Aetna and CVS declined to comment ",2018-07-12,Reuters,https://www.investing.com/news/stock-market-news/us-doj-will-not-challenge-aetnacvs-deal--report-1527823,1527823
198813,420329,CVS,Why Is CVS Health  CVS  Down 7 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for CVS Health  NYSE CVS   Shares have lost about 7 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is CVS Health due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  CVS Health s PBM Selling Season Remains Solid  Retail GrowsCVS Health Corporation s fourth quarter 2018 adjusted earnings per share  EPS  of  2 14 surged 11 5  year over year and exceeded the Zacks Consensus Estimate by 3 4   The quarter s adjusted EPS considered certain transaction and integration costs related to the recently closed acquisition of Aetna  NYSE AET  and the purchase of Omnicare  It also adjusted certain goodwill impairment related to the LTC reporting unit On a reported basis  the company registered loss of 37 cents per share as compared to the year ago EPS of  3 22 Full year adjusted EPS was  7 08  a 20  rise from the year ago period  This also exceeded the Zacks Consensus Estimate of  6 98 Net revenues in the fourth quarter increased 12 5  year over year to  54 42 billion  This surpassed the Zacks Consensus Estimate by 1 3  The company registered revenues of  194 58 billion in 2018  a 5 3  improvement from the year ago period  This exceeds the Zacks Consensus Estimate of  193 13 billion Quarter in Details Pharmacy Services revenues increased 2 2  to  34 09 billion in the reported quarter  driven by growth in total pharmacy claims volume  This was  however  partially offset by continued client price compression Total pharmacy claims processed increased 5 6  on a 30 day equivalent basis driven by net new business and the continued adoption of Maintenance Choice offerings Revenues from CVS Health s Retail LTC were up by 5 4  year over year to  22 03 billion  According to the company  the result was based on increased prescription volume and branded drug price inflation  partially offset by continued reimbursement pressure and the impact of recent generic introductions  Front store revenues increased in the reported quarter primarily banking on improvement in health product sales Total prescription volume grew 8 6  driven by the continued adoption of patient care programs and collaborations with PBMs as well as preferred status in a number of Medicare Part D networks during 2018 LTC business in the quarter however  was facing industry wide challenges like lower occupancy rates in skilled nursing facilities  significant deterioration in the financial health of numerous skilled nursing facility customers which resulted in a number of customer bankruptcies in 2018  These have adversely affected the company s ability to grow the business at the rate that was originally estimated when the company acquired Omnicare Following the closing of CVS Health s acquisition of Aetna  the company has integrated Aetna s Health Care segment to its business and renamed it as Health Care Benefits segment  In the reported quarter  the company registered revenues of  5 55 billion within this segment Gross profit improved 67 1  to  13 9 billion  Accordingly  gross margin expanded 833 bps to 25 5   Adjusted operating margin in the quarter expanded 597 bps to 13 3  OutlookCVS Health has provided its 2019 guidance Adjusted EPS is expected in the band of  6 68 to  6 88  The Zacks Consensus Estimate for earnings is pegged at  7 38 per share  outside the company s guided range  This apart  its 2019 adjusted operating profit guidance remains in the range  14 8 billion to  15 2 billion Further  the company expects cash flow from operations in the band of  9 8 billion to  10 3 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  8 54  due to these changes 
VGM Scores
At this time  CVS Health has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise CVS Health has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2019-03-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-cvs-health-cvs-down-79-since-last-earnings-report-200400160,200400160
198814,420330,CVS,Premarket analyst action   healthcare,news,Iterum Therapeutics  NASDAQ ITRM  initiated with Outperform rating and  24  100  upside  price target at RBC  Initiated with Buy rating and  18 price target at Leerink  Initiated with Buy rating and  20 price target at Needham Bluebird bio  NASDAQ BLUE  upgraded to Outperform with a  230  30  upside  price target at Evercore ISI  Shares up 1  premarket CVS Health  NYSE CVS  added to US 1 list at BofA Merrill Lynch  Shares down 1  premarket Helius Medical Technologies  NASDAQ HSDT  downgraded to Neutral at BTIG Research Madrigal Pharmaceuticals  NASDAQ MDGL  downgraded to Neutral at Evercore ISI Now read ,2018-06-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1498360,1498360
198815,420331,CVS,Casino and L Oreal team up to launch new beauty stores,news,By Pascale Denis PARIS  Reuters    French supermarket chain  Casino   PA CASP  and cosmetics group L Oreal  PA OREP  are launching new beauty stores in Paris this weekend  the latest effort by brick and mortar retailers to retain customers in the face of online competition  The two companies said on Friday that the new stores    dubbed  le drugstore parisien     will offer beauty products and healthcare goods  as well as over the counter medicines  For Casino  the tie up with L Oreal marks its latest move away from grocery stores  as France s traditional retailers seek new ways to appeal to shoppers  The first two outlets will open this weekend in the chic 9th and 6th districts of Paris  attracting shoppers with hairdresser and drycleaning services  shoe shining machines and mobile phone charging points  For L Oreal  the stores will give its products greater exposure  Unlike large pharmacy chains such as CVS Health  NYSE CVS  and Duane Reade in the United States or Boots in Britain  French pharmacies stock only medicines and a limited range of personal products and often have restricted opening hours  The  drugstore  outlets  longer opening hours are aimed at reflecting changing  modern lifestyles   A spokeswoman for Casino said a third  drugstore  could open in Paris if the first two did well  and that Casino and L Oreal might expand the concept abroad   The companies did not give any financial details or targets for the  drugstores   Department stores in the French capital are also seeking to give consumers a more interesting shopping experience to lure them away from buying goods online  In January  Le Printemps opened a food hall on the 7th and 8th floors of its Haussmann building dedicated to men s fashion and luxury group LVMH  PA LVMH  opened a second upmarket La Grande Epicerie store in Paris s posh 16th district last year ,2018-06-22,Reuters,https://www.investing.com/news/stock-market-news/casino-and-loreal-team-up-to-launch-new-beauty-stores-1503547,1503547
198816,420332,CVS,U S  fines CVS for failing to report opioid theft in New York,news,"By Jonathan Stempel NEW YORK  Reuters    CVS Health Corp  NYSE CVS  agreed to pay a  1 5 million civil fine to resolve U S  charges that some of its pharmacies in Nassau and Suffolk counties in New York failed to report in a timely manner the loss or theft of prescription drugs  including the opioid hydrocodone  Richard Donoghue  the U S  Attorney for the Eastern District of New York  on Thursday said delays contribute to opioid abuse  and that CVS  failures impeded the ability of Drug Enforcement Administration agents to investigate  violating federal law  CVS  based in Woonsocket  Rhode Island  did not immediately respond to a request for comment   This settlement is significant because it shows that big chain pharmacies  like CVS  are taking responsibility for violating federal law  which is a step in the right direction for curbing the opioid epidemic   DEA Special Agent in Charge James Hunt said in a statement  Opioids  including prescription painkillers and heroin  played a role in a record 42 249 U S  deaths in 2016  according to the U S  Centers for Disease Control and Prevention  CVS has more than 130 pharmacies in Nassau and Suffolk  according to its website  
The company reached a  5 million settlement with the U S  government last July over similar claims involving pharmacies in California ",2018-06-28,Reuters,https://www.investing.com/news/stock-market-news/us-fines-cvs-for-failing-to-report-opioid-theft-in-new-york-1511745,1511745
198819,420335,CVS,CVS Health  CVS  Q4 Earnings And Revenues Beat Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  2 14 per share  beating the Zacks Consensus Estimate of  2 07 per share  This compares to earnings of  1 92 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 38   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  1 71 per share when it actually produced earnings of  1 73  delivering a surprise of 1 17  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  54 42 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 1 34   This compares to year ago revenues of  48 39 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have added about 6 7  since the beginning of the year versus the S P 500 s gain of 10 9  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 64 on  59 65 billion in revenues for the coming quarter and  7 38 on  245 21 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the top 28  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-q4-earnings-and-revenues-beat-estimates-200390022,200390022
198822,420338,CVS,Why The Earnings Surprise Streak Could Continue For CVS Health  CVS ,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider CVS Health  NYSE CVS   This company  which is in the Zacks Retail   Pharmacies and Drug Stores industry  shows potential for another earnings beat 
This drugstore chain and pharmacy benefits manager has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 3 07  
For the last reported quarter  CVS Health came out with earnings of  1 73 per share versus the Zacks Consensus Estimate of  1 71 per share  representing a surprise of 1 17   For the previous quarter  the company was expected to post earnings of  1 61 per share and it actually produced earnings of  1 69 per share  delivering a surprise of 4 97  
Price and EPS Surprise

For CVS Health  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
CVS Health currently has an Earnings ESP of  0 31   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on February 20  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-cvs-health-cvs-200383286,200383286
198823,420339,CVS,CVS Health  CVS  Earnings Expected To Grow  Should You Buy ,opinion,"CVS Health  NYSE CVS  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 20  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drugstore chain and pharmacy benefits manager is expected to post quarterly earnings of  2 07 per share in its upcoming report  which represents a year over year change of  7 8  
Revenues are expected to be  53 71 billion  up 11  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 19  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for CVS Health 
For CVS Health  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 11  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that CVS Health will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that CVS Health would post earnings of  1 71 per share when it actually produced earnings of  1 73  delivering a surprise of  1 17  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
CVS Health appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-earnings-expected-to-grow-should-you-buy-200387528,200387528
198824,420340,CVS,Key Factors Likely To Shape CVS Health s  CVS  Q4 Earnings,opinion,CVS Health Corporation   NYSE CVS   is scheduled to report fourth quarter and 2018 results on Feb 20  before the opening bell  In the last reported quarter  the company delivered a positive surprise of 1 17   the average trailing four quarter beat being 3 55  Let s take a look at how things are shaping up prior to this announcement Factors at PlayCVS Health has so far progressed well with its 2019 PBM selling season  Per the last reported quarterly numbers  client retention rate was higher than the year ago quarterly rates and the company completed more than 90  of its 2019 renewals  This momentum is expected to be seen in the to be reported quarter as well Despite a tough pricing competition  CVS Health is currently gaining on high level of service and execution  a competitive pricing and a unique integrated model CVS Health Corporation Price and EPS Surprise   The company is also upbeat about sustaining a solid year over year revenue trend during the fourth quarter of 2018  thereby realizing gains from the Pharmacy Services segment  Such a performance can be attributed to higher specialty pharmacy and pharmacy network claim volumes as well as brand inflation Management stated that CVS Health s specialty business is its top priority to help it expand its customer base  The company is poised to capitalize on this opportunity on the back of wide and differentiated offerings including Specialty Connect Further  the company expects drug price inflation  product launches and higher utilization to fuel growth  We expect the Pharmacy Services segment to be a stable growth platform Within the PBM Segment  the company projects revenues to grow in high single digits during the fourth quarter The Zacks Consensus Estimate for the Pharmacy Services segment revenues is pegged at  34 88 billion  reflecting a 1 9  increase on a year over year basis Within the Retail Long Term Care Segment  CVS Health is likely to progress on comp script growth from a continued adoption of Patient Care Programs  successful partnering with PBMs and health plans across the industry including preferred position in a number of Med D networks this year  However  the company is worried about the challenges in the Long Term Care business  which are anticipated to weigh more heavily on its second half Retail Long Term Care growth expectations   For the fourth quarter  CVS Health estimates the company s Retail Long Term Care revenues to be down by mid teens The Zacks Consensus Estimate for the Retail Long Term Care segment revenues is pegged at  21 8 billion  representing a 4 3  improvement on a year over year basis Overall  downsides such as persistent reimbursement pressure  rising generic dispensing rate and recent generic drug introductions have been affecting the business Here is What Our Quantitative Model Predicts Our proven Zacks model shows that a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has maximum chances of beating estimates if it also has a positive  CVS Health has a Zacks Rank  3  which increases the predictive power of ESP  It also has an Earnings ESP of  3 29   together which a likely earnings surprise can be predicted for the stock this season You can uncover the best stocks to buy or sell before they re reported with our  Meanwhile  the Zacks Consensus Estimate for fourth quarter adjusted EPS of  2 07 indicates a 7 8  rise year over year Other Stocks to ConsiderFollowing are a few other medical stocks worth considering with the right combination of elements to also beat on earnings in the upcoming quarterly results BioDelivery Sciences International  Inc    NASDAQ BDSI   has an Earnings ESP of  38 46  and a Zacks Rank of 1  You can see  MacroGenics  Inc    NASDAQ MGNX   has an Earnings ESP of  5 44  and a Zacks Rank  2 TG Therapeutics  Inc    NASDAQ TGTX   has an Earnings ESP of  0 55  and is a Zacks  1 Ranked player Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/key-factors-likely-to-shape-cvs-healths-cvs-q4-earnings-200388727,200388727
198825,420341,CVS,Should Value Investors Pick CVS Health  CVS  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put CVS Health Corporation   NYSE CVS   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  CVS Health has a trailing twelve months PE ratio of 10 2  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 5  If we focus on the long term PE trend  CVS Health s current PE level puts it below its midpoint over the past five years  Moreover  the current level is fairly below the highs for this stock  suggesting it might be a good entry point Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 11 4  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that CVS Health has a forward PE ratio  price relative to this year s earnings  of just 9 4  so it is fair to say that a slightly more value oriented path may be ahead for CVS Health stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  CVS Health has a P S ratio of about 0 4  This is significantly lower than the S P 500 average  which comes in at 3 4 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  CVS is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  CVS Health currently has a Zacks Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes CVS Health a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for CVS Health is just 0 9  a level that is slightly lower than the industry average of 1 0  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  CVS is a solid choice on the value front from multiple angles What About the Stock Overall Though CVS Health might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of D  This gives CVS a Zacks VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter as well as the full year has seen one estimate go higher in the past sixty days compared to four lower As a result  the current quarter consensus estimate has remained stable in the past two months  while the full year estimate has increased 1 5   You can see the consensus estimate trend and recent price action for the stock in the chart below CVS Health Corporation Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineCVS Health is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a robust industry rank  among the Top 41   should boost investor confidence However over the past two years  the industry has underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-02-17,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-cvs-health-cvs-stock-now-200389299,200389299
198829,420345,CVS,CVS Health Sees Hammer Chart Pattern  Time To Buy ,opinion,"CVS Health Corporation   NYSE CVS   has been struggling lately  but the selling pressure may be coming to an end soon  That is because CVS recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom 
  
  What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 4 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if CVS stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-sees-hammer-chart-pattern-time-to-buy-200375090,200375090
198830,420346,CVS,CVS Health  CVS  Dips More Than Broader Markets  What You Should Know,opinion,"CVS Health  NYSE CVS  closed at  65 34 in the latest trading session  marking a  0 71  move from the prior day  This change lagged the S P 500 s 0 53  loss on the day  At the same time  the Dow lost 0 36   and the tech heavy Nasdaq lost 0 94  
Coming into today  shares of the drugstore chain and pharmacy benefits manager had lost 10 3  in the past month  In that same time  the Retail Wholesale sector lost 0 45   while the S P 500 lost 1 47  
Wall Street will be looking for positivity from CVS as it approaches its next earnings report date  This is expected to be February 14  2019  On that day  CVS is projected to report earnings of  2 14 per share  which would represent year over year growth of 11 46   Meanwhile  our latest consensus estimate is calling for revenue of  49 20 billion  up 1 69  from the prior year quarter 
Investors should also note any recent changes to analyst estimates for CVS  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 4 36  higher  CVS is currently sporting a Zacks Rank of  2  Buy  
In terms of valuation  CVS is currently trading at a Forward P E ratio of 8 68  Its industry sports an average Forward P E of 10 99  so we one might conclude that CVS is trading at a discount comparatively 
Investors should also note that CVS has a PEG ratio of 0 79 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  CVS s industry had an average PEG ratio of 1 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 74  putting it in the top 29  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow CVS in the coming trading sessions  be sure to utilize Zacks com ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-dips-more-than-broader-markets-what-you-should-know-200375423,200375423
198831,420347,CVS,CVS Health  CVS  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  CVS Health  NYSE CVS  closed at  66 11  marking a  1 83  move from the previous day  This change outpaced the S P 500 s 0 22  gain on the day  Elsewhere  the Dow gained 0 7   while the tech heavy Nasdaq added 0 08  
Heading into today  shares of the drugstore chain and pharmacy benefits manager had gained 3 18  over the past month  lagging the Retail Wholesale sector s gain of 12 32  and the S P 500 s gain of 9 27  in that time 
Investors will be hoping for strength from CVS as it approaches its next earnings release  which is expected to be February 14  2019  In that report  analysts expect CVS to post earnings of  2 12 per share  This would mark year over year growth of 10 42   Our most recent consensus estimate is calling for quarterly revenue of  50 73 billion  up 4 85  from the year ago period 
It is also important to note the recent changes to analyst estimates for CVS  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 1 38  higher  CVS is currently a Zacks Rank  3  Hold  
In terms of valuation  CVS is currently trading at a Forward P E ratio of 8 81  This valuation marks a discount compared to its industry s average Forward P E of 10 98 
Meanwhile  CVS s PEG ratio is currently 0 88  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  CVS s industry had an average PEG ratio of 1 05 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 95  putting it in the top 38  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow CVS in the coming trading sessions  be sure to utilize Zacks com ",2019-01-23,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-outpaces-stock-market-gains-what-you-should-know-200378734,200378734
198835,420351,CVS,Aetna is fined by New York for leaking members  HIV status,news,"By Jonathan Stempel NEW YORK  Reuters     Aetna Inc   NYSE AET  will pay a  1 15 million civil fine and improve its privacy practices to settle charges that it leaked the HIV positive status of 2 460 New York members in a mailing where it used envelopes with large transparent windows  New York Attorney General Eric Schneiderman on Tuesday said names  addresses  claim numbers and HIV medication instructions in the July 28  2017 mailing were  clearly visible  to outsiders because of how Aetna folded letters and inserted them into the envelopes  The mailing was intended to notify members of a class action settlement permitting them to buy HIV medication at brick and mortar pharmacies rather than by mail  where their privacy might be compromised if neighbors or family saw the drug packages  While about 1 million Americans live with HIV or AIDS  the associated stigma can lead to a denial of proper healthcare  discrimination and other negative consequences  according to settlement papers signed by Aetna and Schneiderman s office   Through its own carelessness  Aetna blatantly violated its promise to safeguard members  private health information   the attorney general said in a statement  Schneiderman said his office uncovered similar issues with a Sept  25  2017 mailing by Aetna to 163 New York members with atrial fibrillation  an irregular heartbeat condition  The Hartford  Connecticut based company did not admit or deny wrongdoing  and agreed to retain an independent consultant for two years to monitor its efforts to improve member privacy  It agreed last week to a  17 2 million settlement in the federal court in Philadelphia of private litigation over similar claims by more than 11 000 members in New York and other states   We have worked to address the potential impact to members following this unfortunate incident   Aetna said in a statement   We are implementing measures designed to ensure something like this does not happen again as part of our commitment to best practices in protecting sensitive health information   Aetna agreed last month to be bought by CVS Health Corp  NYSE CVS  in a  69 billion transaction  
HIV is short for human immunodeficiency virus  and AIDS for Acquired Immunodeficiency Syndrome ",2018-01-23,Reuters,https://www.investing.com/news/stock-market-news/aetna-is-fined-by-new-york-for-leaking-members-hiv-status-1141766,1141766
198836,420352,CVS,Health insurer Aetna quarterly profit soars 75 5 percent,news, Reuters     Aetna Inc   N AET   which has agreed to be bought by CVS Health Inc  N CVS   reported a 75 5 percent rise in quarterly profit on Tuesday  due to lower restructuring and transaction and integration related costs  U S  drugstore operator CVS agreed in December to acquire Aetna for  69 billion seeking to tackle soaring healthcare spending through lower cost medical services in pharmacies  Net income attributable to Aetna rose to  244 million  or 74 cents per share  in the fourth quarter ended Dec  31  from  139 million  or 39 cents per share  a year earlier ,2018-01-30,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-aetna-quarterly-profit-soars-755-percent-1169267,1169267
198837,420353,CVS,Economic Calendar  Top Things to Watch ,news,"Investing com    On Monday  the ISM non manufacturing PMI for January is released in a light week on the economic calendar 

The U S  House of Representatives will vote on Tuesday on a spending bill to fund the federal government beyond Feb  8  when existing funds expire 

General Motors  NYSE GM   CVS Health  NYSE CVS   Kellogg and Chipotle are among some of the companies reporting earnings this week 

China is to release data on trade and inflation this week  which investors will scour for clues on both global and domestic Chinese demand 

Rate decisions by central banks in the UK  Australia and New Zealand will also be in focus ",2018-02-05,Investing.com,https://www.investing.com/news/economy-news/economic-calendar-top-things-to-watch-1195651,1195651
198838,420354,CVS,CVS fourth quarter profit jumps in wake of U S  tax law,news,"NEW YORK  Reuters    CVS Health Corp  N CVS   which said in December it would buy health insurer  Aetna Inc   N AET  in a  69 billion deal  posted a jump in profit on Thursday  helped by savings from the biggest overhaul of the U S  tax code in 30 years 
Net income attributable to the company rose 92 6 percent to  3 3 billion  or  3 2 per share  in the fourth quarter ended Dec  31  from  1 7 billion  or  1 59 per share  a year earlier  helped by an income tax benefit of  1 5 billion 
Excluding tax savings  the company earned  1 92 per share  beating analysts  average estimate of  1 89  according to Thomson Reuters I B E S 
Revenue rose 5 3 percent to  48 4 billion ",2018-02-08,Reuters,https://www.investing.com/news/stock-market-news/cvs-fourth-quarter-profit-jumps-in-wake-of-us-tax-law-1215120,1215120
198842,420358,CVS,CVS Health Aetna Synergy Impressive  PBM Selling Season Solid,opinion,On Dec 11  we issued an updated research report on CVS Health   NYSE CVS    An increasing demand for PBM  Pharmacy Benefit Management  and specialty pharmacy was a major growth driver for the stock  The company carries a Zacks Rank  3  Hold  On Nov 29  CVS Health completed its long awaited  70 billion consolidation of insurance giant Aetna  NYSE AET   The culmination of this huge deal marks the creation of a new healthcare powerhouse  which combines CVS Health s broad pharmacy business with Aetna s giant insurance base CVS Health now expects to earn  750 million from near term synergies with low  to mid single digit accretion in the second year post the transaction s closure  Per the company  shareholders can look forward to several outcomes with respect to near term synergy including an enhanced competitive positioning and a new combined platform that might redefine access to high quality care at low cost  thereby substantially accelerating the consolidated business  growth CVS Health Corporation Price   Notably  with regard to its 2019 PBM selling season  CVS Health has wrapped up more than 70  of its client renewals  roughly in line with the previous year s tally  The retention rate is currently higher than the figures reported over the last few years However  per management  the company sees fewer RFP  Request for Proposals  opportunities in the market as compared to the past few years  Despite this  current gross wins stand at an impressive level of  1 8 billion with net new business of approximately  200 million Significantly  in spite of tough pricing competition  CVS Health is currently gaining well  Further  this upside reflects high levels of service and execution  competitive pricing along with a unique integrated model  which allows the company to provide differentiated products and services that have potential to generate savings  better health outcomes as well as convenience On the flip side  the company worries about witnessing fewer RFP  Requests for Proposals  opportunities in the market than what it has been observing over the past few years  This might pose an obstacle to its PBM selling season performance in the coming quarters  Also  according to CVS Health  Omnicare business performance should persist to be soft through the second half of 2018 Shares of CVS Health have underperformed its  in the past six months  The stock has gained 10 5  compared with the 14 9  rise of the industry Key PicksSome better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and Surmodics  Inc   NASDAQ SRDX   Veeva Systems  long term earnings growth rate is estimated at 19 2   The stock sports a Zacks Rank  1  Strong Buy   You can see  Integer Holdings has an earnings growth rate of 30 3  for the ongoing year and a Zacks Rank  2  Buy  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-aetna-synergy-impressive-pbm-selling-season-solid-200367403,200367403
198843,420359,CVS,CVS Health  CVS  Stock Moves  1 66   What You Should Know,opinion,"CVS Health  NYSE CVS  closed at  70 69 in the latest trading session  marking a  1 66  move from the prior day  This move was narrower than the S P 500 s daily loss of 2 08   Meanwhile  the Dow lost 2 11   and the Nasdaq  a tech heavy index  lost 2 27  
Prior to today s trading  shares of the drugstore chain and pharmacy benefits manager had lost 9 97  over the past month  This has lagged the Retail Wholesale sector s loss of 4 18  and the S P 500 s loss of 3 6  in that time 
Investors will be hoping for strength from CVS as it approaches its next earnings release  which is expected to be February 14  2019  On that day  CVS is projected to report earnings of  2 12 per share  which would represent year over year growth of 10 42   Our most recent consensus estimate is calling for quarterly revenue of  50 40 billion  up 4 16  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  7 02 per share and revenue of  189 58 billion  These totals would mark changes of  18 98  and  2 61   respectively  from last year 
Any recent changes to analyst estimates for CVS should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 19  lower  CVS is currently sporting a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that CVS has a Forward P E ratio of 10 24 right now  This represents a discount compared to its industry s average Forward P E of 12 06 
Investors should also note that CVS has a PEG ratio of 0 94 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Retail   Pharmacies and Drug Stores was holding an average PEG ratio of 1 17 at yesterday s closing price 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 106  which puts it in the top 41  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow CVS in the coming trading sessions  be sure to utilize Zacks com ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-stock-moves-166-what-you-should-know-200368908,200368908
198844,420360,CVS,CVS Health  CVS  Stock Moves  1 22   What You Should Know,opinion,"CVS Health  NYSE CVS  closed at  62 92 in the latest trading session  marking a  1 22  move from the prior day  This change was narrower than the S P 500 s 2 71  loss on the day  At the same time  the Dow lost 2 91   and the tech heavy Nasdaq lost 2 21  
Coming into today  shares of the drugstore chain and pharmacy benefits manager had lost 15 17  in the past month  In that same time  the Retail Wholesale sector lost 8 9   while the S P 500 lost 8 68  
CVS will be looking to display strength as it nears its next earnings release  which is expected to be February 14  2019  In that report  analysts expect CVS to post earnings of  2 11 per share  This would mark year over year growth of 9 9   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  50 40 billion  up 4 16  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  7 02 per share and revenue of  189 58 billion  These totals would mark changes of  18 98  and  2 61   respectively  from last year 
It is also important to note the recent changes to analyst estimates for CVS  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 09  lower within the past month  CVS is currently sporting a Zacks Rank of  3  Hold  
Investors should also note CVS s current valuation metrics  including its Forward P E ratio of 9 07  This valuation marks a discount compared to its industry s average Forward P E of 10 3 
It is also worth noting that CVS currently has a PEG ratio of 0 83  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CVS s industry had an average PEG ratio of 1 05 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 93  which puts it in the top 36  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-12-24,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-stock-moves-122-what-you-should-know-200370790,200370790
198845,420361,CVS,Hospital operators in merger talks to form U S  industry leader  WSJ,news,NEW YORK  Reuters    Ascension Health and Providence St  Joseph Health are in talks about a merger between the two Catholic non profits that would create the largest U S  hospital chain  the Wall Street Journal reported on Sunday  citing people familiar with the discussions   A deal between St  Louis based Ascension and Renton  Washington based Providence would give the combined entity 191 hospitals in 27 states and annual revenue of  44 8 billion  the Journal reported  That would surpass the current largest U S  hospital operator  HCA Healthcare Inc  N HCA   a for profit company   Providence declined to comment on the report  Ascension did not respond to a request for comment   The two have been in talks about a deal for months but have not reached an agreement  the Journal reported  The paper said that unlike for profit companies  mergers of nonprofit hospital operators do not typically involve one entity buying the other   The merger talks come at a pivotal time in the industry  as a series of deals  major changes to the 2010 Affordable Care Act  dubbed Obamacare  and rising drug prices have reshaped the U S  healthcare landscape   Last week  Catholic Health Initiatives  and Dignity Health announced that they had signed a definitive agreement to align their organizations  The merger would result in the formation of a large and diverse Catholic health system  On Dec  3  CVS Health Corp  N CVS  and  Aetna Inc   N AET  proposed a  69 billion merger  arguing it would enable the companies to tackle soaring healthcare spending by offering lower cost medical services in pharmacies  That deal  the year s largest  would combine one of the nation s biggest pharmacy benefits managers and pharmacy operators with one of its oldest health insurers ,2017-12-10,Reuters,https://www.investing.com/news/stock-market-news/hospital-operators-in-merger-talks-to-create-us-industry-leader-wsj-974883,974883
198846,420362,CVS,CVS plans to keep Aetna s headquarters in Connecticut,news,NEW YORK  Reuters    CVS Health Inc  N CVS  said on Friday that it plans to keep Aetna Inc s  N AET  headquarters in Connecticut after it completes its  69 billion acquisition of the U S  health insurer   We have no plans to relocate Aetna s operations from Hartford and  in fact  view Hartford as the future location of our center of excellence for the insurance business   CVS spokeswoman Carolyn Castel said in an email  CVS will continue to be headquartered in Rhode Island  The company s CEO met with Connecticut Governor Dannel Malloy as well as Hartford Mayor Luke Bronin on Thursday  Aetna had said last year that it planned to move its corporate headquarters to New York in 2018  CVS struck its deal to buy Aetna last month  combining one of the nation s largest pharmacy benefits managers and pharmacy operators with one of its oldest health insurers  whose national business ranges from employer healthcare to government plans ,2018-01-12,Reuters,https://www.investing.com/news/stock-market-news/cvs-plans-to-keep-aetnas-headquarters-in-connecticut-1098737,1098737
198850,420366,CVS,Opening Bell  Stocks Climb Ahead Of Key Fed Speech  USD Eyes 17 Month High ,opinion,"Stocks rally after White House s Kudlow says trade deal is possible
Trade hopes drive market despite anomaly of Materials and Industrials underperformance
US Treasury yields flirt with a top reversal  a bearish signal for equities
Bitcoin climbs back above  4 000

Key Events
European shares and futures on the Dow  S P 500 and NASDAQ 100 flashed green across the board  extending the rally seen yesterday on Wall Street  as investors found some steady footing ahead of a crucial speech by Federal Chair Jerome Powell 
The STOXX Europe 600 rallied  buoyed by miners and energy producers  as traders took their cues from a bullish Asian session where regional benchmarks such as Japan s Nikkei 225 outperformed   1 02   though the Japanese benchmark closed well below its highs  paring 2 29 percent from its intraday high  Australia s S P ASX 200   0 06 percent  was the only regional index to close in negative territory  dragged lower by materials stocks 
Global Financial Affairs
Yesterday  US equities extended a rebound on hopes of easing trade tensions between the world s two largest economies  The natural exception were small cap stocks   0 80    whose luster fades each time traders see a light at the end of the US China trade dispute tunnel  Conversely  the Dow Jones Industrial Average outperformed   0 44 percent   suggesting optimism on a trade resolution was the main market driver during the session 
Equities did in fact reverse losses after the White House s chief economic adviser Larry Kudlow said the meeting between China s leader Xi Jinping and US President Donald Trump is an opportunity to  turn the page  on trade relations  Ironically  Kudlow s reassurance did nothing for trade dispute proxy sector Materials   1 22    the clear underperformer  Industrials   0 17    the other most affected sector during trade jitters  also lagged behind  We found no explanation for this anomaly 
The S P 500 advanced 0 33 percent  sealing two day gains of 1 87   The second worst performing sector after Materials was Energy whose fate is tied with oil s woes which still managed to close more than a full percentage point above the main laggard   0 28    Health care   1 04   fared as the day s winner  advancing for a third straight day as CVS Health  NYSE CVS  s and Aetna  NYSE AET  shares continued to surge after winning state approval for their  69 billion merger on Monday 

CVS gained 2 13  on Tuesday  bringing its three day gains to 5 87   Technically  the trading pattern is developing a potential massive H S bottom since November 2016 
The NASDAQ Composite   0 01   barely managed to hold on to this week s gains 

Meanwhile  the yield on 10 year Treasurys extended a consolidation after Fed Vice Chairman Richard Clarida supported gradual rate hikes ahead of Powell s speech today 

The dollar initially edged higher but later wavered around neutral levels  Technically  the greenback reached 0 6  below the November 12 close and 0 20 percent from the November 12 high  Any additional gains will extend the medium term uptrend and take the USD to the highest levels since June 2017 
The pound was mildly positive amid new developments in the battle between UK Prime Minister Theresa May and Parliament  as May appeared to abandon her attempts to get her draft Bexit proposal voted without amendments  European bonds and the euro meandered 
Bitcoin climbed above  4 000 after plunging earlier in the week 
Brent crude also rebounded to about  61 a barrel  though it later slipped into negative territory  Overall  the recent shifts in the oil market seem to have swayed the direction of the broader commodities spectrum this year 
Later today  Powell s speech will be scrutinized for any clue  however subtle  on whether the pace of the Fed s interest rate tightening will slow down to any extent  Recently  investors have reacted strongly to the continued removal of the central bank s unprecedented accommodation  which was the main tailwind for the longest bull market on record  Clarida said risks to the US economy are  less skewed to the downside   while St  Louis Fed President James Bullard was more cautious  telling Reuters that officials must monitor possible  cracks  in the American recovery and that growth is going to slow in 2019 and 2020 
We have repeatedly argued that interest rates are the main driver of long lasting market moves  while the US China trade story will be less impactful in the longer term  Nevertheless  trader focus will also be turning to the long awaited meeting between Trump and Xi Jinping in Buenos Aires this week  with the outcome remaining highly uncertain after Trump s recent mixed messages 
Up Ahead

Presidents Donald Trump and Xi Jinping plan to meet at the G 20 summit in Argentina that kicks off on Friday 
Federal Reserve Chairman Jerome Powell addresses the New York Economic Club on Wednesday 
Thursday sees the release of the minutes from the Federal Open Market Committee s November meeting 

Market Moves
Stocks

Futures on the S P 500 climbed 0 1 percent  to the highest level in more than a week 
The Stoxx Europe 600 gained 0 5 percent to the highest level in two weeks 
The MSCI All Country World Index edged 0 2 percent higher to the highest level in more than a week 
The MSCI Emerging Market Index increased 0 8 percent to the highest level in more than a week on the biggest climb in almost two weeks 

Currencies

The Dollar Index climbed more than 0 1 percent to the highest in more than two weeks 
The Japanese yen dropped 0 1 percent to 113 86 per dollar  the weakest level in almost three weeks 
The British pound gained less than 0 05 percent to  1 2749 
The MSCI Emerging Markets Currency Index gained less than 0 05 percent 

Bonds

The yield on 10 year Treasuries increased less than one basis point to 3 06 percent 
Germany s 10 year yield slipped one basis point to 0 34 percent 
Britain s 10 year yield declined one basis point to 1 382 percent 
The spread of Italy s 10 year bonds over Germany s advanced two basis points to 2 956 percentage points 

Commodities

The Bloomberg Commodity Index ticked 0 3 percent higher  the first advance in a week 
LME copper advanced 0 4 percent to  6 146 50 per metric ton  the biggest gain in a week 
Gold slid 0 2 percent to  1 213 19 an ounce  the weakest level in two weeks ",2018-11-28,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/opening-bell-200362945,200362945
198851,420367,CVS,CVS Health Closes Aetna Deal  Focuses More On Pharmacy Wing,opinion,CVS Health Corporation   NYSE CVS   has finally completed the long awaited  70 billion consolidation of Aetna  NYSE AET   This came close on the heels of the company getting the final regulatory approval required for wrapping up this colossal merger The culmination of this huge deal marks the creation of a new healthcare powerhouse  which combines CVS Health s broad pharmacy business with Aetna s giant insurance base  In a nut shell  the combined entity is aiming to create a new health care model that is local  easier to use  less expensive and provides advanced care  With this news  shares of CVS Health inched up 0 8  to  80 27 at the close of business on Nov 28 Transaction DetailUnder the terms of the transaction  each outstanding share of Aetna has been exchanged for  145 in cash and 0 8378 shares of CVS Health common stock  The purchase consideration of Aetna is valued at  212 per share or approximately  70 billion  Including the assumption of Aetna s debt  the total worth of the transaction is  78 billion  The combined company s shares will be listed under the NYSE with the ticker symbol CVS  Post integration  Aetna will operate as a stand alone business within the CVS Health enterprise A Strategic ConsolidationPer CVS Health  the combined company on one hand will provide customers with the powerful health resources of CVS Health in communities across the country  While on the other  it will offer customers with Aetna s network of providers for high quality care  This will help building lasting relationships with consumers  making it easier for them to access information  resources and services CVS health stated that the combined company s new products and services will be broadly available to the health care marketplace  regardless of one s insurer  pharmacy benefit manager  PBM  or pharmacy of choice  Legacy CVS Health s offerings like retail pharmacy services  specialty pharmacy and long term care plus walk in clinical services and PBM services  will continue to be fully accessible to other health plans  Aetna members will also consistently have a broad network of pharmacies including community based independent pharmacies  CVS Pharmacy will steadily participate within the pharmacy networks for other PBMs and health plans With regard to the new health care model  CVS Health announced that in the coming months  it will introduce new programs and services targeting improving access to care  health outcomes and reduction in medical costs for all consumers  These programs specifically will pursue better and more efficient management of chronic disease using the networks  technology and the people of the combined company Synergy Benefits  A GlimpseCVS Health is highly optimistic about this merger  Per the company  this move has great potential in the long haul to deliver a significant incremental value in terms of developing products and generating growth opportunities as a uniquely integrated retailer  pharmacy benefits manager and a far sighted health planner During CVS Health s third quarter 2018 earnings call earlier this month  it notified that the combined entity is expected to generate more than  750 million in savings in the second year of the acquisition s completion by just merging both companies  existing assets and capabilities  A majority of these synergies will be derived from lower corporate expenses and the conjoining of both companies  operations along with some cutbacks in medical costs Per CVS Health  shareholders can look forward to several outcomes with respect to the near term synergy including an enhanced competitive positioning and a new unified platform that might redefine access to high quality care at low cost  thus substantially accelerating the consolidated business  growth Share Price PerformanceShares of CVS Health have underperformed its  in the past six months  The stock has rallied 21 3  compared with the 24 6  rise of the industry Zacks Rank and Key PicksCVS Health currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   Integer Holdings has an expected earnings growth rate of 30 3  for the current year and a Zacks Rank  2  Buy  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 currently Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  1  Strong Buy  at present  You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-closes-aetna-deal-focuses-more-on-pharmacy-wing-200363963,200363963
198852,420368,CVS,CVS Health  CVS  Stock Moves  0 77   What You Should Know,opinion,"CVS Health  NYSE CVS  closed at  78 91 in the latest trading session  marking a  0 77  move from the prior day  This change was narrower than the S P 500 s 3 24  loss on the day  Elsewhere  the Dow lost 3 1   while the tech heavy Nasdaq lost 3 8  
Prior to today s trading  shares of the drugstore chain and pharmacy benefits manager had gained 8 8  over the past month  This has outpaced the Retail Wholesale sector s gain of 2 95  and the S P 500 s gain of 2 73  in that time 
Wall Street will be looking for positivity from CVS as it approaches its next earnings report date  This is expected to be February 14  2019  On that day  CVS is projected to report earnings of  2 13 per share  which would represent year over year growth of 10 94   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  50 38 billion  up 4 13  from the year ago period 
CVS s full year Zacks Consensus Estimates are calling for earnings of  7 03 per share and revenue of  189 54 billion  These results would represent year over year changes of  19 15  and  2 59   respectively 
Any recent changes to analyst estimates for CVS should also be noted by investors  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 31  lower  CVS is currently sporting a Zacks Rank of  3  Hold  
Investors should also note CVS s current valuation metrics  including its Forward P E ratio of 11 31  This valuation marks a discount compared to its industry s average Forward P E of 13 11 
Meanwhile  CVS s PEG ratio is currently 1 14  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Retail   Pharmacies and Drug Stores was holding an average PEG ratio of 1 15 at yesterday s closing price 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This industry currently has a Zacks Industry Rank of 68  which puts it in the top 26  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-stock-moves-077-what-you-should-know-200365057,200365057
198853,420369,CVS,Mixed Trade War Signals  The Moonves Scandal    CVS  Drug Price Plan,opinion,"On today s episode of Free Lunch  Ryan McQueeney discusses the latest drama in the U S  China trade war  new developments in Les Moonves  departure from CBS  and a new drug pricing plan from pharmacy giant CVS 
Want more video content from Zacks  Subscribe to  now 
Free Lunch is presented by Zacks Investment Research  It is streamed live  four times per week  and features breaking news and analysis from Zacks strategists  Free Lunch is available on YouTube  Facebook  NASDAQ FB  Live  Twitter  Ustream  and more 
The U S  stock market is closed Wednesday in observance of the National Day of Mourning for President George H W  Bush  Futures trading is open  however  and some investors are trying to figure out their next move after one of the worst trading sessions of 2018 on Tuesday 
One factor that Wall Street is considering this week is the uncertainty surrounding U S  China trade talks  Over the weekend  it seemed that a G20 meeting between officials from both sides went well  with initial reports suggesting that a 90 day halt on new tariffs had been agreed to 
But on Tuesday  a series of tweets from President Trump and rumors of frustration and confusion from the Chinese sent stocks tumbling  as all of a sudden the existence of a 90 day truce looked questionable 
That concern was cooled to an extent overnight  with Chinese officials announcing that they are  confident in implementing  trade commitments made to the U S  Still  questions remain  Does that statement refer to a truce  or reported pledges to buy more U S  goods  Could it also include movement on intellectual property issues  What about the topic of cracking down on fentanyl  Clear answers to these questions are seemingly unavailable right now 
Elsewhere  we learned about the ongoing scandal related to Les Moonves  departure from CBS   NYSE CBS    The former chief executive recently left CBS after being accused of sexual misconduct  and now  according to a new report from the New York Times  it looks like the network might be able to avoid paying Moonves   120 million severance package 
Moonves may have disqualified himself from that massive payout by destroying evidence and lying to investigators  the Times reported 
Another big story today comes from CVS   NYSE CVS    which just closed its merger with Aetna  NYSE AET  last week  A huge talking point behind that deal was that it would allow CVS new ways to save customers money on drugs and treatments 
Today  CVS announced what may be its first step in that direction  a new pricing strategy for its prescription benefit subsidiary CVS Caremark  Among other things  this plan will allow CVS to pass through 100  of drug rebates to its health plan clients 
Make sure to check out today s show for more information on all of these stories 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/mixed-trade-war-signals-the-moonves-scandal--cvs-drug-price-plan-200365373,200365373
198854,420370,CVS,Why Is CVS Health  CVS  Up 0 2  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for CVS Health  NYSE CVS   Shares have added about 0 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is CVS Health due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  CVS Health s PBM Selling Season Remains Solid  Retail GrowsCVS Health third quarter 2018 adjusted earnings per share  EPS  of  1 73 surged 15 3  year over year and exceeded the Zacks Consensus Estimate of  1 71  The quarter s adjusted EPS considered certain transaction and integration costs related to the proposed acquisition of Aetna  NYSE AET  and the purchase of Omnicare On a reported basis  earnings came in at  1 36 per share in the quarter  a 7 9  improvement year over year Net revenues in the third quarter increased 2 4  year over year to  47 27 billion  This surpassed the Zacks Consensus Estimate by 0 2  Quarter in Details Pharmacy Services revenues increased 2 6  to  33 8 billion in the reported quarter  driven by growth in pharmacy network and mail choice claim volume as well as brand inflation  This was  however  partially offset by continued price compression Pharmacy network claims processed during the quarter climbed 5 4  to 394 5 million on a 30 day equivalent basis  backed by net new business growth  Also  the Mail Choice claim processed count was 71 8 million  up 7 4  on a 30 day equivalent basis on continued adoption of Maintenance Choice offeringsand an increase in specialty pharmacy claims Revenues from CVS Health s Retail LTC were up by 6 4  year over year to  20 9 billion  According to the company  a 9 2  increase in same store prescriptions on a 30 day equivalent basis  continued adoption of Patient Care Programs  alliances with PBMs and health plans  inclusion in a number of additional Medicare Part D networks and brand inflation were partially offset by continued reimbursement pressure Front store same store sales were up 0 8  year over year on continued to benefit from strength in the company s consumer health care and beauty care categories Pharmacy same store sales increased 8 7  in the reported quarter driven by the increase in pharmacy same store prescription volumes  partially offset by continued reimbursement pressure and a negative impact of approximately 190 basis points due to recent generic introductions The generic dispensing rate  the proportion of all generic prescriptions to total number of prescriptions dispensed  increased approximately 20 bps to 87 2  at the Pharmacy Services segment and improved around 10 bps to 87 3  at the Retail LTC segment Gross profit improved 2 9  to  7 3 billion  Accordingly  gross margin expanded 9 bps to 15 5   Adjusted operating margin in the quarter however  contracted 43 bps to 4 9  CVS Health exited the third quarter 2018 with cash and cash equivalents and short term investments of  41 7 billion compared with  43 9 billion at the end of the second quarter  Year to date  net cash provided by operating activities was  6 4 billion  as compared to  8 1 billion a year ago OutlookCVS Health reaffirmed its earlier projection to deliver full year 2018 adjusted EPS in the band of  6 98 to  7 08  The Zacks Consensus Estimate for earnings is pegged at  7 05 per share  within but near to the upper end of the company s guided range  This apart  its 2018 adjusted operating profit growth guidance still remains in the range of  0 75   to up 0 75  Further  the company expects cash flow from operations of  9 billion and free cash flow of  7 billion in 2018 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  CVS Health has an average Growth Score of C  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  CVS Health has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-cvs-health-cvs-up-02-since-last-earnings-report-200365703,200365703
198855,420371,CVS,The year s biggest deal is far from certain,news,"CVS Health  NYSE CVS  s massive acquisition of Aetna  NYSE AET  could face heightened regulatory scrutiny amid the Trump administration s new regulatory regime 
Aetna s stock is trading about 10  below the per share offer price  reflecting investor uncertainty that the deal will get approval 

 A year ago  CVS Health s  69 billion acquisition of Aetna would ve probably skated past regulatory proceedings  But things have changed under the Trump administration  and investors don t look particularly confident that the mega deal will be approved 
This uncertainty around the deal   the biggest to be announced in 2017   is being reflected by Aetna s stock  which is trading near  184 a share  roughly 10  below the  207 a share offer made by CVS 
This discount serves as a handy gauge of sentiment around the deal   if investors think approval is likely  they will trade Aetna s shares near the proposed deal price   and its depth at present time doesn t paint the most promising picture 
In the minds of investors  the deal s sticking point is Makan Delrahim  the US Department of Justice s new antitrust chief  In his short time on the job  he s been less receptive to so called  vertical  mergers  which involve the combination of two companies that hold different places in the same supply chain 
Case in point  Delrahim s recent handling of AT T  NYSE T  s attempted acquisition of Time Warner  While it may appear to be a textbook vertical deal  the Justice Department has sued to block it  calling the deal anti competitive and warning against higher monthly television bills for customers 
Still  the Trump administration s resistance of the deal must be taken with a grain of salt  considering the president s past criticisms of CNN  which is owned by Time Warner  Trump was expressing displeasure around the merger as far back as 2016  when he said in a speech that it was  too much concentration of power in the hands of too few  
So the question now becomes  will Delharim  and by extension the Trump administration  be as tough on future vertical mergers as they ve been on the AT T Time Warner deal  Are they leading a new crusade against this type of deal  or was that a specific case driven by a personal agenda 
One large deciding factor could be the effect the proposed CVS Aetna merger has on drug prices  If the two firms are able to combine to lower middleman expenses  that might allow the deal to survive the regulatory gauntlet 
And that  in turn  would likely boost Aetna s stock price closer to the offer price of  207  if not above it  The company s stock climbed 1 8  to  184 48 in early trading on Monday  Meanwhile  CVS s shares dropped 3 2  ",2017-12-05,Business Insider,https://www.investing.com/news/stock-market-news/the-years-biggest-deal-is-far-from-certain-954688,954688
198856,420372,CVS,CVS expects Justice Department to handle review of Aetna deal,news,"WASHINGTON  Reuters    CVS Health Corp  NYSE CVS  expects the U S  Justice Department to do the antitrust review of its planned acquisition of health insurer  Aetna Inc   NYSE AET   a spokesman for the drugstore chain operator said  CVS Health Corp and Aetna announced the  69 billion deal on Dec  3  arguing it would enable the companies to tackle soaring healthcare spending by offering lower cost medical services in pharmacies   The Justice Department and U S  Federal Trade Commission share the job of reviewing mergers to make sure they do not hurt consumers  The deal  the year s largest  will combine one of the nation s biggest pharmacy benefits managers and pharmacy operators with one of its oldest health insurers   Asked which antitrust agency would review the deal  CVS spokesman David Palombi late on Thursday said   Our expectation is that it will be the Justice Department   No matter who reviews the deal  six antitrust experts have told Reuters that they expect it to be approved since most of the two companies  business is in separate markets   Two said they believed the Justice Department could try to stop the transaction for fear that customers would face higher drug prices or have less choice  The U S  government tends to block mergers if the combining companies are competitors in a concentrated market   
Deals like this one  where companies make acquisitions up or down the supply chain  tend to be considered to be inherently efficient  The big exception is if there is a fear that the purchasing companies  rivals would lose critical access to the suppliers  products  That is the case with AT T  NYSE T  Inc s deal for  Time Warner  Inc  NYSE TWX   which the Justice Department has sued to stop ",2017-12-08,Reuters,https://www.investing.com/news/stock-market-news/cvs-expects-justice-department-to-handle-review-of-aetna-deal-971044,971044
198858,420374,CVS,CVS Health  CVS  Q3 Earnings And Revenues Surpass Estimates,opinion,"CVS Health  NYSE CVS  came out with quarterly earnings of  1 73 per share  beating the Zacks Consensus Estimate of  1 71 per share  This compares to earnings of  1 50 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 17   A quarter ago  it was expected that this drugstore chain and pharmacy benefits manager would post earnings of  1 61 per share when it actually produced earnings of  1 69  delivering a surprise of 4 97  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
CVS Health  which belongs to the Zacks Retail   Pharmacies and Drug Stores industry  posted revenues of  47 27 billion for the quarter ended September 2018  surpassing the Zacks Consensus Estimate by 0 17   This compares to year ago revenues of  46 18 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
CVS Health shares have added about 1 6  since the beginning of the year versus the S P 500 s gain of 2 4  
What s Next for CVS Health 
While CVS Health has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for CVS Health was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 16 on  49 30 billion in revenues for the coming quarter and  7 04 on  188 87 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Retail   Pharmacies and Drug Stores is currently in the top 1  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-q3-earnings-and-revenues-surpass-estimates-200355337,200355337
198859,420375,CVS,CVS Health  CVS  Gains As Market Dips  What You Should Know,opinion,"CVS Health  NYSE CVS  closed the most recent trading day at  80 34  moving  0 64  from the previous trading session  The stock outpaced the S P 500 s daily loss of 1 97   Meanwhile  the Dow lost 2 32   and the Nasdaq  a tech heavy index  lost 2 78  
Heading into today  shares of the drugstore chain and pharmacy benefits manager had gained 9 07  over the past month  outpacing the Retail Wholesale sector s loss of 1 88  and the S P 500 s loss of 3 33  in that time 
Investors will be hoping for strength from CVS as it approaches its next earnings release  which is expected to be February 14  2019  The company is expected to report EPS of  2 15  up 11 98  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  49 42 billion  up 2 14  from the prior year quarter 
CVS s full year Zacks Consensus Estimates are calling for earnings of  7 04 per share and revenue of  189 04 billion  These results would represent year over year changes of  19 32  and  2 31   respectively 
Any recent changes to analyst estimates for CVS should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 05  lower  CVS currently has a Zacks Rank of  3  Hold  
Looking at its valuation  CVS is holding a Forward P E ratio of 11 34  This represents a discount compared to its industry s average Forward P E of 12 59 
It is also worth noting that CVS currently has a PEG ratio of 1 06  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Retail   Pharmacies and Drug Stores industry currently had an average PEG ratio of 1 1 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 9  putting it in the top 4  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-gains-as-market-dips-what-you-should-know-200358450,200358450
198860,420376,CVS,CVS Health  CVS  Stock Sinks As Market Gains  What You Should Know,opinion,"In the latest trading session  CVS Health  NYSE CVS  closed at  75 07  marking a  0 6  move from the previous day  This change lagged the S P 500 s daily gain of 0 3   At the same time  the Dow 0   and the tech heavy Nasdaq gained 0 92  
Prior to today s trading  shares of the drugstore chain and pharmacy benefits manager had gained 4 24  over the past month  This has outpaced the Retail Wholesale sector s loss of 5  and the S P 500 s loss of 4 37  in that time 
CVS will be looking to display strength as it nears its next earnings release  which is expected to be February 14  2019  In that report  analysts expect CVS to post earnings of  2 13 per share  This would mark year over year growth of 10 94   Meanwhile  our latest consensus estimate is calling for revenue of  49 77 billion  up 2 86  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  7 03 per share and revenue of  189 37 billion  which would represent changes of  19 15  and  2 49   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for CVS  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 33  lower within the past month  CVS currently has a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that CVS has a Forward P E ratio of 10 75 right now  This represents a discount compared to its industry s average Forward P E of 12 19 
Also  we should mention that CVS has a PEG ratio of 1 01  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CVS s industry had an average PEG ratio of 1 09 as of yesterday s close 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 10  putting it in the top 4  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow CVS in the coming trading sessions  be sure to utilize Zacks com ",2018-11-21,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-stock-sinks-as-market-gains-what-you-should-know-200361581,200361581
198861,420377,CVS,CVS Health disrupted by computer issue,news,CVS Health  NYSE CVS  is down in early trading amid reports of computer problems at pharmacies that are preventing some customers from filling orders  The company says an internal network infrastructure issue is to blame  CVS  1 44  premarket to  69 48  Now read ,2017-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/cvs-health-disrupted-by-computer-issue-863988,863988
198862,420378,CVS,Diplomat Pharmacy plunges as investors fret over rapid PBM push,news, Reuters    Shares of  Diplomat Pharmacy  Inc  N DPLO  tumbled 20 percent on Thursday after the company acquired a second pharmacy benefit manager in less than a month  sparking concerns it is expanding into a business that is under heightened regulatory scrutiny  The specialty pharmacy said on Wednesday that it would buy Missouri based pharmacy benefit manager LDI Integrated Pharmacy Services for  388 mln in cash and  80 mln in stock  The company last week said it would buy National Pharmaceutical Services  Some analysts were not excited by the company s latest move  noting there are long term questions on the viability of the pharmacy benefit manager  PBM  market  Baird analyst Eric Coldwell said the deal is at a time when PBMs are trying to diversify and are arguably on the downslope and in a price war   We see many stock risks in this deal and it feels like Diplomat overpaid for another asset that makes it look more and more like the rest of our supply chain coverage   said Eric Coldwell  downgrading the stock to  neutral  from  overweight   PBMs negotiate drug benefits for health insurance plans and employers  and along with others in the pharmaceutical supply chain  have been weighed down by intense scrutiny over soaring drug prices     Mizuho analyst Ann Hynes said integrating the two PBMS in short order could be a challenge  But on a conference call on Wednesday discussing the deal Diplomat Chief Executive Philip Hagerman said the company has all the capabilities and resources to both compete and thrive in the PBM market space  Until Thursday s steep decline  Diplomat s shares had climbed about 51 percent this year  Cowen   Co analyst said the deals help the company transition towards a broader healthcare company  with the business model similar to that of CVS Health  N CVS  and Express Scripts  O ESRX   which trade at lower valuations  Diplomat currently trades at 22 9x forward 12 month earnings  compared with 11 1x for CVS Health and 7 9x for Express Scripts  according to Thomson Reuters data ,2017-11-16,Reuters,https://www.investing.com/news/stock-market-news/diplomat-pharmacy-plunges-as-investors-fret-over-rapid-pbm-push-872679,872679
198863,420379,CVS,CVS closes in on deal to buy health insurer Aetna  source,news,"By Carl O Donnell  Reuters    CVS Health Corp  N CVS  is moving closer to a more than  66 billion cash and stock deal to buy health insurer  Aetna Inc   N AET  that could be announced as early as Monday  a source familiar with the matter said on Thursday  The companies are in advanced stages of negotiating a deal that would value Aetna at between  200 and  205 per share and would be comprised mainly of cash  according to a Wall Street Journal report  Shares of both companies rose on the news  with the enhanced cash component viewed as a positive surprise  CVS shares were up 3 9 percent and Aetna gained 1 3 percent  Jeff Jonas  portfolio manager for Gabelli Funds  said the reported price was a bit less than he had expected    The bigger deal is if they re going to be paying mostly cash it would be much more accretive to CVS   he said   Initially I d been thinking anywhere from a third to a half in stock and it s a pretty depressed stock price  This is actually much more positive than I thought   added Jonas  whose fund holds both stocks  Sources told Reuters earlier this month that the deal would value the company at more than  200 per share  The deal would combine CVS  one of the largest U S  pharmacy benefits managers  PBMs  and drugstore chains  with Aetna  one of the oldest health insurers  whose far reaching business ranges from employer healthcare to government plans nationwide  Healthcare consolidation has been a popular route for insurers and pharmacies  under pressure from the government and large corporations to lower soaring medical costs  PBMs negotiate drug benefits for health insurance plans and employers  and have in recent years taken an increasingly aggressive stance in price negotiations with drugmakers  They often extract discounts and after market rebates from drugmakers in exchange for including their medicines in PBM preferred formularies with low co payments  
A tie up with Aetna could give CVS more leverage in its price negotiations with drug makers ",2017-11-30,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-closes-in-on-deal-to-buy-health-insurer-aetna-wsj-934681,934681
198864,420380,CVS,CVS Health  CVS  Gains But Lags Market  What You Should Know,opinion,"CVS Health  NYSE CVS  closed the most recent trading day at  72 84  moving  0 61  from the previous trading session  This change lagged the S P 500 s 1 09  gain on the day  Elsewhere  the Dow gained 0 97   while the tech heavy Nasdaq added 2 01  
Prior to today s trading  shares of the drugstore chain and pharmacy benefits manager had lost 8 64  over the past month  This has was narrower than the Retail Wholesale sector s loss of 13 73  and lagged the S P 500 s loss of 7 81  in that time 
Investors will be hoping for strength from CVS as it approaches its next earnings release  which is expected to be November 6  2018  In that report  analysts expect CVS to post earnings of  1 71 per share  This would mark year over year growth of 14   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  47 19 billion  up 2 18  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  7 01 per share and revenue of  188 88 billion  which would represent changes of  18 81  and  2 23   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for CVS  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 02  higher  CVS currently has a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that CVS has a Forward P E ratio of 10 32 right now  For comparison  its industry has an average Forward P E of 12 06  which means CVS is trading at a discount to the group 
It is also worth noting that CVS currently has a PEG ratio of 0 97  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Retail   Pharmacies and Drug Stores stocks are  on average  holding a PEG ratio of 1 12 based on yesterday s closing prices 
The Retail   Pharmacies and Drug Stores industry is part of the Retail Wholesale sector  This group has a Zacks Industry Rank of 24  putting it in the top 9  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-gains-but-lags-market-what-you-should-know-200352672,200352672
198875,420391,CVS,CVS  Aetna aim to finalize deal as early as December  sources,news,"By Carl O Donnell and Greg Roumeliotis  Reuters    U S  pharmacy operator CVS Health Corp  N CVS  and health insurer  Aetna Inc   N AET  are working toward finalizing merger terms and announcing a deal for more than  70 billion as early as December  according to people familiar with the matter  The deal would combine CVS  one of the largest U S  pharmacy benefits managers and drugstore chains  with Aetna  one of the oldest health insurers  whose far reaching business ranges from employer healthcare to government plans nationwide  The companies have agreed that CVS will split its consideration for the deal between cash and CVS stock  a deal structure that would minimize tax liabilities for Aetna shareholders  the sources said  A deal will probably value Aetna at significantly more than  200 per share  the sources said  adding that the companies will agree to an exact price closer to signing the deal in December  The sources asked not to be identified because the negotiations are confidential  Aetna declined to comment  while CVS did not respond to a request for comment  Aetna shares rose as much as 6 percent on the news and ended trading up 2 7 percent on Friday at  176 99  They have risen over 10 percent since Oct  26  when the Wall Street Journal first reported that CVS and Aetna were in merger talks  CVS shares ended trading down 0 2 percent at  69 25  giving the company a market capitalization of  70 billion  Healthcare consolidation has been a popular route for insurers and pharmacies  under pressure from the government and large corporations to lower soaring medical costs  Pharmacy benefit managers  PBMs  such as CVS negotiate drug benefits for health insurance plans and employers  and have in recent years taken an increasingly aggressive stance in price negotiations with drugmakers  They often extract discounts and after market rebates from drugmakers in exchange for including their medicines in PBM formularies with low co payments  A tie up with Aetna could give CVS more leverage in its price negotiations with drug makers   The deal would follow years of major changes to the U S  health insurance industry under former President Barack Obama  whose 2010 Affordable Care Act created new ground rules for how insurers operate and expanded insurance to 20 million more Americans  
Republican President Donald Trump has promised to turn back many of the Affordable Care Act s facets  but Congress has not been able to agree on a repeal or a replacement  The lack of progress  along with Trump s executive order to bring down healthcare costs  has created uncertainty for insurers as they head into 2018 ",2017-11-03,Reuters,https://www.investing.com/news/stock-market-news/cvs-aetna-aim-to-finalize-deal-as-early-as-december-sources-763813,763813
198878,420394,CVS,CVS Call Options Hot Ahead Of Earnings,opinion,"Options Traders  Analysts Optimistic On CVS
CVS Health  NYSE CVS  stock is 0 8  higher at  65 85 in today s trading as investors gear up for the drugstore giant s second quarter earnings report  scheduled for before the market opens  tomorrow  Aug  8  Below  we will take a look at how CVS has been faring on the charts  and what the options market is pricing in for the stock s post earnings moves 
Start with technicals  CVS Health has been on a downtrend since hitting a year to date peak in late January and more recently has been stuck in a series lower highs  More recently  losses have been limited by a floor of support found at the  63 mark and today s breakout attempt has been capped by the 120 day moving average   a trendline that has acted as a ceiling of resistance for the shares in the past 

Looking toward earnings  CVS has closed lower the day after the company reports in six of the last eight quarters  including the last five in a row  Looking back eight quarters  the shares have moved 4 1  the day after earnings  on average  regardless of direction  This time around  the options market is pricing in a slightly larger than usual 6  move for tomorrow s trading 
Options traders have been leaning bullish on the drugstore chain ahead of earnings  This is per data from the International Securities Exchange  ISE   Chicago Board Options Exchange  CBOE   and NASDAQ OMX PHLX  PHLX   showing CVS Health stock with a 10 day call put volume ratio of 2 52  ranking in the 77th percentile of its annual range  This shows that during the past two weeks of trading  calls have been bought over puts at a faster than usual clip 
Analysts are echoing this optimistic sentiment toward the security  Of the 15 brokerage firms covering the stock  12 sport  buy  or  strong buy  recommendations  Plus  the stock s average 12 month price target comes in at a more than 30  premium to current levels 
Lastly  short interest on CVS Health rose 7  during the most recent reporting period  and now represents nearly 5  of the stock s total available float  At the average daily trading volume  it would take well over a week for shorts to cover their bearish bets ",2018-08-07,Schaeffer's Investment Research,https://www.investing.com/analysis/cvs-call-options-hot-ahead-of-earnings-200337078,200337078
198883,420399,CVS,CVS Health in talks to buy health insurer Aetna  WSJ,news," Reuters    Drug retailer CVS Health Corp  N CVS  is in talks to buy health insurer  Aetna Inc   N AET   the Wall Street Journal reported on Thursday  citing sources  Aetna s shares closed up 11 5 percent at  178 60  after hitting  184 98  CVS Health s stock closed down 2 9 percent at  73 31  
Aetna had a market cap of  53 2 billion as of Wednesday s close  according to Thomson Reuters data ",2017-10-26,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-in-talks-to-buy-health-insurer-aetna-wsj-548740,548740
198891,420407,CVS,Should Value Investors Consider CVS Health  CVS  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put CVS Health Corporation   NYSE CVS   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  CVS Health has a trailing twelve months PE ratio of nearly 11 0  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 5  If we focus on the long term PE trend  CVS Health s current PE level puts it below its midpoint over the past five years  In fact  the current level stands close to the lows for the stock  indicating that it could be a solid entry point Further  the stock s PE also compares favorably with the Zacks Retail Wholesale sector s trailing twelve months PE ratio  which stands at 31 3  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that CVS Health has a forward PE ratio  price relative to this year s earnings  of just 9 5  so it is fair to say that a slightly more value oriented path may be ahead for CVS Health stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  CVS Health has a P S ratio of about 0 4  This is significantly lower than the S P 500 average  which comes in at 3 4 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years  If anything  CVS is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  CVS Health currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes CVS Health a solid choice for value investors What About the Stock Overall Though CVS Health might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of B and a Momentum Score of C  This gives CVS a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Notably  the company s recent earnings estimates have been quite encouraging  The current quarter has seen 13 estimates go higher in the past sixty days compared to one downward revision  while the full year estimate has seen 15 upward and one downward revision in the same time period This has had a meaningful impact on the consensus estimate  as the current quarter consensus estimate has risen by 9 5  in the past two months  while the full year estimate has jumped 9 1   You can see the consensus estimate trend and recent price action for the stock in the chart below CVS Health Corporation Price and Consensus    However  this somewhat bullish trend has likely not yet been reflected in the stock  as we have just a Zacks Rank  3  Hold   which indicates expectations of in line performance in the near term  Nonetheless  the positive analyst sentiment hints at favorable ongoing prospects Bottom LineCVS Health is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Despite having a Zacks Rank  3  the stock belongs to an industry which is ranked among the Top 29  out of more than 250 Zacks industries  which indicates that broader factors are favorable for the company So  it might pay for value investors to delve deeper into the company s prospects  as fundamentals indicate that this stock could be a compelling pick 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-cvs-health-cvs-stock-now-200324942,200324942
198901,420417,CVS,Weekend Update  VIX Buy Signal Confirmed ,opinion,"VIX revisited its 2 year Ending Diagonal trendline one week after punching through it during Options Expiration  The move appears reflexive  but this time the VIX did not go beneath the trendline  Re crossing the mid Cycle resistance at 13 62 confirms the VIX buy signal 
 ZeroHedge  One of the catalysts cited for the recent breakout in the S P 500 was the corresponding breakdown in the VIX  which as we noted on Wednesday breached the triangle formation in which it had been trapped since February  sliding to the downside and erasing the elevated levels seen in the post Feb 5 panic 
However  while the VIX has tumbled  the realized volume in the market continues to be surprisingly high  That s the take of Goldman s derivatives strategist Rocky Fishman  who writes today that  the VIX closed yesterday at its lowest level since January   a level which as he shows in the chart below  is  too low given how much the SPX is moving  
SPX hits trendline resistance 

This week  SPX continued its rally toward the 2 year trend line at 2730 00  tagging it on Friday  Some would debate whether it remains on a sell signal  If so  a close beneath Intermediate term support at 2705 61 re confirms the sell signal 
 ABCNews  Health care companies led U S  indexes modestly higher on Wall Street  closing out the market s biggest weekly gain since March 
Drug makers and other health companies ended broadly higher Friday after President Donald Trump announced plans to rein in drug prices that didn t seem to pose immediate threats to health care company profits 
CVS Health  NYSE CVS  rose 3 2 percent and Merck  NYSE MRK  climbed 2 8 percent 
Those gains outweighed losses in technology companies  Chipmaker NVIDIA  NASDAQ NVDA  fell 2 2 percent 
The S P 500 index rose 4 points  or 0 2 percent  to 2 727 
To read the entire report Please click on the pdf File Below ",2018-05-13,Anthony M. Cherniawski,https://www.investing.com/analysis/weekend-update-200315752,200315752
198916,420432,CVS,Same store sales fall at CVS,news,CVS Health  NYSE CVS  reports same store sales in the front end of its stores fell 4 9  in Q1 to top the consensus expectation for a 6  drop  Revenue in the pharmacy services segment increased 8 5  Y Y to  31 2B on a 10  jump in network claims processed  Pharmacy same store sales declined 4 7  vs   4 2  consensus  Operating profit fell 18  during the quarter as charges tied to the closure of retail stores factored in  CVS backs prior guidance for 2017 EPS of  5 77 to  5 93 Previously  CVS Health beats by  0 07  beats on revenue  May 2  CVS  0 43  premarket to  81 61  Now read  Triple Threat Investing With CVS,2017-05-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/same-store-sales-fall-at-cvs-479260,479260
198924,420440,CVS,CVS Health to cut about 600 jobs over next two months,news," Reuters    CVS Health Corp  N CVS  said it would cut about 600 jobs  mostly at its corporate offices in Rhode Island  Illinois and Arizona over the next two months  citing an increasingly competitive environment  The drugstore chain operator  which is expected to report third quarter results next week  employs more than 240 000 people in the United States  
Employees being affected will be allowed to apply for other positions in the company  the company said in a statement ",2016-11-03,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-to-cut-about-600-jobs-over-next-two-months-437452,437452
198925,420441,CVS,CVS Health revenues up 16   non GAAP EPS up 28  in Q3  updates 2016 and 2017 guidance  shares off 15  premarket,news,CVS Health  CVS  Q3 results  Revenues   44 615M   15 5    Operating Income   2 817M   20 8    Net Income   1 542M   24 7    EPS   1 43   30 0    Non GAAP EPS   1 64   28 1    Quick Assets   2 263M   11 2    CF Ops   7 948M   64 2   Q4 Guidance  GAAP EPS   1 52   1 58  Adjusted EPS   1 64   1 70 2016 Guidance  GAAP EPS   4 84   4 90 from  4 92   5 00  Adjusted EPS   5 77   5 83 from  5 81   5 89  CF Ops   9 3B  9 5B  FCF   6 8B   7 0B 2017 Preliminary Outlook  GAAP EPS   5 16   5 33  Non GAAP EPS   5 77   5 93 Shares are down 15  premarket ,2016-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/cvs-health-revenues-up-16;-non-gaap-eps-up-28-in-q3;-updates-2016-and-2017-guidance;-shares-off-15-premarket-438714,438714
198926,420442,CVS,Sanofi  Novo Nordisk and Lilly named in patients  price fixing suit,news,"By Erica Teichert NEW YORK  Reuters    Three of the biggest makers of diabetes treatments  Sanofi  PA SASY  SA   Novo Nordisk   CO NOVOb  and Eli Lilly and Co  were named in a class action lawsuit about price fixing filed by a group of patients  The suit  filed on Monday in a federal court in Massachusetts  said the companies have simultaneously hiked the price of insulin by over 150 percent during the past five years  
Plaintiffs claim that Sanofi  Novo Nordisk and Eli Lilly raised their public benchmark price for insulin products while maintaining a lower  true  price they charged large pharmacy benefit managers like Express Scripts  CVS Health  NYSE CVS  and OptumRX  The PBMs act as intermediaries with health insurers and keep a percentage of the price difference  according to the lawsuit  The lawsuit  which seeks class action status  alleged violations of the federal racketeering statute  which allows for triple damages  as well as consumer protection laws in virtually every state ",2017-01-30,Reuters,"https://www.investing.com/news/stock-market-news/sanofi,-novo-nordisk-and-lilly-named-in-patients'-price-fixing-suit-456677",456677
198933,420449,CVS,CVS Health  CVS  Plans To Boost Hourly Minimum Wage Rate,opinion,"CVS Health Corporation   NYSE CVS   recently announced three major programs that will allow the company to share the tax benefit earned from the implementation of the latest U S  Tax Cuts and Jobs Act with employees  This news comes on the heels of the company s promising fourth quarter 2017 results  Along with the results  the company exhibited unwavering commitment toward employees  welfare According to management  the improvement in employee wages and benefits totaled  425 million annually  These are long term and compensation investments  expected to create growth opportunities for the company and its employees The programs include the following three employee focused investments First  CVS Health will lift the starting wage rate to  11 an hour for hourly employees  effective April 2018  With a view to grow its retail stores into a healthcare destination  the company plans to adjust pay ranges and rates for many of its retail pharmacy technicians  front store associates and other hourly retail employees later this year  CVS Health Corporation Price and Consensus
     Second  the company wishes to consistently offer affordable healthcare services to workers by not increasing employee premiums for 2018 19  despite a 5  year over year rise in medical and prescription costs  CVS Health will absorb the entire increase for the 100 000 employees who are part of the company sponsored health plan Finally  a new paid parental leave plan will be put into effect starting April 1  2018  for full time employees  Per management  an employee who welcomes a new child can take up to four weeks away from work at 100  of their pay  so as to ensure proper care of the newborn Additionally  management indicated that it will put the remaining benefits earned from tax savings back into the business  The company expects to channelize this money toward data analytics  care management solutions and store service  in order to improve health outcomes  reduce cost for patients and also debt reduction related to the planned acquisition of Aetna  NYSE AET  Recent AccoladesRecently  CVS Health has been recognized as one of the World s Most Admired Companies by Fortune Magazine  The company was honored as No  39 on corporate rankings  up six spots from the previous year in terms of corporate performance and reputation and ability to attract and retain talented people  quality of services  management  innovation and social responsibility Price PerformanceOver the last six months  CVS Health has outperformed the   The stock has lost 11 9   lower than the industry s decline of 13 6    Zacks Rank   Stocks to ConsiderCVS Health carries a Zacks Rank  3  Hold  
Some better ranked stocks in the broader medical space are Amphastar Pharmaceuticals Inc    NASDAQ AMPH    HCA Healthcare  Inc    NYSE HCA   and athenahealth Inc    NASDAQ ATHN    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Amphastar has an impressive expected long term growth rate of 25   In the last six months  the stock has rallied 25 3  HCA Healthcare has a projected long term growth rate of 11 5   In the last three months  the stock has gained 29 2  athenahealth has a long term growth rate of 23 1   Over the last three months  the stock has rallied 6 8  The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-plans-to-boost-hourly-minimum-wage-rate-200289866,200289866
198934,420450,CVS,Pharmacy Services Aid CVS Health  Aetna Deal An Upside Too,opinion,On Feb 13  we issued an updated research report on CVS Health Corporation   NYSE CVS    The company carries a Zacks Rank  3  Hold  This leading provider of integrated services across the entire spectrum of pharmacy care has been outperforming the broader  over the past year  The stock has lost 12 2  compared with the broader industry s 18  decline Notably  CVS Health exited the fourth quarter of 2017 on a solid note with both earnings and revenues surpassing the Zacks Consensus Estimate  Year over year growth in the top line was driven by a strong Pharmacy Services segment  which in turn benefited from an upside in the Specialty Pharmacy  Investors are hopeful about the company expected to earn  750 million drawn from near term synergies as a result of the Aetna  NYSE AET  acquisition deal post the transaction s closure Per the company  shareholders can look forward to several outcomes with respect to near term synergy including enhanced competitive positioning and a new combined platform  which might redefine access to high quality care at low cost  substantially accelerating growth of the consolidated business We are also upbeat about the company s strong Pharmacy Services business  which has been flourishing on a solid Specialty Pharmacy subsegment  In fact management stated that the company s specialty business is its top priority in winning new customers and retaining the old  loyal ones  Accordingly  CVS Health is poised to capitalize on this opportunity with wide and differentiated offerings including Specialty Connect Additionally  management expects drug price inflation  product launches  higher utilization and new PBM clients to fuel growth  Also  the Pharmacy Services segment appears as a stable growth platform With regard to its 2018 PBM  Pharmacy Benefit Management  selling season  CVS Health is noted to have progressed well in the fourth quarter  The company boasts gross client wins of approximately  6 2 billion and net new business of  2 4 billion with a client retention rate of about 96 5   Good news is that the company also advances with its 2019 selling season Moreover  the company s strong cash balance allows it to carry out share repurchases On the flip side  CVS Health s highly competitive retail pharmacy business is a big concern  Precisely  the company faces some stiff competition in the pharmacy segment due to availability of low cost pharmacy options and other retail businesses consistently adding pharmacy departments in its portfolio  Particularly  discount retailers have made substantial inroads into gaining a major market share  Moreover  CVS Health has delivered sluggish numbers within the retail Long Term Care business in the recent past  The company s decision to restrict itself from participating in the TRICARE network and many fully insured prime networks was dictated by the negative impact on Pharmacy sales and script comps Stocks Worth a LookSome better ranked stocks in the broader medical space are Centene Corporation   NYSE CNC    athenahealth  Inc    NASDAQ ATHN   and BIOVERATIV Inc    NASDAQ BIVV    each sporting a Zacks Rank  1  Strong Buy   You can see  Centene has an impressive projected long term growth rate of 14 6   The stock has returned 23 2  over the last six months athenahealth has an expected long term growth rate of 23 1   The stock has gained 7 3  over the last three months BIOVERATIV has an expected long term growth rate of 14   The stock has soared 87 2  over the last three months The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/pharmacy-services-aid-cvs-health-aetna-deal-an-upside-too-200291097,200291097
198939,420455,CVS,Torched pharmacy that became symbol of Baltimore riots reopens ,news,"By Donna Owens BALTIMORE  Reuters    A CVS Health Corp  NYSE CVS  pharmacy in Baltimore has reopened nearly a year after images of it being torched last April made it a symbol of rioting that erupted over the death of a black man from injuries sustained while in police custody  The drugstore on Pennsylvania Avenue in West Baltimore was rebuilt and opened its doors on Sunday  company officials said on Monday   We have a long history of serving inner city communities and we are 100 percent committed to serving our patients and customers in Baltimore   said CVS spokeswoman Erin Britt  The pharmacy became an emblem of unrest that tore through Baltimore after the death of Freddie Gray  25  from a neck injury suffered in police custody  Rioters looted the store and then set it ablaze  Television images and photos of the burning store were broadcast around the world  The area in front of the gutted pharmacy became a focal point for rallies and protests in the days following Gray s death  The drugstore was among about 400 businesses across the city damaged in the rioting  A second CVS shuttered after the unrest reopened in late February after a renovation   A 24 year old man pleaded who pleaded guilty in connection with the pharmacy fire was sentenced in November to four years in federal prison  
Six police officers have been charged in Gray s death  His death was one of a series of incidents that sparked the movement Black Lives Matter and led to protests in many American cities over police treatment of minorities ",2016-03-07,Reuters,https://www.investing.com/news/stock-market-news/torched-pharmacy-that-became-symbol-of-baltimore-riots-reopens-388461,388461
198946,420462,CVS,iFOREX Daily Analysis   February 07 2018,opinion,"The US Dollar traded on Tuesday almost unchanged against other major currencies as the US Dollar Index  USDX  closed 0 05  lower  The South African Rand  ZAR  traded over 1  stronger against the Dollar and again close to the previous weeks  lows in the USD ZAR as speculations over the possible removal of controversial president Jacob Zuma intensified 
Gold fell to a three weeks low as with the recovering equity market  investors sold bonds  leading to the US 10 year Treasury note yielding over 2 8   Higher interest rates put gold under pressure as there is less incentive to put money in non interest bearing safe haven products  Oil gained towards the end of the trading session while the API inventory numbers surprisingly showed a draw on crude oil stockpiles 
Equity markets clearly recovered from Monday s sell off  While not matching the losses  stock market indices had one of the best trading days in months  Despite the recovery the Volatility Index  VIX  was still around twice as high as before the sell off  indicating that there is still fear in the market 
Cryptocurrencies were also seen trading higher for the first in days  However this week is still set to be the fifth week in a row for the Bitcoin to trade lower  The US Congress had a hearing on the topic of cryptocurrencies  where among other things the SEC stated that they believe that every Initial Coin Offering  ICO  is a sale of securities  where the agency possesses regulatory oversight  ICOs are a popular way for start ups to raise money on the cryptocurrency market 
On Wednesday Germany publishes Industrial Production  IP  data  followed by France with Merchandise Trade and Italy with Retail Sales  In the United Kingdom the Halifax House Price Index  HPI  will be published  In the US the Mortgage Bankers  Association  MBA  will release multiple statistics regarding the state of the mortgage market 
EUR USD
The EUR USD traded at the end of the day only slightly over the closing level on Monday but tested lower boundaries close to the 1 23 level  In the Euro Zone the German Manufacturers  Orders statistic showed considerable resilience as over the month the level gained 3 8   expected  0 8    previous  0 4    while in the US the trade balance deficit widened to 53 1 billion dollars 
On Wednesday Germany publishes Industrial Production  IP  data  followed by France with Merchandise Trade and Italy with Retail Sales  In the US the Mortgage Bankers  Association  MBA  will release multiple statistics regarding the state of the mortgage market 
 Pivot 1 2435Support 1 23151 2281 222Resistance 1 24351 24751 252Scenario 1 short positions below 1 2435 with targets at 1 2315   1 2280 in extension Scenario 2 above 1 2435 look for further upside with 1 2475   1 2520 as targets Comment the RSI is mixed to bearish 
Gold
As equities recovered and the US 10 year Treasury yield soared up to over 2 8  after dipping below 2 7  during Monday s sell off  Gold fell by over one percent during Tuesday s trading  The speech by Federal Reserve President James Bullard from St  Louis where he favored lower interest for the future did little to keep gold from declining 
As the state of the job market is taken by the Federal Reserve also under consideration how to plan monetary policy  Wednesday s US Jobless Claims numbers could be of interest to traders 
 Pivot 1333 5Support 1316 251309 51305 5Resistance 1333 51337 751346Scenario 1 short positions below 1333 50 with targets at 1316 25   1309 50 in extension Scenario 2 above 1333 50 look for further upside with 1337 75   1346 00 as targets Comment the RSI broke below a rising trend line  Prices broke below a rising channel 
WTI Oil
Oil traded higher towards the end of the day as contrary to market expectations the crude oil inventories according to a statistic from the American Petroleum Institute  API  showed inventories down by 1 1 million barrels  whereas the majority of traders expected a build in inventories  On Wednesday the Energy Information Administration  EIA  publishes its crude oil inventory numbers  which in recent weeks showed sometimes different inventory estimates than those of the API 
 Pivot 64 45Support 62 9562 561 8Resistance 64 4565 1565 5Scenario 1 short positions below 64 45 with targets at 62 95   62 50 in extension Scenario 2 above 64 45 look for further upside with 65 15   65 50 as targets Comment the RSI is mixed to bearish 
US 500
US equity indices were significantly up on Tuesday after Monday s sell off  The gains were in all major indices  such as the S P 500  US 500  over 2   Especially basic materials  US Basic Materials ETF  2 25   and cyclical  US Cyclicals ETF  1 89   stocks were higher  while utilities  US Utilities ETF  1 83   still showed losses 
General Motors  NYSE GM    4 98   stocks traded higher with higher earnings and margins reported  Snapchat traded only 1 15  higher during Tuesday s trading session but raced above the  17 IPO prices at times during after hours trading as the company reported accelerated user growth and sales figures 
On Wednesday among others Rio Tinto  LON RIO  and Sanofi  PA SASY  are due to release financial statements  while on Thursday AIG  CVS Health  NYSE CVS   Nvidia and Twitter are due to release earnings numbers 
 Pivot  2615   Support  2615 2579 5 2530  Resistance  2731 2764 2811     Scenario 1  long positions above 2615 00 with targets at 2731 00   2764 00 in extension    Scenario 2  below 2615 00 look for further downside with 2579 50   2530 00 as targets    Comment  the RSI is bullish and calls for further upside  The index broke above an ascending triangle bottom pattern ",2018-02-07,iFOREX,https://www.investing.com/analysis/iforex-daily-analysis--february-072018-200287835,200287835
198947,420463,CVS,CVS Health  CVS  Beats On Q4 Earnings   Revenues Estimates,opinion,Ever bought medicines or cosmetics over the counter  Yes  then you may have walked into one of the 9 652 retail CVS pharmacy stores of the largest pharmacy healthcare services provider in the U S  CVS Health Corporation   NYSE CVS    This Rhode Island based company has more than 900 walk in medical clinics CVS MinuteClinic and currently possesses a customer satisfaction rate of 95  Currently  CVS Health has a Zacks Rank  3  Hold  but that could change following its fourth quarter 2017 earnings report which has just released   You can see    We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate remained steady at  1 89 per share over the last 60 days CVS Health s adjusted earnings per share of  1 92 outpaced this estimate by 1 6   However  this figure decreased by 12 3  in the year ago quarter CVS Health Corporation Price and EPS Surprise    Revenues  CVS Health posted revenues of  48 4 billion up 5 3  y y  surpassed the Zacks Consensus Estimate for revenues of  47 52 billion Key Stats  For the fourth quarter CVS Health s Pharmacy Services segment revenues increased 9 3  year over year to  34 2 billion  while revenues from Retail LTC segment increased 0 3  year over year to  20 9 billion  During the fourth quarter  CVS Health opened 65 new retail locations and closed 13 retail locations  Further  the company relocated five retail locations  As of Dec 31  2017  CVS health operated 9 803 retail locations  including pharmacies in Target stores  in 49 states  the District of Columbia  Puerto Rico and Brazil Major Factors  CVS Health witnessed year over year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation  partially offset by continued price compression and increased generic dispensing  Also  we are encouraged to note that the company has returned to growth in Retail LTC segment in the reported quarter  The company has also updated its full year 2018 guidance to reflect the effects of the U S  tax reform Stock Price  Following the earnings release  share prices have not shown any movement in the pre market trading session Check back later for our full write up on this CVS Health earnings report later Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-cvs-beats-on-q4-earnings--revenues-estimates-200288435,200288435
198953,420469,CVS,CVS Health Grows On Pharmacy Services  Retail Remains A Drag,opinion,On Jan 12  we issued an updated research report on CVS Health   NYSE CVS    The company carries a Zacks Rank  3  Hold  This leading provider of integrated services across the entire spectrum of pharmacy care has been outperforming the broader  over the past six months  The stock has inched up 0 7  against the industry s 2 9  decline  We are upbeat about the company s strong Pharmacy Services business  which has been growing on a solid Specialty Pharmacy subsegment  Management stated that the company s specialty business is its top priority in gaining new customers and retaining the old  loyal ones  Accordingly  CVS Health is poised to capitalize on this opportunity on the back of wide and differentiated offerings including Specialty Connect Management expects drug price inflation  product launches  higher utilization and new PBM clients to fuel growth  We expect the Pharmacy Services segment to be a stable growth platform We are also impressed with CVS Health s robust PBM  Pharmacy Benefit Management  selling season  showing a solid progress from the last quarter  While gross new business totaled  6 billion  net new business reached  2 3 billion  These figures take into account the FEP  Federal Employee Program  specialty contract loss but exclude the impact from individual Medicare Part D program  The company has already completed about 90  of client renewals for 2018 Additionally  it is encouraging to make a note of the company s latest announcement to buy all outstanding shares of a diversified health care benefits company   Aetna  NYSE AET    in a cash and stock deal worth approximately  207 per share or almost  69 billion  considering a rough estimate of Aetna s debt  the total transaction value is projected at  77 billion  The company expects this takeover to be completed in the second half of 2018  subject to approval by the company s shareholders  regulatory bodies as well as fulfillment of certain other customary closing conditions  On the deal s successful closure  CVS Health estimates  750 million of near term synergies with low to mid single digit accretion in the second year post the transaction s completion Additionally  the company has a strong cash balance allowing it to carry out share repurchases On the flip side  the company s highly competitive retail pharmacy business is a big concern  Precisely  the company faces some stiff competition in the pharmacy segment  This is because availability of low cost pharmacy options and other retail businesses continue to add pharmacy departments in the portfolio  Particularly  discount retailers have made substantial inroads in gaining a major market share  Moreover  CVS Health has delivered sluggish numbers within the retail Long Term Care business in the recent past  Per the company  this decision to restrict itself from participating in the TRICARE network and many fully insured prime networks was due to the negative impact on Pharmacy sales and script comps Key PicksSome better ranked stocks in the broader medical space are Bio Rad Laboratories   NYSE BIO    Centene Corporation   NYSE CNC   and Molina Healthcare Inc    NYSE MOH    each sporting a Zacks Rank  1  Strong Buy   You can see  Bio Rad has a whopping expected growth rate of 141 5  for the first quarter of 2018  The stock has jumped 35   surpassing the broader industry over a year Centene has an expected long term growth rate of 14   The stock s performance on the bourses has been solid in a year s time with a high return of 70 4  For 2018  Molina Healthcare has a robust projected growth rate of 178 6   In the last three months  the stock has surged 37 8   higher than the broader industry s rally of 17 9  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-grows-on-pharmacy-services-retail-remains-a-drag-200280725,200280725
198960,420476,CVS,CVS Health in  48 million settlement of lawsuit over hiding loss,news,"By Jonathan Stempel  Reuters    CVS Health Corp  N CVS  reached a  48 million settlement of a lawsuit accusing the U S  drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business  culminating in a plunge in its stock price  The all cash settlement with investors led by three Massachusetts public pension funds was disclosed in a Monday filing with the federal court in Providence  Rhode Island  CVS  share price tumbled 20 1 percent on Nov  5  2009  after the company  then known as CVS Caremark  revealed the loss of contracts representing about  4 5 billion of annual revenue  Shareholders said this disclosure blindsided them  after CVS officials had repeatedly assured them that the company was doing an excellent job integrating the former Caremark Rx Inc and retaining clients  CVS bought Caremark in March 2007 and changed its name to CVS Health last September  The settlement requires court approval and awaits class action certification for shareholders from Oct  30  2008  to Nov  4  2009  CVS denied wrongdoing  CVS spokeswoman Carolyn Castel said the payment will be covered by insurance and that the Woonsocket  Rhode Island based company settled to avoid the  burden  uncertainty and expense of continuing litigation   In April 2014  CVS agreed to pay  20 million to settle U S  Securities and Exchange Commission civil charges related to the PBM business  and its accounting for an unrelated acquisition  The  48 million is just 1 percent of CVS  annual profit  but the plaintiffs  lawyers in court papers called the accord  a very good recovery   given the risks of continued litigation  They estimated the sum at 5 33 percent of the potential  900 million of  recoverable damages  in the litigation  The lead plaintiffs are the City of Brockton Retirement System  Norfolk County Retirement System and Plymouth County Retirement System  Their lawyers  led by Robbins Geller Rudman   Dowd and Labaton Sucharow  plan to seek legal fees of up to 30 percent of the settlement amount  court papers show  
The case  which has a different named plaintiff and defendant  is Medoff v  CVS Caremark Corp et al  U S  District Court  District of Rhode Island  No  09 00554 ",2015-09-16,Reuters,https://www.investing.com/news/stock-market-news/cvs-health-in-$48-million-settlement-of-lawsuit-over-stock-plunge-361878,361878
198961,420477,CVS,Exclusive  Target pharmacy workers form union  first in company s history,news,"By Nandita Bose CHICAGO  Reuters    A group of pharmacy workers within Target Corp s store in Brooklyn  New York  have won a vote to form a microunion  making it the first unionized store at the retailer since its inception in 1902  Earlier on Wednesday  Reuters was first to report that a group of pharmacists and pharmacy technicians won an initial ballot  7 2  to form the union  according to a filing on the National Labor Relations Board website and union officials  Target said it was  disappointed  by the vote within its store and will appeal the NLRB s decision to allow the vote to proceed   Target is in the process of selling its pharmacy business to CVS Health Corp  NYSE CVS    Because of the pending sale of the business  we don t believe it was appropriate for the NLRB to move forward with the petition   spokeswoman Molly Snyder told Reuters   We believe it should have been dismissed and made that argument at the hearing   The National Labor Relations Board in 2011 ruled that so called micro unions are appropriate within a company s operations when their members share  a community of interest    That decision was upheld by a U S  appeals court  spurring the board in 2014 to extend the standard to retail stores in a case involving fragrance and cosmetic department workers at Macy s Inc  The National Retail Federation and other industry groups have said the decisions would wreak havoc on stores  pitting groups of employees against each other and forcing companies to negotiate with multiple unions that could have competing interests  Union groups say the NLRB ruling in favor of microunions is appropriate to the modern day workplace  where employees often are asked to staff multiple departments   Target  which up until now has not had any unionized stores or microunions  said it twice previously has overcome serious attempts at unionization  The first occurred in Detroit in the 1990s  and the second came at its Valley Street store in New York City in 2011    It is a big win for us   said Lou Solicito  organizing director of the United Food and Commercial Workers union that supported the vote   
 We are ready to bargain a contract with Target   he said ",2015-09-16,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-target-pharmacy-workers-form-union,-first-in-company's-history-362000",362000
198962,420478,CVS,Clinton plan on U S  drug costs adds to pressure for lower prices,news,"By Bill Berkrot NEW YORK  Reuters    Hillary Clinton s campaign promise on Tuesday to cap prescription drug costs for U S  consumers lends weight to efforts by health insurers  doctors  groups and consumers to address skyrocketing prices  industry experts said  Clinton  in the lead among Democratic presidential candidates  unveiled a plan that includes a  250 monthly cap on out of pocket costs prescription drugs  allowing the Medicare plan for the elderly to negotiate drug pricing and permitting Americans to purchase drugs from other countries at lower cost  In light of massive opposition expected from drug lobbyists and Republican lawmakers  it is uncertain the proposal will ever progress  Clinton is seeking the Democratic nomination for the November 2016 presidential election  But her campaign trail attack on high drug prices and  excessive profiteering  by drugmakers touched a raw nerve for consumers and makes public anger harder to ignore  policy experts said   Once the public gets really pissed  politicians are going to have to have answers and then it gets out of the control of particular lobbyists or companies   said Dr  Ezekiel Emanuel  an oncologist at the University of Pennsylvania School of Medicine and a former adviser to the Obama administration   A sell off in drug manufacturer shares on Tuesday reflected expectations that the pharmaceutical industry will be under greater pressure on pricing   Drug companies routinely raise prices on commonly used medications and are proposing ever higher prices on new therapies approved for the U S  market  But companies that manage pharmacy benefits for insurers such as Express Scripts and CVS Health  NYSE CVS  are demanding more evidence of a drug s efficacy over less expensive treatment options and bigger discounts when two or more medicines offer similar outcomes    It s going to take private sector activity  to address the problem of high drug prices  said Ira Loss  pharma and biotech analyst for policy research group Washington Analysis   In her comments  Clinton focused on the latest example of extreme price hikes  Small biotech Turing Pharmaceuticals raised the cost of Daraprim  an old treatment for a dangerous parasitic infection  to  750 a tablet from  13 50 after acquiring it  the New York Times reported  ROOM TO NEGOTIATE As opposition to rising drug prices grows  long standing reluctance to introduce price controls in the United States is being challenged  Medicare by law cannot negotiate drug prices  But a recent poll found a vast majority of Americans now believe Medicare should be allowed to push for greater discounts  Drugmakers have insisted that lowering or limiting drug prices will hamper their ability to invest in research and lead to fewer new therapies    The proposal released today by the Clinton campaign would do irreparable harm to the nation s health innovation system   Biotechnology Industry Organization CEO Jim Greenwood said in a statement   The industry estimates it costs between  1 billion and  2 billion to bring a drug to market  Drugmakers also argue that the price of true breakthrough medications should reflect the savings from helping patients avoid the long term complications of serious illnesses  
 A lot of tremendous hospitalization costs are being displaced by  new  medicines    Pfizer  Inc  NYSE PFE  research chief Mikael Dolsten said ",2015-09-22,Reuters,https://www.investing.com/news/politics-news/clinton-plan-on-u.s.-drug-costs-adds-to-pressure-for-lower-prices-362880,362880
198967,420483,CVS,Big Pharma s Plan B,opinion,"Big pharma seems set to follow a script that it has followed before    and one that many other industries have followed  Faced by growth challenges  regulatory challenges  and the decreasing effectiveness of price hikes as a growth strategy  big pharma companies look set for a wave of mergers and acquisitions  Consolidation is already happening in other parts of the healthcare sector    for example  the recent purchase of insurer Aetna  NYSE AET  by pharmacy retailer CVS Health Corp  NYSE CVS  
Big pharma in the United States has long relied on price increases to support profit growth  That history now increasingly faces the wrath of public opinion and the scrutiny of regulators  Companies are still raising prices  but the writing is clearly on the wall  Many major pharma companies raised prices for 2018 in the past week  However  they have spent much of the past year waging a campaign to direct public dissatisfaction about drug prices away from themselves and towards other parts of the drug supply chain  such as insurers and pharmacy benefit managers  PBMs   PBMs are third party administrators of prescription drug programs for commercial health plans  self insured employer plans  and various other private and public health plans  They contract with pharmacies  negotiate discounts and rebates with drug manufacturers  and process and pay prescription drug claims 
In the long run  however  this intra industry war is a distraction  The regulatory writing on the wall has been clear for years  and became clearer during the 2016 election campaign  in which both major candidates called out high drug prices and pledged to use the Federal government s buying power to negotiate them down  Last year s chaos around healthcare reform took those negotiations off the table  However  the current administration s determination to get the  best deal  possible is one of its enduring traits  and come what may politically  we think the era of high drug price increases is drawing to a close  2017 s clarification of approval pathways for biosimilars    generic versions of complex  large molecule drugs    is an example of how the current administration favors direct action through regulators  rather than contentious debate in Congress  wherever possible 
The market s attitude towards pharma and biotech seems to confirm us in this opinion  Since their peaks in mid 2015  pharma has fallen nearly 30   biotechs are flat  and the S P 500 in the same time has returned more than 30   These are industries that are under a cloud because their basic model for growing profits is threatened 

So with pricing power eroding  and likely to erode further  they are likely this year to turn increasingly to an old playbook    mergers and acquisitions  Mergers  when they work  will permit rationalization and cost cutting  Acquisitions will bring in growth by buying it instead of incubating it in house  reducing research and development expenses and allowing venture capital to take the risks  and much of the reward  when it funds the small  development stage biotechnology companies which are the most powerful engines of innovation in modern medicine 
As investors  we see two ways in which this trend could benefit us  One is through a close examination of mergers as they are proposed and occur    where betting on teams that have proven themselves capable of such corporate transformation  and where careful analysis of the synergies suggests that the match will be a fruitful one  can unlock value for shareholders  The second is through careful monitoring of development stage biotech firms    those whose technologies are in  hot  research areas that will attract the attention of large pharma buyers looking for access to new high growth treatments more immune to the impending price wars 
Investment implications   Although the pharmaceutical and biotech industries are facing a moment of truth  and pricing power for drugmakers is being eroded and will continue to be eroded  they are likely to begin moving to another playbook    mergers and acquisitions  Be on the lookout for pharma mergers led by competent and proven teams that are likely to produce streamlined new companies and unlock shareholder value  Also  continue to monitor the landscape of new biotechnologies  in order to find the development stage companies that are likely to be acquisition targets for large  growth hungry pharma firms ",2018-01-12,Tim Shirata,https://www.investing.com/analysis/big-pharmas-plan-b-200279751,200279751
198970,420486,CVS,Shares in CVS Pharmacy move above  100  after 8  earnings gain,news,"Investing com    Shares in CVS Health Corp  NYSE CVS  edged up above  100  after the nation s second largest drugstore chain reported an 8  spike in first quarter earnings on Friday 
Fueled by gains in its pharmacy benefits management division  CVS posted earnings of  1 22 billion  up from  1 13 billion over the same period in 2014  The division  which negotiates prices customers pay for prescription drugs  saw its revenues soar 18  over the period to  24 billion  CVS also posted strong earnings in its specialty drugs division  spurred by gains among its Cancer  Hepatitis C and Multiple Sclerosis prescription drug sales 
 We delivered better than expected results this quarter  primarily driven by stronger than expected prescription volumes as well as favorable purchasing and rebate economics in the PBM   CVS Pharmacy CEO Larry Merlo said in a statement   Adjusted EPS increased 12 2   to  1 14  five cents above the high end of our guidance range  with operating profit in the retail business in line with our expectations and operating profit in the PBM exceeding our expectations  We also generated approximately  1 6 billion in free cash flow  and we continued to return significant value to our shareholders through our disciplined capital allocation practices  
CVS Pharmacy s sales from its drugstore division fell 3  to  17 billion  a decline the company attributes to its decision to discontinue sales of tobacco products  CVS officials said Friday that the drugstore division likely would have posted gains for the quarter if it still offered tobacco products for sale 
CVS also raised its 2015 outlook for annual earnings per share of 5 08 to 5 19  above forecasts of 5 16 
 We are already off to a solid start in the 2016 PBM selling season  Our integrated model allows us to provide differentiated products and services that generate savings for our clients while providing better health outcomes and convenience for patients  We remain very well positioned with our distinctive  channel agnostic solutions  which are resonating strongly in the marketplace   Merlo added 
Shares in CVS rose 1 18  to 100 46 on Friday ",2015-05-01,Investing.com,"https://www.investing.com/news/stock-market-news/shares-in-cvs-pharmacy-move-above-$100,-after-8-earnings-gain-339913",339913
198971,420487,CVS,Baltimore asks Justice Department to investigate police practices,news,"By Ian Simpson  Reuters    Baltimore Mayor Stephanie Rawlings Blake asked the U S  Justice Department on Wednesday to investigate the city s police department for civil rights violations after the death of a black man from injuries sustained in police custody  The investigation will look into police practices such as frisks  street stops of suspects and arrests to see if they violate the U S  Constitution  Rawlings Blake said at a news conference  The request follows the April 19 death of Freddie Gray  25  who sustained spinal injuries after being arrested  His death sparked protests and a day of arson and looting in the largely black city  Maryland Governor Larry Hogan lifted a state of emergency for Baltimore on Wednesday   We cannot be timid in addressing this problem and I am a mayor that does not shy away from our city s big challenges   Rawlings Blake said  Six officers were charged last week in the case  which involves the latest in a series of U S  deaths of unarmed black men involving police officers  The mayor said the city would seek to have its 3 200 member police department equipped with body cameras by the end of the year  Advocates see cameras as a way to monitor police encounters with civilians  Attorney General Loretta Lynch is considering Rawlings Blake s request  the Justice Department said  Lynch met the mayor  police officials and community leaders on Tuesday  Rawlings Blake  a Democrat who took office in 2010  said the request was part of her years long effort to reform police  She said the department had made progress  with complaints last year of excessive force down by 46 percent  But improvements had not gone far enough  Rawlings Blake said  Gray s death provoked a day of rioting on April 27 in which a number of businesses were looted and a CVS Health Corp  N CVS  location was burned  The pharmacy chain said on Wednesday that it would rebuild the store  The Justice Department has conducted similar reviews of U S  police departments  An investigation of police in Ferguson  Missouri  where an officer shot dead an unarmed black teenager last year  concluded in March that the department routinely engaged in racially biased practices  The Justice Department is investigating possible civil rights violations in Gray s death  Last October  officials in Baltimore asked the Justice Department to begin an informal collaborative review of the city s police department after the Baltimore Sun reported that Baltimore had paid almost  6 million since 2011 to settle lawsuits alleging police brutality and other misconduct  The American Civil Liberties Union said on Wednesday that it had requested information about surveillance flights over Baltimore by the Federal Bureau of Investigation and other agencies that it said may have improperly surveilled and targeted the public  
The FBI did not immediately respond to a request for comment on the ACLU statement ",2015-05-06,Reuters,https://www.investing.com/news/world-news/baltimore-asks-justice-department-to-review-police-practices-340545,340545
198982,420498,CVS,Energy shares lead Wall Street to worst day since early October,news,"By Sinead Carew
NEW YORK  Reuters    The S P 500 had its worst day in almost three months on Monday  with energy shares leading the decline as global economic concerns were compounded by swooning oil prices 
The S P closed off 1 8 percent in its first four day losing streak since December 2013 and its biggest drop since Oct  9  It fell as much as 1 99 percent in the session while the Dow Jones Industrial Average tumbled as much as 2 percent 
Crude oil futures prices dropped to their lowest since 2009 amid a global supply glut and lackluster demand  U S  crude fell 5 percent to below  50 a barrel 
The euro fell to a near nine year low against the dollar of  1 18605 on the EBS platform  tumbling on political uncertainty in Greece and fears of a possible Greek exit from the euro zone 
The Greece question was front and center for Paul Nolte  portfolio manager at Kingsview Asset Management 
 What you ve done is thrown that entire area up for grabs  it will be very hard to see much in the way of economic growth if Greece has to go back to their currency   he said   It would create a lot more chaos and take everybody s focus away from economic growth  
There were more than three times as many declining stocks on the New York Stock Exchange as advancing issues and more than twice as many Nasdaq losers than gainers 
Strength in the dollar also put more pressure on dollar denominated commodities  A measure of the greenback against a basket of major currencies  DXY  hit its highest since December 2005 
The Dow Jones industrial average  DJI  fell 331 34 points  or 1 86 percent  to 17 501 65  the S P 500  SPX  lost 37 62 points  or 1 83 percent  to 2 020 58 and the Nasdaq Composite  IXIC  dropped 74 24 points  or 1 57 percent  to 4 652 57 
The S P 500 energy sector closed off 4 percent  its largest daily percentage decline since November 28  It fell almost 20 percent in the second half of last year 
The health sector   the S P s best performer on Monday  still fell 0 6 percent  Medical device maker Boston Scientific  N BSX  was the S P s biggest winner with a 4 pct gain after a brokerage upgrade 
Another bright spot was Gilead Sciences Inc  O GILD  whose shares rose percent after CVS Health Corp  N CVS   one of the largest U S  managers of drug benefits  said it will give Gilead s hepatitis C treatment preferred status and cover competitor AbbVie Inc s  N ABBV  treatment only as an exception  AbbVie shares lost 2 percent 
Declining issues outnumbered advancing ones on the NYSE by 2 413 to 714  for a 3 38 to 1 ratio on the downside  on the Nasdaq  1 961 issues fell and 801 advanced for a 2 45 to 1 ratio favoring decliners 
The benchmark S P 500 index was posting 6 new 52 week highs and 6 new lows  the Nasdaq Composite was recording 54 new highs and 44 new lows 
About 7 09 billion shares traded on U S  exchanges  above the 6 87 billion December average  according to data from BATS Global Markets 

 Additional reporting by Rodrigo Campos  Chuck Mikolajczak and Ryan Vlastelica  Editing by Bernadette Baum  Nick Zieminski and Meredith Mazzilli ",2015-01-05,Reuters,"https://www.investing.com/news/stock-market-news/futures-tick-lower,-energy-stocks-to-weigh-on-wall-st.-322093",322093
198983,420499,CVS,U S  worker freed from Cuba to be guest at Obama annual speech,news,"By Sarah N  Lynch WASHINGTON  Reuters    The U S  aid worker whose release from a Cuban prison helped pave the way toward restoring diplomatic ties with the communist nation will be among the White House s top guests for Tuesday s State of the Union address  Alan Gross and his wife Judy were reunited late last year  after Pope Francis helped play a major role in securing his freedom as part of a prisoner exchange  Obama later credited the historic exchange as the catalyst that led the U S  to chance its stance toward Cuba  breaking a more than 50 year impasse between the two nations  The White House on Monday announced that Gross and his wife will be among the more than 20 other guests to sit with First Lady Michelle Obama  Jill Biden and presidential adviser Valerie Jarrett when the president gives his annual address at the U S  Capitol Tuesday evening  In addition to Gross  other guests on the First Lady s list include astronaut Scott Kelly  who will soon embark on a year long mission to live and work at the International Space Station  and CVS Health Corp Chief Executive Larry Merlo  who made headlines in 2014 when his company became the first major pharmacy chain to stop selling tobacco in its stores  The majority of the guest list  however  consists of many average Americans who may be struggling with employment  affordable education  illnesses or housing   areas that President Barack Obama will likely discuss in his speech as he lays out his policy objectives for 2015   Some of the guests are current or former students at community colleges around the country  an area Obama is expected to discuss as part of his proposal to make community college free for some students  President Obama and his wife are also inviting Americans who previously wrote to the White House about things going on in their lives   One guest is 13 year old Malik Bryant of Chicago s South Side  who wrote a letter to Santa Claus saying he just wanted to be  safe   Another is a student who qualified for relief under Obama s immigration policy designed to help illegal immigrant children obtain a work permit and avoid deportation  Meanwhile Monday  some Republicans announced they were bringing guests who represented visions at odds with Obama s policies  Florida Republican Senator Marco Rubio  whose parents were born in Cuba  said he is inviting Cuban activist Rosa Mar a Pay    
Her father was killed in an car wreck that some believe was retaliation by the Cuban government because of his efforts to bring democracy to the country ",2015-01-19,Reuters,https://www.investing.com/news/politics-news/u.s.-worker-freed-from-cuba-to-be-guest-at-obama-annual-speech-324105,324105
198988,420504,CVS,3 Healthcare Stocks To Buy After CVS   Aetna Deal,opinion,"The healthcare industry is headed for a shakeup after CVS Health   NYSE CVS   officially announced its purchase of healthcare benefits giant Aetna   NYSE AET   on Monday 
CVS acquired the health insurer in a cash and stock deal worth roughly  69 billion  Including debt  the deal is valued at  77 billion  The merger will allow the companies to offer more  at CVS stores 
 This combination brings together the expertise of two great companies to remake the consumer health care experience   CVS CEO Larry J  Merlo said in a  
 We look forward to working with the talented people at Aetna to position the combined company as America s front door to quality health care  integrating more closely the work of doctors  pharmacists  other health care professionals and health benefits companies to create a platform that is easier to use and less expensive for consumers  
CVS hopes the Aetna buyout will give the drug store giant the ability to become even more of a one stop shop  This mega merger could also help to slowly reshape some of the U S  healthcare industry  However  shares of both CVS and Aetna dipped on Monday following the announcement 
With all of this said  let s take a look at three healthcare industry stocks that might prove enticing to investors as the industry continues to shift 
1        Centene Corporation   NYSE CNC  
Shares of this HMO provider  which serves the under insured and uninsured with health plans through Medicaid  Medicare  and other programs  have skyrocketed 78 91  this year  At the moment  Centene is a Zacks Rank  2  Buy  and scored an  A  for Value and a  B  for Growth in our Style Scores system 
For the current year  based on our Zacks Consensus Estimates  Centene s revenues are projected to climb nearly 18  to  47 84 billion  Centene s earnings are expected to surge 12 42   And within the last 60 days  Centene has received 11 positive full year earnings estimate revisions against zero downgrades 
Centene also sports a 0 37 price to sales ratio  which marks a discount compared to the  Medical   HMO s  industry s average  On top of that  the healthcare power is currently trading at 20 30x earnings  helping further demonstrate Centene s solid value 
2        Triple S Management Corporation   NYSE GTS  
This San Juan  Puerto Rico based independent licensee of the Blue Cross Blue Shield Association is currently a Zacks Rank  1  Strong Buy  stock that rocks an overall  A  VGM grade  Before Monday s 1  climb  which helped Triple S  stock price hit a new 52 week high  shares of the healthcare company had gained 38  this year more than double the S P 500 s pace 
Triple S  0 23 P S ratio  which marks a nearly 60  discount compared to the  Medical   HMO s  industry s average  helped the company score an  A  for Value in our Style Scores system  What s more  the company s current quarter EPS are expected to surge 92 86   according to our current Zacks Consensus Estimates  On top of that  Triple S  full year earnings are projected to jump from  0 13 per share a year ago to  1 23 per share or 846  
3        athenahealth  Inc    NASDAQ ATHN  
Athenahealth is a top provider of internet based healthcare IT services  This company specializes in online and web services from record keeping software to back office operations for an array of healthcare providers  Athenahealth is currently a Zacks Rank  1  Strong Buy  and earned a  B  grade for both Growth and Momentum in our Style Scores system 
Within the last 60 days  the company received seven positive earnings estimate revisions for its current quarter and full year  paired with no downgrades  Our current Zacks Consensus Estimates are calling for Athenahealth s full year earnings to gain 6 44  
On top of that  Athenahealth full year revenues are expected surge 12 46  and hit  1 22 billion  What s more  shares of Athenahealth have already climbed 26 14  this year 
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/3-healthcare-stocks-to-buy-after-cvs--aetna-deal-200270416,200270416
198989,420505,CVS, Company News For Dec 5  2017,opinion,Aetna Inc s   NYSE AET   shares decreased 1 4  after CVS Health   NYSE CVS   announced it was buying the healthcare benefits giant for around  69 billionShares of General Cable Corporation   NYSE BGC   climbed 35 1  after the company agreed to be acquired by Prysmian Groupfor  1 5 billion or  30 per shareFoundation Medicine  Inc s   NASDAQ FMI   shares fell 0 6  after its subsidiary unit won the approval of the U S  Food and Drug Administration for a cancer testShares of Exactech  Inc    NASDAQ EXAC   jumped 19 1  after the company agreed to be taken over by TPG Capital for  737 million or  49 25 a share,2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-dec-5-2017-200270732,200270732
199011,420527,CVS,Company News For Nov 7  2017,opinion,Shares of ON Semiconductor Corporation   NASDAQ ON   fell 1 1  after reporting third quarter adjusted earnings per share of  0 30  missing the Zacks Consensus Estimate of  0 40Berkshire Hathaway Inc s  shares decreased 0 3  after posting third quarter operating earnings of  1 40 per share  lower than the Zacks Consensus Estimate of  1 88Shares of Sprint Corporation   NYSE S   declined 11 5  after long awaited merger talks between the company and T Mobile   NYSE S   were called off over the weekendCVS Health  NYSE CVS  Corporation s   NYSE S   shares slumped 3 5  after posting third quarter adjusted earnings per share of  1 50  down 8 5  year over year,2017-11-06,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-7-2017-200263377,200263377
199043,420559,CVS,Buy Or Sell CVS Stock Before Earnings ,opinion,"CVS  NYSE CVS  is a large cap company that operates within the food and staples retailing industry  Its market cap is  80 billion today  and the total one year return is  17 66  for shareholders 
CVS stock is underperforming the market  It s beaten down  but it reports earnings on Tuesday  So is it a good time to buy  To answer this question  we ve turned to the Investment U Stock Grader  Our Research Team built this system to diagnose the financial health of a company 
Our system looks at six key metrics   
  Earnings per Share   EPS  Growth  CVS reported a recent EPS growth rate of  10 58   That s below the food and staples retailing industry average of 31 4   That s not a good sign  We like to see companies that have higher earnings growth 
  Price to Earnings   P E   The average price to earnings ratio of the food and staples retailing industry is 31 17  And CVS s ratio comes in at 14 36  It s trading at a better value than many of its competitors 
  Debt to Equity   The debt to equity ratio for CVS stock is 81 06  That s above the food and staples retailing industry average of 66 31  That s not a good sign  CVS s debt levels should be lower 
  Free Cash Flow per Share Growth   CVS s FCF has been higher than that of its competitors over the last year  That s good for investors  In general  if a company is growing its FCF  it will be able to pay down debt  buy back stock  pay out more in dividends and or invest money back into the business to help boost growth  It s one of our most important fundamental factors 
  Profit Margins   The profit margin of CVS comes in at 2 14  today  And generally  the higher  the better  We also like to see this margin above that of its competitors  CVS s profit margin is below the food and staples retailing average of 3 19   So that s a negative indicator for investors 
  Return on Equity   Return on equity tells us how much profit a company produces with the money shareholders invest  The ROE for CVS is 14 67   and that s below its industry average ROE of 16 15  ",2017-08-06,Investment U,https://www.investing.com/analysis/buy-or-sell-cvs-stock-before-earnings-200205523,200205523
199082,420598,CVS,Healthcare  After Election  Here s Where To Pick Up Shares,opinion,"Thomson Reuter s quick peek at Healthcare earnings as of 11 7 16 

As of Monday in terms of Q3  16  Healthcare is still growing revenue at 7  driving earnings growth of 7 5  
If readers look at the above chart   Healthcare Distributors  looks to be the trouble spot  with companies in that category reporting just 25  of those company s reporting better than consensus revenue  75  of thise companies missed their revenue estimates 
The real issue is what happens to Healthcare in 2017  here is a quick table of the Healthcare sectors  expected  2017 earnings growth 

11 4 16   8 8 
10 28 16   9 5 
10 21 16   10 
10 14 16   10 1 
10 7 16   10 2 
9 30 16   10 2 
9 23 16   10 3 

While there is some downward pressure as long as the numbers stay above  mid single digits  HealthCare should be OK 
CVS s  NYSE CVS  guide down yesterday morning was a shocker  Although the stock is found in Consumer Staples  CVS is tied to the Healthcare sector  and the warning around the retail drug segment for 2017 wasn t good  I expected the PBM to be under pressure  not the retail drug segment 
Clients are currently  underweight  Healthcare with the largest position being Pfizer  NYSE PFE   Clients do own a little iShares Nasdaq Biotechnology  NASDAQ IBB   and some iShares US Pharmaceuticals  NYSE IHE   and VanEck Vectors Pharmaceutical  NASDAQ PPH   but the positions are small right now 
How Prop 61 does in California and the composition of the Senate will matter  It is price controls that are the biggest risk over the next year 
Bristol Meyers  BMY  has gotten crushed  Pfizer is down from  38 to  31  and testing its uptrend line  Merck  NYSE MRK  is acting very well  I do think there is still value in the old school large cap pharma stocks ",2016-11-09,Brian Gilmartin,https://www.investing.com/analysis/health-care-sector:-investors-need-to-pick-up-spots-200163575,200163575
199093,420609,CVS,Top Trade Ideas For The Week October 17  2016  CVS,opinion,"Here is your Bonus Idea with links to the full Top Ten 
CVS Health  NYSE CVS   started moving lower in August of 2015  It took a few steps down but found support at 86 50 in February 2016  It bounced hard from there and rallied for 3 months to a high in May  That was short of the August 2015 high  Since then it has been falling again  2 weeks ago the price had retraced the entire move and was sitting at 86 50 again  Last week the stock started to move higher and ended the week right at the September low bounce before the last little dip 
This is at the 88 6  retracement of the broader move  A push higher here could be the start of the next leg higher  The RSI is moving up and making a higher high and the MACD is crossed up and rising  The next level of possible resistance comes at 90 80 and then 92 10 followed by 94 20 and 96 60  then 98 20  This stock has been ping ponging off of the Fibonacci levels  Short interest is low at 1 5  and the company is expected to report earnings next on November 8th  The stock also goes ex dividend on Thursday 
The options chains show large open interest this week at the 89 and 91 strikes on the call side  This suggests more upside  November 11 Expiry options  the first after the earnings report have been lightly traded except for some open interest on the 87 Puts  November monthly options have biggest open interest on the Put side at the 85 strike and sizable at 90  The Call side is much bigger though and spread from 90 to 110 
CVS Health  Ticker  CVS
Trade Idea 1  Buy the stock on a move over 88 80 with a stop at 86 50
Trade Idea 2  Buy the stock on a move over 88 80 with a November 11 Expiry 87 88 5 91 5 Put Spread Collar  buying the 88 5 87 Put Spread and selling the 91 5 Put  all for free  
Trade Idea 3  Buy the November 85 90 Bull Risk Reversal  48 cents  
Trade Idea 4  Buy the October November 90 Call Calendar   1 25  
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into October Options Expiration week the equity markets continue to show some weakness  especially in the small caps 
Elsewhere look for Gold consolidate with a downward bias if it resolves soon while Crude Oil continues to plow higher  The US Dollar Index also looks to continue higher while US Treasuries continue lower  The Shanghai Composite and Emerging Markets look best to continue to bide time moving sideways 
Volatility looks to remain low but creeping higher  sucking out the tailwind from the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts show clear weakness in the IWM  with the SPY and QQQ a little stronger short term  The QQQ is the best looking longer term  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2016-10-17,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-october-17,-2016:-bonus-idea-200159092",200159092
199094,420610,CVS,CVS Health  CVS  Q3  Tops Earnings  Misses On Revenue ,opinion,Ever bought medicines or cosmetics over the counter  Yes  then you may have walked into one of the 9 652 retail CVS pharmacy stores of the largest pharmacy healthcare services provider in the U S    CVS Health Corporation   NYSE CVS    This Rhode Island based company s more than 900 walk in medical clinics CVS MinuteClinic currently possess a customer satisfaction rate of 95  Currently  CVS Health has a Zacks Rank  3  Hold  but that could change following its third quarter 2016 earnings report which has just released   You can see    We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate remained steady at  1 57 per share over the last 60 days CVS Health s adjusted earnings per share of  1 64 beat this estimate by 4 4  CVS HEALTH CORP Price and EPS Surprise   Revenues  CVS Health posted revenues of  44 6 billion  missing the Zacks Consensus Estimate for revenues of  45 3 billion Key Stats  CVS Health s Pharmacy Services segment revenues increased 19 2  to  30 4 billion  while revenues from Retail LTC segment improved 12 5  year over year to  20 1 billion During the third quarter  CVS Health opened 48 new retail stores and closed 6 retail stores  Further  the company relocated 11 retail drugstores Major Factors  CVS Health ended third quarter of 2016 on a mixed note  with its bottom line exceeding the Zacks Consensus Estimate  while the top line missing the same Moreover  management narrowed the company s 2016 adjusted EPS guidance  which disappoints us  For the third quarter  the generic dispensing rate increased 160 basis points to 85 4  in the Pharmacy Services Segment and 100 basis points to 85 8  in the Retail LTC Segment Stock Price  Following the earnings release  share prices dropped 12 4  in the pre market trading session Check back later for our full write up on this CVS Health earnings report later Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-07,Zacks Investment Research,"https://www.investing.com/analysis/cvs-health-(cvs)-q3:-tops-earnings,-misses-on-revenue-200163443",200163443
199104,420620,CVS,CVS Pharmacy Discontinues Homeopathic Teething Products,opinion,CVS Health Corporation s   NYSE CVS   subsidiary  CVS Pharmacy recently announced the voluntary withdrawal of its homeopathic teething products from online and retail stores  This withdrawal comes on the heels of the U S  FDA s warning to consumers to discontinue the usage of these products  Reportedly  these products pose a serious threat to the health of children and infants CVS Pharmacy offered homeopathic teething products in the form of tablets and gels  both through its retail and online stores  Now  the company has categorized this product line under  do not sell  in its store register system to prevent further sale of these items  These items include three Baby Orajel Naturals products  two CVS Homeopathic Infant s Teething products and five Hyland s Baby products Meanwhile  the FDA warning came after it received reports that homeopathic teething products are causing seizures  breathing issues  muscle problems  excessive drowsiness  skin problems  constipation  urination troubles or agitation among children  The FDA is advising parents to immediately dispose of the products in use CVS HEALTH CORP Price    Typically  homeopathic remedies are said to have active ingredients that are not hazardous  However  extensive research has shown that these homeopathic products are being manufactured improperly As per Medgadget report  the World Health Organization  WHO  has revealed that homeopathy has become the second largest medicine system  displaying an annual growth rate of 20 25  globally  The worldwide homeopathic market is expected to see a significant surge in the years to come  CVS Health  which has so far reaped benefits out of this surge  is now expected to face a huge blow from the product recall  We expect this recall to hurt the company s Pharmacy segment to a great extent Zacks Rank   Key PicksCVS Health currently has a Zacks Rank  3  Hold   Better ranked stocks in the medical product sector are GW Pharmaceuticals plc   NASDAQ GWPH    Quidel Corp    NASDAQ QDEL   and NuVasive  Inc    NASDAQ NUVA    GW Pharmaceuticals and Quidel sport a Zacks Rank  1  Strong Buy  while NuVasive carries a Zacks Rank  2  Buy   You can seeGW Pharmaceuticals recorded a 91 14  gain year to date  far better than the S P 500 s 6 08  over the same time frame  The trailing 4 quarter average earning surprise also remains positive at 41 67  Quidel gained 13 87  in the past one year  higher than the S P 500 s 11 02   Over the next five years  the stock is estimated to record earnings growth rate of 20   higher than the industry average of 14 8   NuVasive surged 31 9  over the past one year compared to the S P 500 s 11 02   Over the next five years  the stock is expected to see 16 7  earnings growth compared to the industry average of 14 8  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-02,Zacks Investment Research,https://www.investing.com/analysis/cvs-pharmacy-discontinues-homeopathic-teething-products-200156721,200156721
199111,420627,CVS,CVS Health  CVS  Works To Cut Down On Readmission Rates,opinion,"Leading pharmacy services provider  CVS Health   NYSE CVS   recently conducted a study on medication reconciliation programs under CVS Health Research Institute  As per the findings of this study  this program will help in improving patient s health and reduce the risk of readmission by 50   This will accordingly help in saving unnecessary healthcare costs The medication reconciliation program deals with a patient s transition from hospital to home under the supervision of a pharmacist  The study dealt with readmission cases of over 260 members  for a period of above five months  under national health plans  The findings showed that  the overall risk of readmission decreased to 11  from 22  for those enrolled under the program 
Additionally  the health plan resulted in savings of  2 for every  1 spent on the program  resulting in savings of over  1300 per patient   This study is expected to prove as a major boost in terms of market adoption of CVS Health s Medication reconciliation program  taking into consideration the huge healthcare readmission cost the nation has to bear each year According to recent data  one out of seven hospital discharged patients is readmitted within 30 days leading to an additional  41 billion of health care costs annually  The company is confident about its research outcome  and believes this to lead to an efficient healthcare system in susceptible population Recently  CVS Health announced that its retail medical clinic  MinuteClinic  had opened new locations in Northern Virginia  Moreover its specialty pharmacy has been honored with Specialty Pharmacy accreditation from URAC  a Washington  DC based health care accrediting organization that establishes quality standards for the health care industry With its focus on helping patients return to normal life  initiative to help patients for a safe livelihood and along with their new services CVS Health is expected to remain on growth trajectory over the longer term At present  CVS Health carries a Zacks Rank  4  Sell   However  with the recent flow of positive news  there might be an uptrend in its share price Key PicksBetter ranked stocks in the medical sector are Diplomat Pharmacy  Inc    NYSE DPLO     Herbalife Ltd    NYSE HLF   and Progressive Care  Inc    While Diplomat Pharmacy and Herbalife sport a Zacks Rank  1  Strong Buy   Progressive Care carries a Zacks Rank  2  Buy  ",2016-07-11,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-(cvs)-works-to-cut-down-on-readmission-rates-200141182,200141182
199112,420628,CVS,CVS Health Corporation Downgraded By Vetr Inc  To Hold,opinion,"CVS Health Corporation  NYSE CVS  was downgraded by  from a  strong buy  rating to a  hold  rating in a note issued to investors on Monday  They presently have a  95 44 price target on the pharmacy operator s stock   s target price indicates a potential upside of 1 49  from the stock s current price 
Shares of CVS Health Corporation  NYSE CVS  traded down 2 60  during trading on Monday  hitting  94 04  7 405 196 shares of the stock were exchanged  CVS Health Corporation has a one year low of  81 37 and a one year high of  113 65  The stock s 50 day moving average price is  95 72 and its 200 day moving average price is  98 31  The stock has a market cap of  101 00 billion and a PE ratio of 20 44 
CVS Health Corporation  NYSE CVS  last posted its quarterly earnings results on Tuesday  May 3rd  The pharmacy operator reported  1 18 earnings per share for the quarter  topping the Zacks  consensus estimate of  1 16 by  0 02  During the same period last year  the business earned  1 14 earnings per share  The firm had revenue of  43 20 billion for the quarter  compared to analysts  expectations of  43 01 billion  The firm s revenue for the quarter was up 18 9  on a year over year basis  Equities research analysts predict that CVS Health Corporation will post  5 82 EPS for the current year 
The firm also recently disclosed a quarterly dividend  which will be paid on Monday  August 1st  Shareholders of record on Thursday  July 21st will be given a  0 425 dividend  The ex dividend date is Tuesday  July 19th  This represents a  1 70 annualized dividend and a yield of 1 81  
A number of other equities research analysts also recently weighed in on the company  Morgan Stanley downgraded CVS Health Corporation from an  overweight  rating to an  equal weight  rating and cut their price target for the stock from  111 00 to  104 00 in a research note on Monday  June 20th  Credit Suisse Group AG reaffirmed a  buy  rating and set a  115 00 price target on shares of CVS Health Corporation in a research note on Sunday  June 5th  Jefferies Group reaffirmed a  buy  rating on shares of CVS Health Corporation in a research note on Monday  July 4th  Deutsche Bank AG raised their price target on CVS Health Corporation from  99 00 to  105 00 and gave the stock a  hold  rating in a research note on Wednesday  June 22nd  Finally  Mizuho reaffirmed a  buy  rating and set a  108 00 price target  down from  117 00  on shares of CVS Health Corporation in a research note on Thursday  June 23rd  One analyst has rated the stock with a sell rating  five have issued a hold rating  seventeen have given a buy rating and one has issued a strong buy rating to the company  The stock has a consensus rating of  Buy  and a consensus price target of  112 98 
In other news  EVP Troyen A  Brennan sold 7 517 shares of the business s stock in a transaction on Thursday  May 5th  The stock was sold at an average price of  105 00  for a total transaction of  789 285 00  Following the completion of the sale  the executive vice president now owns 69 601 shares in the company  valued at  7 308 105  The transaction was disclosed in a filing with the SEC  which is available at   Also  CEO Larry J  Merlo sold 38 247 shares of the business s stock in a transaction on Thursday  May 5th  The stock was sold at an average price of  105 00  for a total value of  4 015 935 00  Following the sale  the chief executive officer now owns 280 381 shares of the company s stock  valued at approximately  29 440 005  The disclosure for this sale can be found  
Several large investors have recently added to or reduced their stakes in CVS  East Coast Asset Management LLC  increased its stake in CVS Health Corporation by 0 3  in the first quarter  East Coast Asset Management LLC  now owns 2 424 shares of the pharmacy operator s stock worth  251 000 after buying an additional 8 shares during the last quarter  Palladium Partners LLC increased its stake in CVS Health Corporation by 1 0  in the second quarter  Palladium Partners LLC now owns 3 724 shares of the pharmacy operator s stock worth  356 000 after buying an additional 38 shares during the last quarter  Harvest Capital Management Inc  increased its stake in CVS Health Corporation by 0 8  in the second quarter  Harvest Capital Management Inc  now owns 5 195 shares of the pharmacy operator s stock worth  497 000 after buying an additional 40 shares during the last quarter  Nicolet Bankshares Inc  increased its stake in CVS Health Corporation by 1 1  in the first quarter  Nicolet Bankshares Inc  now owns 4 738 shares of the pharmacy operator s stock worth  491 000 after buying an additional 50 shares during the last quarter  Finally  Adirondack Trust Co  increased its stake in CVS Health Corporation by 0 4  in the second quarter  Adirondack Trust Co  now owns 13 787 shares of the pharmacy operator s stock worth  1 320 000 after buying an additional 50 shares during the last quarter 
CVS Health Corporation  together with its subsidiaries  is a pharmacy company  The Company operates through three business segments  Pharmacy Services  Retail Pharmacy and Corporate  The Pharmacy Services segment provides a range of pharmacy benefit management  PBM  services and operates under the CVS caremark Pharmacy Services  Novologix and Navarro Health Services names ",2016-07-26,MarketBeat.com,https://www.investing.com/analysis/cvs-health-corporation-(cvs)-downgraded-by-vetr-inc.-to-hold-200144075,200144075
199118,420634,CVS,Earnings Trades  PFE  HAL  CVS ,opinion,Lots Of Earnings Trades Today  PFE  NYSE PFE   Halliburton Company  NYSE HAL   CVS Health Corp  NYSE CVS  and more,2016-05-03,Nicholas Santiago,"https://www.investing.com/analysis/lots-of-earnings-trades-today:-pfe,-hal,-cvs---more-200127594",200127594
199119,420635,CVS,Orexo  Putting CVS Caremark In The Past ,opinion,"Orexo AB  ST ORX  has successfully navigated a challenging Q1 16 with the loss of CVS Health Corp  NYSE CVS  exclusive status at restricted plans  emerging with positive operating cash flow due to working capital and a focus on cost control  total spend down 17  vs Q4   In the near term  management priorities are Zubsolv revenue growth  balanced with appropriate sales investment to target profitability  Investment will increase as Zubsolv s market access and reimbursement position improves  and federal legislation is passed significantly expanding the available market  Global expansion with a potential new ex US partner for Zubsolv represents further upside  a deal is targeted for Q216  with European filing planned in H216 

Zubsolv  Balanced investment to capture growth
Increased investment in promotional activities depends on opportunities to gain market share  market access improvements and legislative change nationally  Increasing the number of patients with unrestricted access to Zubsolv and further growing the profitable cash and commercial segments are a key focus  Federally  proposed changes to government policy would expand access to opioid dependence treatment through both current and new prescribers 
To read the entire report Please click on the pdf File Below",2016-05-09,Edison,https://www.investing.com/analysis/orexo---putting-cvs-caremark-in-the-past-200128771,200128771
199125,420641,CVS,Orexo  Short Term Pain On Cusp Of Long Term Gains ,opinion,"Orexo  ST ORX  Zubsolv sales of SEK417m were up 83  on FY14  against overall 7 8  market growth  As expected  its 6 4  market share at end FY15 was eroded in January due to the loss of favourable reimbursement status at CVS Caremark  N CVS   Nevertheless  a 5  price rise  effective February  coupled with a targeted sales effort and stronger marketing message  should help drive sales  particularly as Zubsolv s reimbursement position improves  With changes in federal legislation on the cusp of significantly increasing the available market  expanding use of medical assisted treatment and increasing the number of prescribers  Zubsolv remains well positioned  Global expansion with a potential new partner represents further upside 

To read the entire report Please click on the pdf File Below",2016-02-17,Edison,https://www.investing.com/analysis/short-term-pain;-on-the-cusp-of-longer-term-gains-200118622,200118622
199126,420642,CVS,Vernalis   Establishing A Firm Foundation ,opinion,"Vernalis  LON VER  reported a modest  0 6m in Tuzistra XR sales over the first four months post launch due to the mild cough cold season  The US launch of this prescription only  Rx   extended release  ER  cough cold medicine is the first step in Vernalis s transition into a commercial stage speciality pharma company  targeting a  3 5bn market opportunity  The emphasis for year one of Tuzistra XR commercialisation is operational  establishing the platform for future sales growth  However  financial performance  in particular  during its second year on the market  will be an important determinant of whether Vernalis will need to raise new funds near term 

Solid operational progress offsets modest sales
Tuzistra XR s slow launch into a mild season suggests FY16 consensus forecasts will fall despite a later peak than typical  So far  Vernalis has achieved an average net price per Rx of  70 75 based on a  177 wholesale acquisition cost per average 168ml Rx  Commercial focus is on improving physician awareness of and patient accessibility to Tuzistra XR  Improved reimbursement is vital  Tier 3 status has been achieved at c 55  of plans  vs 75 80  target   CVS Caremark  NYSE CVS  is a major gap 
To read the entire report Please click on the pdf File Below",2016-04-06,Edison,https://www.investing.com/analysis/vernalis---establishing-a-firm-foundation-200124173,200124173
199131,420647,CVS,Orexo Zubsolv Gains  US Moves To Increase Treatment ,opinion,"Zubsolv gains  US moves to increase treatmentA positive Q315 with Zubsolv sales broadly in line with expectations  coupled with a number of positive and potentially significant developments  continues to support our thesis that Orexo s  ST ORX  share price is overly discounting Zubsolv s potential  The US government has announced plans to expand access to opioid dependence treatment  which could substantially increase the US market opportunity  reinforcing our current peak sales forecasts  This is in addition to key market share gains  induction label approval and two new PBM agreements  Our valuation is updated to SEK5 8bn  with the decrease owing to Abstral generics and the impact of the CVS  N CVS  loss to 2016 Zubsolv sales 

Zubsolv  Market share gains all roundZubsolv made market share gains in Q315  growing in the main commercial market and regaining share in the highly profitable cash segment  This helped to boost the gross net sales ratio  also aided by a one off revision related to assumed rebate levels  The commercial segment remains the main focus for Orexo and Zubsolv continues to increase its share  which will be key for driving future growth 
First US government moves to increase accessIn what could potentially be significant changes to the US opioid dependence market  the US government has announced plans to increase access to medication assisted treatment  MAT   such as with Zubsolv  with goals to double the number of physicians authorised to prescribe buprenorphine  This is currently limited to 30 000 physicians  with around 6 000 active in treating  all have a 100 patient cap  If realised  these goals could substantially expand the current market 
Intensive discussions for Zubsolv ex US and OX51Orexo remains in active discussions for both Zubsolv outside of the US and for pain product OX51  Orexo reiterated its focus to find the right partner committed to maximising each opportunity 
To Read the Entire Report Please Click on the pdf File Below",2015-11-10,Edison,https://www.investing.com/analysis/orexo-zubsolv-gains-270822,270822
199132,420648,CVS,A Pretty Crummy Day On Wall Street,opinion,"It was a pretty crummy day on Wall Street on Thursday  although a lot of stocks we follow did well  We re going to take a look at both longs and shorts here 
Pacific Biosciences of California  O PACB  is making a move  up 65 cents to 10 77  or 6 4   on 2 million shares on Thursday  The swing trade is acting well again  It had a beautiful swing on it  it consolidated  and on Thursday it may have started to move  Watch this stock on Friday  If it gets through the 10 95 11 00 area  it could head up to the 12 13 zone  That s the target 
Rewalk Robotics Ltd  O RWLK  had the biggest day of its history on Thursday  It opened at 7 82  ran up to 13 59  before backing off and closing at 11 00  still up 5 00  or 83   on a whopping 7 million shares  with 12 days to cover  It may very well follow through and take it up to 14 15 
Stocks on the Short Side 
Buffalo Wild Wings Inc  O BWLD  got crushed a month and a half ago  formed a big bear wedge  and looks like it might collapse  On Thursday it was down another 2 80 to 156 85  If it takes out 156 00 on Friday  then it could have a rapid drop down at least 10 points 
Papa JohnS International Inc  O PZZA  is finally breaking after the big hit last week  A wedge formed  a swing was put on it  and it looks like it s coming fruition  On Thursday it dropped 1 21 to 56 34  If it gets below 53 00  the next target is 49 50 
Other stocks on the long side include Advaxis Inc  O ADXS   American Superconductor Corporation  O AMSC   Eldorado Resorts LLC  O ERI   Second Sight Medical Products  O EYES   Globant SA  N GLOB   Kandi Technologies Group Inc  O KNDI   ProShares UltraShort Bloomberg Crude Oil  N SCO   and SolarCity Corporation  O SCTY  
Stocks on the short side include CEB Inc  N CEB   Criteo Sa  O CRTO   CVS Health Corporation  N CVS   Harman International Industries  N HAR   Incorporated  N HAR   Qualys Inc  O QLYS   Red Robin Gourmet Burgers Inc  O RRGB   and Williams Sonoma Inc  N WSM  ",2015-12-17,Harry Boxer,"https://www.investing.com/analysis/pacb,-rwlk,-bwld,-pzza-376259",376259
199137,420653,CVS,Anatomy Of A Trade  CVS,opinion,"The broad markets are making new all time highs  Stocks are breaking out everywhere  You want to participate but you keep hearing from the television that the market is due for a correction  I could tell you to just turn off the television  but there ways to deal with this discomfort as well  Let me illustrate what I am doing with one stock right now 
CVS Health  NYSE CVS  had a great run higher over the back half of 2014  Since February though it pulled back in a shallow retrenchment  It bottomed a few weeks ago when the long lower shadows appeared on the weekly candles on the chart below  That chart shows the rising trend with the 20 week SMA  and that it reconnected with that moving average as it bottomed  Now moving back higher  the price is over the 20 week SMA and has support from the RSI to continue 
That momentum indicator remained bullish through out the pullback  The MACD though continues to look lower  but is flattening  The volatility indicator  the Bollinger Bands  are getting tighter  This is often a precursor to a move  All sets up for a big move higher  And looking at the move up into the pullback  you could establish a target over 125 

I added this stock to client accounts but with a twist  As a long term position  I protected the downside until the early august earnings report by adding a August 100 95 Put Spread  This cost about  1 20  and with the price of the stock at 102 60 gives about  3 80 in risk  assuming I stop the stock if it moves under 100  But to reduce that cost somewhat I also sold a June 26 Expiry Covered Call on the 105 Strike for about 80 cents  This drops my risk to only  3 
But the story is not over yet  By selling that Covered Call  I have capped the upside in the trade  but only for 1 month  My goal will be to continue to sell covered calls as these expire  or move out the maturity  to collect more premium and further lower my cost on the protective collar to zero or below  With weekly options in CVS this is very possible 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2015-05-20,Gregory W. Harmon,https://www.investing.com/analysis/anatomy-of-a-trade--cvs-252350,252350
199148,420664,CVS,Short Drug Pushers,opinion,A couple of drug retailers looked attractive on the short side to me today     Rite Aid Corporation  NYSE RAD  and CVS Health Corp  NYSE CVS   each shown here   for those loony enough to still give shorting a try ,2014-11-20,Tim Knight,https://www.investing.com/analysis/short-drug-pushers-233251,233251
199149,420665,CVS,Looking At CVS For A Christmas Gift,opinion,"My mom likes to go to CVS Health Corp  NYSE CVS  to find gifts for all the holidays  Not like to fill the  I want a pony  request for my kids  But to find some cute furry animal specifically themed to that particular holiday  Ladybugs holding a heart for Valentine s Day  a black cat with a witch s hat for Halloween  a turkey with a pilgrim hat for Thanksgiving 
Our house is full of them  Now that Christmas is approaching we will likely see a set of cuddly polar bears with a red elf hat  It is all great  and the kids love it but Mom  maybe you can get them a different kind of gift from CVS this year 

The chart for CVS stock has been in a good uptrend since this time in 2011  It took a pause  going through a consolidation through the first half of the fall until breaking higher in late October  But since early November another consolidation has set in  It has traded in a channel between 89 15 and 91 40 since Veterans day  by the way   no presents from then   It appears it may be ready to break that channel higher now  The 20 day SMA is rising and acting as support  The momentum indicator RSI is moving back up as it bounces above the mid line and the MACD is rounding out  for a reversal higher  A move above the channel would target a run to 100  Why not give the grandkids a possible 11  return this year 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-12-11,Gregory W. Harmon,https://www.investing.com/analysis/looking-at-cvs-for-a-christmas-gift-235497,235497
199157,420673,CVS,CVS First Retail Pharmacy To Voluntary Give Up Sale Of Cigarettes,opinion,"CVS Corporation  NYSE CVS  is set to report FQ1 2014 earnings before the market opens on Friday  May 2nd  As we discussed last month in more detail  CVS Caremark will be the first of the 3 largest players in retail pharmacies to voluntarily give up sales of cigarettes and tobacco products by October 1st of this year  In the end of March peer Walgreen  WAG  reported disappointing earnings while in early April we saw great numbers out of Rite Aid  RAD   This quarter we are seeing a wide range of estimates on CVS s earnings  signaling uncertainty around CVS given the mixed data  Here s what investors expect from CVS on Friday 
The current Wall Street consensus expectation is for CVS to report 1 05 EPS and  32 538B revenue while the current Estimize com consensus from 17 Buy Side and Independent contributing analysts is  1 07 EPS and  32 516B in revenue  This quarter the buy side as represented by the Estimize com community is expecting CVS to beat EPS estimates from Wall Street by 2c per share while coming up  22 million short on revenue 
Over the past 6 quarters the consensus from Estimize com has been more accurate than Wall Street in forecasting CVS s EPS and revenue 5 times each  By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time  but more importantly it does a better job of representing the market s actual expectations  It has been confirmed by Deutsche Bank Quant  Research and an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  In this case we are seeing a small to moderate difference of estimates between Estimize and Wall Street 

The distribution of estimates published by analysts on the Estimize com platform range from  1 02 to  1 18 EPS and from  32 117B to  32 700B in revenues  This quarter we re seeing a wider range of estimates on CVS than usual 
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A wider distribution of EPS estimates signals less agreement in the market  which could mean greater volatility post earnings 

Throughout the quarter both Wall Street and the Estimize community both raised their EPS and revenue expectations  The Wall Street EPS consensus rose from 98c to  1 05 while the Estimize consensus climbed from 97c to  1 07  Meanwhile the Wall Street revenue consensus increased from  32 110B to  32 538B while the Estimize consensus rose from  32 225B to  32 516B   Timeliness is correlated with accuracy and upward analyst revisions going into an earnings report are often a bullish indicator 

The analyst with the highest estimate confidence rating this quarter is turbinecity who projects  1 06 EPS and  32 569B in revenue  turbinecity was our Winter 2014 season winner and is ranked 3rd overall among over 4 350 contributing analysts  Over the past 2 years turbinecity has been more accurate than Wall Street in forecasting EPS and revenue 59  and 54  of the time respectively throughout over 2000 estimates  Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case turbinecity expects CVS to beat the estimates on revenue but report between the expectations of Wall Street and Estimize on EPS 
On Friday CVS Caremark will be the third of the big 3 pharmacy chains to report earnings  So far we saw great numbers from Rite Aid but a disappointing report from Walgreen  Investors are showing a wide range of estimates on the Estimize com platfor which signals uncertanty around this report  With that being said the consensus from the community is that CVS will beat EPS estimates by 2c per share but come up slightly short of Wall Street s revenue projection 
Get access to estimates for CVS published by your Buy Side and Independent analyst peers and follow the rest of earnings season by heading over to Estimize com  Register for free to create your own estimates and see how you stack up to Wall Street ",2014-05-02,Estimize,https://www.investing.com/analysis/cvs-first-retail-pharmacy-to-voluntary-give-up-sale-of-cigarettes-211433,211433
199158,420674,CVS,Diagnosing CVS As It Tests All Time Highs,opinion,"CVS Corporation  NYSE CVS  broke above short term resistance earlier this week and is testing the all time high price level  Stocks making new all time highs are often described by pundits as one that you should  take off some risk  in  Does that really make any sense  If you sell every stock that makes an all time high then as the market keeps making all time highs you will be on the sidelines watching  uninvested  I guess the bright side is that you will have more time to play golf or what ever else you enjoy 
I am not trying to discourage proper risk management  but come on  You got to be in it to win it  So what do you do  With a stock like CVS there are plenty of options  Literally 

The chart does have some things in it that raise caution  The bearish Shark Harmonic has a Potential Reversal Zone  PRZ  at 79 nearby  Of course that could always morph into a longer Shark with PRZ at 80 05  Or the prior top could halt its progress  But the momentum indicators  RSI and MACD  suggest there is more upside 
If you are long this stock already then you can add protection by buying a collar  This is selling a covered call and buying a put or put spread  With earnings coming up on August 5th  maybe a August 9 Expiry 78 75 Put Spread  offered at 62 cents as I write   That is less than 1  cost to protect the downside to the 200 day moving average  below the last consolidation  And if you sold the August 29 Expiry 81 Calls  making them Covered Calls  the options combination comes at no cost  and still allows for 2 5  upside over the next month 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-07-25,Gregory W. Harmon,https://www.investing.com/analysis/diagnosing-cvs-as-it-tests-all-time-highs-220572,220572
199159,420675,CVS,Listening To The Megaphone In CVS,opinion,"CVS Corp   NYSE CVS  has been a very strong stock  It has been in an uptrend since breaking out of a consolidation range at then end of 2011  Like every stock it has not had a straight walk higher  There have been pullbacks and advances that have moved it higher  Many of those pullbacks have reversed upon touching or just below the 100 day Simple Moving Average  SMA   This happened last week as well  So what is different now 
The chart above shows that trend and the importance of the 100 day SMA  But it also shows the making of an expanding wedge pattern  Also known as a Megaphone  traders like to think if it as a reversal or topping pattern  And it can be  But it is more formally an expanding range and can be watched for a break both ways  In the present iteration the break would look for a  6 50 move  so over 84 the target becomes 90 50  But failure at the top trend line of the megaphone carries a potential trade back to the bottom of the pattern  From there you can look again for a break or reversal 
Disclosure  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-10-23,Gregory W. Harmon,https://www.investing.com/analysis/listening-to-the-megaphone-in-cvs-229989,229989
199168,420684,CVS,CVS Caremark Corp  Undervalued Dividend Growth Stock,opinion,This article is going to look at CVS Caremark Corp  CVS  through the lens of FAST Graphs    fundamentals analyzer software tool  The 12 year historical chart on CVS Caremark Corp shows that the company is undervalued  The prudent investor seeking growth and a rising income stream might want to look more in depth at CVS Caremark Corp for possible addition to his own portfolio Earnings Determine Market Price  The following earnings and price correlated FAST Graphs  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings  Earnings   Price Correlated Fundamentals at a GlanceA quick glance at the historical earnings and price correlated FAST Graphs  on CVS Caremark Corp shows a picture of undervaluation based upon the historical earnings growth rate of 13 8  and a current P E of 14  Analysts are forecasting the earnings growth to continue at about 13 4   and when you look at the forecasting graph below  the stock appears undervalued  it s inside of the value corridor of the five orange lines   based on future growth  CVS Caremark Corp  Historical Earnings  Price  Dividends and Normal P E Since 2002Performance Table CVS Caremark CorpThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 11 1  capital appreciation  green circle   long term shareholders of CVS Caremark Corp  assuming an initial investment of  1 000  would have received an additional  199 60 in dividends  blue highlighting  that increased their total return from 11 1  to 11 7  per annum versus 3 5   red circle  in the S P 500 The following graph plots the historical P E ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as low as it has been since 2002 A further indication of valuation can be seen by examining a company s current P S ratio relative to its historical P S ratio  The current P S ratio for CVS Caremark Corp is  48 which is historically low Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 23 leading analysts reporting to Capital IQ forecast CVS Caremark Corp s long term earnings growth at 13 4   orange circle   CVS Caremark Corp has low long term debt at 20  of capital  CVS Caremark Corp is currently trading at a P E of 14  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  based upon forecasted earnings growth of 13 4   CVS Caremark Corp s share price would  93 76 at the end of 2018  brown circle on EYE Chart   which would represent a 16 1  annual rate of total return which includes dividends paid  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in CVS Caremark Corp to an equal investment in 10 year Treasury bonds illustrates that CVS Caremark Corp s expected earnings would be 7 5  purple circle  times that of the 10 year T bond interest  see EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure  No position at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-12-05,F.A.S.T. Graphs,https://www.investing.com/analysis/cvs-caremark-corp:-undervalued-dividend-growth-stock-146204,146204
